研究

業績等

2023年開く閉じる

Hirose Y, Oda Y, Kobayashi T, Okada K, Iyo M.
Effectiveness of Brexpiprazole in a Patient With Bipolar Disorder and Comorbid Persistent Genital Arousal Disorder/Genito-Pelvic Dysesthesia: A Case Report Cureus. 2023 Dec 11;15(12):e50349. doi: 10.7759/cureus.50349. eCollection 2023 Dec.
Tachibana M, Kanahara N, Oda Y, Hasegawa T, Kimura A, Iyo M.
A retrospective clinical practice study comparing the usefulness of dual-orexin receptor antagonists and a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists J Clin Sleep Med. 2023 Dec 8. doi: 10.5664/jcsm.10946. Online ahead of print.
Ohsako N, Kimura H, Hashimoto T, Hosoda Y, Inaba Y, Iyo M, Nakazato M.
A pilot trial of an online guided self-help cognitive behavioral therapy program for bulimia nervosa and binge eating disorder in Japanese patients Biopsychosoc Med. 2023 Nov 10;17(1):37. doi: 10.1186/s13030-023-00294-1.
NiitsuT, Yasui-Furukori N, Inada K, Kanazawa T, Iyo M, Ueno T, Hashimoto R.
Current practice for clozapine-induced leukopenia in Japanese psychiatric hospitals: A nationwide survey Schizophrenia Research. 2023 Oct 27:S0920-9964(23)00372-9. doi:10.1016/j.schres.2023.10.011. Online ahead of print.
Hirose Y, Oda Y, Yoshino K, Yano F, Kimura M, Kimura H, Iyo M, Shirayama Y.
Reduction of claudin-5 and aquaporin-4 in the rat hippocampal CA-1 and CA-3 regions of a learned helplessness model of depression Pharmacol Biochem Behav. 2024 Jan:234:173676. doi: 10.1016/j.pbb.2023.173676.
Tanemura N, Sasaki T, Miyamoto R, Watanabe J, Araki M, Sato J, Chiba T.
Extracting the latent needs of dementia patients and caregivers from transcribed interviews in japanese: an initial assessment of the availability of morpheme selection as input data with Z-scores in machine learning BMC Med Inform Decis Mak. 2023 Oct 5;23(1):203. doi: 10.1186/s12911-023-02303-3.
Idemoto K, Niitsu T, Shiina A, Kobori O, Onodera M, Ota K, Miyazawa A, Tachibana M, Kimura M, Seki R, Hashimoto T, Yoshimura K, Ito S, Nakazato M, Igarashi Y, Shimizu E, Iyo M.
Association between precautionary behaviors againstcoronavirus disease and psychosocial factors in outpatientswith a pre‐existing disease and their attendants Psychiatry and Clinical Neurosciences Reports. DOI: 10.1002/pcn5.141
Yamashita M, Kagitani-Shimono K, Hirano Y, Hamatani S, Nishitani S, Yao A, Kurata S, Kosaka H, Jung M, Yoshida T, Sasaki T, Matsumoto K, Kato Y, Nakanishi M, Tachibana M, Mohri I, Tsuchiya KJ, Tsujikawa T, Okazawa H, Shimizu E, Taniike M, Tomoda A, Mizuno Y.
Child Developmental MRI (CDM) project: protocol for a multi-centre, cross-sectional study on elucidating the pathophysiology of attention-deficit/hyperactivity disorder and autism spectrum disorder through a multi-dimensional approach BMJ Open. 2023 Jun 23;13(6):e070157. doi: 10.1136/bmjopen-2022-070157.
Yamasaki F, Kanahara N, Nakata Y, Koyoshi S, Yanagisawa Y, Saito T, Oiwa T, Kogure M, Sasaki T, Yoshida T, Kimura H, Iyo M.
Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice J Psychopharmacol. 2023 Oct;37(10):992-1002. doi: 10.1177/02698811231177268. Epub 2023 Jul 3.
Iyo M, Akiyoshi H, Sekine D, Shibasaki Y, Mamiya N.
An exploratory database study of factors influencing the continuation of brexpiprazole treatment (prescription) in patients with schizophrenia using information from psychiatric electronic medical records processed with natural language processing Schizophr Res. 2023 May;255:122-131. doi: 10.1016/j.schres.2023.03.008. Epub 2023 Mar 27.
Masumo Y, Kanahara N, Kogure M, Yamasaki F, Nakata Y, Iyo M.
Dopamine supersensitivity psychosis and delay of clozapine treatment in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2023 Mar 1;38(2):102-109. doi: 10.1097/YIC.0000000000000442. Epub 2022
Kanahara N, Kimura H, Kinoshita T, Iyo M, Takekita Y.
Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases. Clin Psychopharmacol Neurosci. 2023 Feb 28;21(1):197-201. doi: 10.9758/cpn.2023.21.1.197.
伊豫 雅臣
認知行動療法的アプローチによるパターイップスが改善したプロゴルファーの一例(原著論文) スポーツ精神医学(1349-4929)20巻 Page55-57(2023.08)
種村 菜奈枝, 町井 湧介, 佐々木 剛, 荒木 通啓, 佐藤 淳子, 千葉 剛
発話者の潜在ニーズ予測とその可視化Word2Vecモデルを用いた機械学習モデルの精度改善に関する検討 情報処理学会論文誌 デジタルプラクティス 4巻3号 Page69-73(2023.07)
仲田 祐介, 金原 信久, 伊豫 雅臣
【オキシトシンの向精神作用と精神疾患治療応用への展望】統合失調症とオキシトシン作動性システム障害(解説) 医学のあゆみ(0039-2359)286巻2号 Page143-147(2023.07)
佐々木剛, 中込和幸, 伊豫雅臣
血液由来試料の解析と縦断データに基づく、子どもの発達障害と気分障害の治療効果及び予後に関する層別化 精神科 42巻6号 Page769-773(2023.6)
佐々木剛
「特集」いま，知っておきたい発達障害 Q&A 98 （分担執筆：日常臨床の発達障害の診断に使いやすいツールを教えてください） 精神医学 65巻5号(2023.05)
金原 信久, 伊豫 雅臣
【バルベナジン(ジスバル)の基礎と臨床】バルベナジンの基礎(解説) 精神科(1347-4790)42巻3号 Page413-418(2023.03)
佐々木 剛
【統合失調症薬物治療ガイド2022―患者と支援者のために―　ワーキンググループ委員 日本神経精神薬理学会,日本臨床精神神経薬理学会（JSCNP）（2023.02）
金原 信久, 伊豫 雅臣
【遅発性ジスキネジア治療の新たな展開-新規治療薬valbenazine】遅発性ジスキネジアの病態仮説(解説) 臨床精神薬理(1343-3474)26巻1号 Page27-35(2023.01)

2022年開く閉じる

Kinouchi T, Terada J, Sakao S, Koshikawa K, Sasaki T, Sugiyama A, Sato S, Sakuma N, Abe M, Shikano K, Hayama N, Shiko Y, Ozawa Y, Ikeda S, Suzuki T, Tatsumi K.
Effects of the combination of atomoxetine and oxybutynin in Japanese patients with obstructive sleep apnoea: A randomized controlled crossover trial Respirology.2022.

Kanahara N, Nakamura M, Shiko Y, Kawasaki Y, Iyo M.
Are serum oxytocin concentrations lower in patients with treatment-resistant schizophrenia?: A 5-year longitudinal study Asian J Psychiatr. 2022 May 6:103157. doi: 10.1016/j.ajp.2022.103157. Online ahead of print.
Miyazawa A, Kanahara N, Shiko Y, Ozawa Y, Kawasaki Y, Komatsu H, Masumo Y, Nakata Y, Iyo M.
The cortical silent period in schizophrenia: A systematic review and meta-analysis focusing on disease stage and antipsychotic medication J Psychopharmacol. 2022 Apr;36(4):479-488. doi: 10.1177/02698811221078751. Epub 2022 Apr 27.
Miyazawa A, Kanahara N, Kogure M, Otsuka I, Okazaki S, Watanabe Y, Yamasaki F, Nakata Y, Oda Y, Hishimoto A, Iyo M.
A preliminary genetic association study of GAD1 and GABAB receptor genes in patients with treatment-resistant schizophrenia Mol Biol Rep. 2022 Mar;49(3):2015-2024. doi: 10.1007/s11033-021-07019-z. Epub 2021 Nov 29.
Kotajima-Murakami H, Takano A, Hirakawa S, Ogai Y, Funada D, Tanibuchi Y, Ban E, Kikuchi M, Tachimori H, Maruo K, Kawashima T, Tomo Y, Sasaki T, Oi H, Matsumoto T, Ikeda K.
Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double-blind, placebo-controlled trial Neuropsychopharmacol Rep. 2022 Mar;42(1):92-104. doi: 10.1002/npr2.12232. Epub 2022 Jan 23.
Hamatani S, Matsumoto K, Takahashi J, Shiko Y, Ozawa Y, Niitsu T, Hirano Y, Shimizu E.
Feasibility of guided internet-based cognitive behavioral therapy for patients with anorexia nervosa. Internet Interv. 2022 Feb 14;27:100504.
Sasaki T, Hashimoto K, Niitsu T, Hosoda Y, Oda Y, Shiko Y, Ozawa Y, Kawasaki Y, Kanahara N, Shiina A, Hashimoto T, Suzuki T, Sugawara T, Hanaoka H, Iyo M.
Ifenprodil tartrate treatment of adolescents with post-traumatic stress disorder: A double-blind, placebo-controlled trial Psychiatry Res. 2022 Feb 25;311:114486. doi: 10.1016/j.psychres.2022.114486.
Shibata S, Oda Y, Ohki N, Ikemizu Y, Hayatsu R, Hirose Y, Iyo M.
Narcolepsy-like symptoms triggered by lemborexant in the context of hyperactive delirium in a patient with bipolar depression: a case report J Clin Sleep Med. 2022 Jan 13. doi: 10.5664/jcsm.9882. Online ahead of print.
Hasegawa T, Seo T, Kubota Y, Sudo T, Yokota K, Miyazaki N, Muranaka A, Hirano S, Yamauchi A, Nagashima K, Iyo M, Sakai I.
Reliability and validity of the Japanese version of the 4A's Test for delirium screening in the elderly patient Asian J Psychiatr. 2022 Jan;67:102918. doi: 10.1016/j.ajp.2021.102918. Epub 2021 Nov 6.
Kanahara N, Yamanaka H, Shiko Y, Kawasaki Y, Iyo M.
The effects of cumulative antipsychotic dose on brain structures in patients with schizophrenia: Observational study of multiple CT scans over a long-term clinical course Psychiatry Res Neuroimaging. 2022 Jan;319:111422. doi: 10.1016/j.pscychresns.2021.111422. Epub 2021 Nov 26.
佐々木 剛
遅発性ジスキネジアとQOL―統合失調症薬物治療ガイドライン委員の経験から 臨床精神薬理　26巻1号 Page37-40（2023）
伊豫 雅臣, 石郷岡 純, 中村 将俊, 坂口 玲子, 岡本 恵佑, Mao Yongcai, Tsai Joyce, Fitzgerald Alison, 高井 健太郎, 樋口 輝彦
二次出版　統合失調症患者におけるlurasidoneの安全性及び有効性　12週間非盲検継続投与試験 臨床精神薬理(1343-3474)25巻5号 Page573-590(2022.05)
伊豫 雅臣, 石郷岡 純, 中村 将俊, 坂口 玲子, 岡本 恵佑, Mao Yongcai, Tsai Joyce, Fitzgerald Alison, 野坂 忠史, 樋口 輝彦
二次出版　急性増悪期の統合失調症患者におけるlurasidoneの有効性および安全性　6週間、ランダム化、二重盲検、プラセボ対照試験 臨床精神薬理(1343-3474)25巻2号 Page205-220(2022.02)
種村菜奈枝
患者参画の視点を取り入れた小児医薬品開発を推進するための基盤研究 薬学研究の進歩 38. 113-117（2022）

2021年開く閉じる

Kishimoto T, Kinoshita S, Bun S, Sato Y, Kitazawa M, Kikuchi T, Sado M, Takamiya A, Mimura M, Nakamae T, Abe Y, Kanazawa T, Kawabata Y, Tomita H, Abe K, Hishimoto A, Asami T, Suda A, Watanabe Y, Amagai T, Sakuma K, Kida H, Funayama M, Kimura H, Sato A, Fujiwara S, Nagao K, Sugiyama N, Takamiya M, Kodama H, Azekawa T.
J-PROTECT Collaborators. Japanese project for telepsychiatry evaluation during COVID-19: Treatment comparison trial (J-PROTECT): Rationale, design, and methodology. Contemp Clin Trials 2021 Dec; 111.
Kimura M, Oda Y, Hirose Y, Kimura H, Yoshino K, Niitsu T, Kanahara N, Shirayama Y, Hashimoto K, Iyo M.
Upregulation of heat-shock protein HSP-70 and glutamate transporter-1/glutamine synthetase in the striatum and hippocampus in haloperidol-induced dopamine-supersensitivity-state rats Pharmacol Biochem Behav. 2021 Dec;211:173288. doi: 10.1016/j.pbb.2021.173288. Epub 2021 Oct 13.
Kogure M, Kanahara N, Miyazawa A, Oishi K, Nakata Y, Oda Y, Iyo M.
Interacting Roles of COMT and GAD1 Genes in Patients with Treatment-Resistant Schizophrenia: a Genetic Association Study of Schizophrenia Patients and Healthy Controls J Mol Neurosci. 2021 Dec;71(12):2575-2582. doi: 10.1007/s12031-021-01866-y. Epub 2021 Jun 14.
Miyazawa A, Kanahara N, Kogure M, Otsuka I, Okazaki S, Watanabe Y, Yamasaki F, Nakata Y, Oda Y, Hishimoto A, Iyo M.
A preliminary genetic association study of GAD1 and GABAB receptor genes in patients with treatment-resistant schizophrenia Mol Biol Rep. 2021 Nov 29. doi: 10.1007/s11033-021-07019-z. Online ahead of print.
Yamamoto T, Sakurai K, Watanabe M, Sakuma I, Kanahara N, Shiina A, Hasegawa T, Watanabe H, Iyo M, Ishibashi R.
Cyclothymic Temperament is Associated with Poor Medication Adherence and Disordered Eating in Type 2 Diabetes Patients: A Case-Control Study Diabetes Ther. 2021 Sep;12(9):2611-2624. doi: 10.1007/s13300-021-01121-y. Epub 2021 Jul 31.
Kimura H
Japanese Society of Neuropsychopharmacology (as an author of English translation team). Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia" Neuropsychopharmacology Reports 2021 Sep;41(3):266-324.
Tsukiji M, Sasaki T, Nakata Y, Ota K, Aoki T, Hara K, Mamada T, Nakane J, Kogure M, Seki R, Idemoto K, Hashimoto T, Koishikawa H, Moriyama T, Suzuki T, Kanahara N, Ishii I, Iyo M, Niitsu T.
Risk factors for early-phase clozapine discontinuation: A nested case-control study Asian J Psychiatr. 2021 Aug;62:102745. doi: 10.1016/j.ajp.2021.102745. Epub 2021 Jun 26.
Hirano S, Sakakibara R, Komatsu N, Shimizu K, Ishikawa M, Hosoi N, Asahi T, Shuno T, Sugihara H, Kanai S, Miura N, Mochida H, Ozawa Y, Iyo M, Kuwabara S.
Characteristics of Early-Onset Dementia in Chiba Prefecture, Japan: A Multicenter Survey Dement Geriatr Cogn Disord. 2021;50(3):283-288. doi: 10.1159/000518294. Epub 2021 Aug 26.
Iyo M, Ishigooka J, Nakamura M, Sakaguchi R, Okamoto K, Mao Y, Tsai J, Fitzgerald A, Takai K, Higuchi T.
Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study Neuropsychiatr Dis Treat. 2021 Aug 16;17:2683-2695. doi: 10.2147/NDT.S320021. eCollection 2021.
Tanemura N, Sasaki T, Sato J
Disease areas requiring pediatric-specific formulations addressed by drug development for pediatric patients: Lessons after the Pediatric Regulation in the European Union Clinical Research Professionals 83号 Page24-35(2021)
Tsukiji M, Sasaki T, Nakata Y, Ota K, Aoki T, Hara K, Mamada T, Nakane J, Kogure M, Seki R, Idemoto K, Hashimoto T, Koishikawa H, Moriyama T, Suzuki T, Kanahara N, Ishii I, Iyo M, Niitsu T.
Risk factors for early-phase clozapine discontinuation: A nested case-control study Asian J Psychiatr. 2021 Aug;62:102745. doi: 10.1016/j.ajp.2021.102745. Epub 2021 Jun 26.
Idemoto K, Niitsu T, Hata T, Ishima T, Yoshida S, Hattori K, Horai T, Otsuka I, Yamamori H, Toda S, Kameno Y, Ota K, Oda Y, Kimura A, Hashimoto T, Mori N, Kikuchi M, Minabe Y, Hashimoto R, Hishimoto A, Nakagome K, Hashimoto K, Iyo M.
Serum levels of glial cell line-derived neurotrophic factor as a biomarker for mood disorders and lithium response Psychiatry Res. 2021 Jul;301:113967. doi: 10.1016/j.psychres.2021.113967. Epub 2021 Apr 27.
Shiina A, Sato A, Iyo M, Igarashi Y.
Identifying factors associated with criminal responsibility by analyzing court trial verdicts Int J Law Psychiatry. Jul-Aug 2021;77:101702. doi: 10.1016/j.ijlp.2021.101702. Epub 2021 May 4.
Oishi K, Niitsu T, Kanahara N, Sato Y, Iwayama Y, Toyota T, Hashimoto T, Sasaki T, Takase M, Shiina A, Yoshikawa T, Iyo M.
Genetic risks of schizophrenia identified in a matched case-control study Eur Arch Psychiatry Clin Neurosci. 2021 Jun;271(4):775-781. doi: 10.1007/s00406-020-01158-3. Epub 2020 Jul 4.
Nakata Y, Kanahara N, Kimura A, Niitsu T, Komatsu H, Oda Y, Nakamura M, Ishikawa M, Hasegawa T, Kamata Y, Yamauchi A, Inazumi K, Kimura H, Shiko Y, Kawasaki Y, Iyo M.
Oxytocin system dysfunction in patient with treatment-resistant schizophrenia: Alterations of blood oxytocin levels and effect of a genetic variant of OXTR. J Psychiatr Res. 2021 Jun;138:219-227. doi: 10.1016/j.jpsychires.2021.03.053. Epub 2021 Mar 30.
Iyo M, Ishigooka J, Nakamura M, Sakaguchi R, Okamoto K, Mao Y, Tsai J, Fitzgerald A, Nosaka T, Higuchi T.
Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study Psychiatry Clin Neurosci. 2021 Apr 23. doi: 10.1111/pcn.13221. Online ahead of print.
Shiina A, Hasegawa T, Iyo M.
Possible effect of blonanserin on gambling disorder: A clinical study protocol and a case report World J Clin Cases. 2021 Apr 16;9(11):2469-2477. doi: 10.12998/wjcc.v9.i11.2469.
Hosoda Y, Ohtani T, Hanazawa H, Tanaka M, Kimura H, Ohsako N, Hashimoto T, Kobori O, Iyo M, Nakazato M.
Establishment of a Japanese version of the Sick, Control, One Stone, Fat, and Food (SCOFF) questionnaire for screening eating disorders in university students BMC Res Notes. 2021 Apr 16;14(1):142. doi: 10.1186/s13104-021-05549-0.
Kimura H, Kanahara N, Iyo M
Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity Behav Brain Res. 2021 Apr 9;403:113126. doi: 10.1016/j.bbr.2021.113126. Epub 2021 Jan 15.
Seki R, Hashimoto T, Tanaka M, Ishii H, Ogawa M, Sato A, Kimura A, Shiina A, Nakazato M, Iyo M.
Identification of psychological features and development of an assessment tool for event-related psychological distress after experiencing non-traumatic stressful events PLoS One. 2021 Mar 31;16(3):e0249126. doi: 10.1371/journal.pone.0249126. eCollection 2021.
Miyazawa A, Kanahara N, Nakata Y, Kodama S, Kimura H, Kimura A, Oda Y, Watanabe H, Iyo M.
Clozapine Prolongs Cortical Silent Period in Patients with Treatment-Resistant Schizophrenia Psychopharmacol Bull. 2021 Mar 16;51(2):20-30.
Kimura M, Oda Y, Kimura H, Nangaku M, Hirose Y, Niitsu T, Kanahara N, Shirayama Y, Hashimoto K, Iyo M
Reduction of dopamine and glycogen synthase kinase-3 signaling in rat striatum after repeated administration of haloperidol Pharmacol Biochem Behav. 2021 Mar;202:173114. doi: 10.1016/j.pbb.2021.173114. Epub 2021 Jan 22.
Tanemura N, Sasaki T, Sato J, Urushihara H
Study factors associated with the incompletion of clinical trials that include pediatric patients: a retrospective analysis of the European Clinical Trials Database and a lesson from the European region Trials. 2021 Mar 12;22(1):204. doi: 10.1186/s13063-021-05143-6.
Nangaku M, Yoshino K, Oda Y, Kimura M, Kimura H, Hirose Y, Shirayama Y, Iyo M
Astroglial glutamate transporter 1 and glutamine synthetase of the nucleus accumbens are involved in the antidepressant-like effects of allopregnanolone in learned helplessness rats Behav Brain Res. 2021 Mar 5;401:113092. doi: 10.1016/j.bbr.2020.113092. Epub 2020 Dec 28.
Shiina A, Niitsu T, Kobori O, Idemoto K, Hashimoto T, Sasaki T, Igarashi Y, Shimizu E, Nakazato M, Hashimoto K, Iyo M.
Perception of and anxiety about COVID-19 infection and risk behaviors for spreading infection: an international comparison Ann Gen Psychiatry. 2021 Feb 18;20(1):13. doi: 10.1186/s12991-021-00334-6.
Kanahara N, Nakata Y, Iyo M
Genetic association study detected misalignment in previous whole exome sequence: association study of ZNF806 and SART3 in tardive dystonia Psychiatr Genet. 2021 Feb 1;31(1):29-31. doi: 10.1097/YPG.0000000000000263.
Kimura M, Oda Y, Oishi K, Yoshino K, Kimura H, Niitsu T, Kanahara N, Shirayama Y, Hashimoto K, Iyo M
Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats Schizophr Res. 2021 Feb;228:1-6. doi: 10.1016/j.schres.2020.11.062. Epub 2021 Jan 8.
Idemoto K, Ishima T, Niitsu T, Hata T, Yoshida S, Hattori K, Horai T, Otsuka I, Yamamori H, Toda S, Kameno Y, Ota K, Oda Y, Kimura A, Hashimoto T, Mori N, Kikuchi M, Minabe Y, Hashimoto R, Hishimoto A, Nakagome K, Iyo M, Hashimoto K.
Platelet-derived growth factor BB: A potential diagnostic blood biomarker for differentiating bipolar disorder from major depressive disorder J Psychiatr Res. 2021 Feb;134:48-56. doi: 10.1016/j.jpsychires.2020.12.051. Epub 2020 Dec 21.
Niitsu T, Oda Y, Idemoto K, Ota K, Liu J, Sasaki T, Nakazato M, Hashimoto K, Iyo M.
Association between serum levels of glial cell line-derived neurotrophic factor and inattention in adult patients with attention deficits/hyperactivity disorder Psychiatry Res. 2021 Feb;296:113674. doi: 10.1016/j.psychres.2020.113674. Epub 2020 Dec 29.
Kanahara N, Nakata Y, Iyo M.
Genetic association study detected misalignment in previous whole exome sequence: association study of ZNF806 and SART3 in tardive dystonia Psychiatr Genet. 2021 Feb 1;31(1):29-31. doi: 10.1097/YPG.0000000000000263.
Shiina A, Niitsu T, Iyo M
Need for self-medication using over-the-counter psychoactive agents: A national survey in Japan PLoS One. 2021 Jan 25;16(1):e0245866. doi: 10.1371/journal.pone.0245866. eCollection 2021.
Kanahara N, Kimura H, Oda Y, Ito F, Iyo M.
Recent discussions on dopamine supersensitivity psychosis: Eight points to consider when diagnosing treatment-resistant schizophrenia Curr Neuropharmacol. 2021 Jan 25. doi: 10.2174/1570159X19666210125152815.
佐々木 剛
摂食障害治療 - 児童青年期と成人期の相違点・注意点・変わらぬ視点 - 児童青年精神医学とその近接領域 62巻5号 Page636-643(2021.11)
伊豫 雅臣
ドパミン過感受性精神病に関する知見　アセナピンの有用性(解説) 熊精協会誌 189号 Page6-24(2021.10)
椎名 明大, 佐藤 愛子, 新津 富央, 五十嵐 禎人, 伊豫 雅臣
医療観察法における鑑定入院の質の評価　鑑定入院アウトカム指標の確立を目指して 精神医学 (0488-1281)63巻6号 Page977-993(2021.06)
種村菜奈枝, 佐々木剛, 佐藤淳子, 神林崇
ナルコレプシー患者が抱えている顕在または潜在ニーズの実態調査 臨床精神医学 50巻6号 Page615-622（2021.06）
佐々木剛
心的外傷後ストレス障害の病態におけるNMDA受容体の役割と新規治療薬の展望　 医学のあゆみ 277巻11号 Page982 - 984 (2021)
伊豫 雅臣
【双極性障害診療を極める】双極性障害と物質使用障害の併存に関する統合的治療(解説/特集) 精神科治療学 (0912-1862)36巻5号 Page551-555(2021.05)
伊豫 雅臣
【新規抗精神病薬lurasidone】Lurasidoneの国内における臨床的位置づけ(統合失調症)(解説/特集) 臨床精神薬理 (1343-3474)24巻4号 Page357-363(2021.04)
金原 信久(千葉大学社会精神保健教育研究センター), 伊豫 雅臣
【不随意運動への対応】薬剤性ジストニア(解説/特集) 精神科 (1347-4790)38巻4号 Page448-453(2021.04)

2020年開く閉じる

Kanahara N, Takase M, Sasaki T, Honma M, Fujita Y, Tadokoro S, Suzuki H, Yamanaka H, Noda S, Yanahashi S, Saiga T, Komatsu N, Simoyama T, Iyo M.
The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study Int Clin Psychopharmacol. 2020 Nov;35(6):338-344. doi: 10.1097/YIC.0000000000000322.
Niitsu T, Hata T, Nishimoto M, Hosoda Y, Kimura A, Oda Y, Suzuki M, Takase N, Seki R, Fujita K, Endo M, Yoshida T, Inoue M, Hattori N, Murakami T, Imamura Y, Ogawa K, Fukami G, Sato T, Kawasaki Y, Hashimoto T, Ishikawa M, Shiina A, Kanahara N, Iyo M; ROADS Study Group.
A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study Asian J Psychiatr. 2020 Oct;53:102369. doi: 10.1016/j.ajp.2020.102369. Epub 2020 Aug 31.
Nanae Tanemura, Tsuyoshi Sasaki, Junko Sato, Hisashi Urushihara
Real World Survey of Patient Engagement Status in Clinical Research: The First Input from Japan Patient, 2020 Oct;13(5):623-632. doi: 10.1007/s40271-020-00436-5.
Muneoka K, Oda Y, Iwata M, Iyo M, Hashimoto K, Shirayama Y.
Monoaminergic balances predict non-depression-like phenotype in Learned Helplessness Paradigm Neuroscience. 2020 Aug 1;440:290-298. doi: 10.1016/j.neuroscience.2020.03.033. Epub 2020 Mar 25.
Yoshino K, Oda Y, Kimura M, Kimura H, Nangaku M, Shirayama Y, Iyo M.
The alterations of glutamate transporter 1 and glutamine synthetase in the rat brain of a learned helplessness model of depression Psychopharmacology (Berl). 2020 Aug;237(8):2547-2553. doi: 10.1007/s00213-020-05555-3. Epub 2020 May 22.
Nakata Y, Kanahara N, Kimura A, Niitsu T, Komatsu H, Oda Y, Ishikawa M, Hasegawa T, Kamata Y, Yamauchi A, Inazumi K, Kimura H, Iyo M.
Autistic traits and cognitive profiles of treatment-resistant schizophrenia Schizophr Res Cogn. 2020 Jul 27;22:100186. doi: 10.1016/j.scog.2020.100186. eCollection 2020 Dec.
Shiina A, Niitsu T, Kobori O, Idemoto K, Hashimoto T, Sasaki T, Igarashi Y, Shimizu E, Nakazato M, Hashimoto K, Iyo M.
Relationship between perception and anxiety about COVID-19 infection and risk behaviors for spreading infection: A national survey in Japan Brain Behav Immun Health. 2020 Jul;6:100101. doi: 10.1016/j.bbih.2020.100101. Epub 2020 Jul 2.
Okato A, Hashimoto T, Tanaka M, Saito N, Endo M, Okayama J, Ichihara A, Eshima S, Handa S, Senda M, Sato Y, Watanabe H, Nakazato M, Iyo M.
Inter-agency collaboration factors affecting multidisciplinary workers' ability to identify child maltreatment BMC Res Notes. 2020 Jul 6;13(1):323. doi: 10.1186/s13104-020-05162-7.
Shigeki Hirano, Keisuke Shimizu, Noriko Murayama, Moeno Ishikawa, Shogo Furukawa, Kazuho Kojima, Ai Ishikawa, Hitoshi Shimada, Hitoshi Shinotoh, Koichi Kashiwado, Tsuyoshi Sasaki, Masaomi Iyo, Satoshi Kuwabara
Relationship between person with dementia and adolescents: A preliminary survey of the Association Between Children and Dementia Elders (ABCDE) Project Nurs Palliat Care, 2020 doi: 10.15761/NPC.100021
Kobayashi R, Oda Y, Hayatsu R, Ohki N, Akutsu M, Oiwa T, Komatsu H, Niitsu T, Sasaki T, Iyo M.
Successful rechallenge with paliperidone after clozapine treatment for a patient with dopamine supersensitivity psychosis SAGE Open Med Case Rep. 2020 Jun 7;8:2050313X20929561. doi: 10.1177/2050313X20929561. eCollection 2020.
Kudo N, Yamamori H, Ishima T, Nemoto K, Yasuda Y, Fujimoto M, Azechi H, Niitsu T, Numata S, Ikeda M, Iyo M, Ohmori T, Fukunaga M, Watanabe Y, Hashimoto K, Hashimoto R.
Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophrenia. Neuropsychopharmacol Rep. 2020 Jun;40(2):150-156. doi: 10.1002/npr2.12098. Epub 2020 Feb 5.
Kudva KG, El Hayek S, Gupta AK, Kurokawa S, Bangshan L, Armas-Villavicencio MVC, Oishi K, Mishra S, Tiensuntisook S, Sartorius N.
Stigma in mental illness: Perspective from eight Asian nations. Asia Pac Psychiatry . 2020 Jun;12():e12380. doi: 10.1111/appy.12380. Epub 2020 Jan 10.
Takase M, Kimura H, Kanahara N, Nakata Y, Iyo M.
Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis. J Psychopharmacol. 2020 May;34(5):540-547. doi: 10.1177/0269881119900982. Epub 2020 Jan 21.
Yuka K, Nishizawa D, Hasegawa J, Uno K, Miyanishi H, Ujike H, Ozaki N, Inada T, Iwata N, Sora I, Iyo M, Yamada M, Kondo N, Won MJ, Naruse N, Uehara-Aoyama K, Ikeda K, Nitta A.
A Single Medical Marker for Diagnosis of Methamphetamine Addiction - DNA Methylation of SHATI/NAT8L Promoter Sites from Patient Blood Curr Pharm Des. 2020;26(2):260-264. doi: 10.2174/1381612826666200110111703.
Tachibana M, Hashimoto T, Tanaka M, Watanabe H, Sato Y, Takeuchi T, Terao T, Kimura S, Koyama A, Ebisawa S, Shizu Y, Nagase T, Hirakawa J, Hatta K, Nakazato M, Iyo M.
Patterns in Psychiatrists' Prescription of Valproate for Female Patients of Childbearing Age With Bipolar Disorder in Japan: A Questionnaire Survey Front Psychiatry. 2020 Apr 15;11:250. doi: 10.3389/fpsyt.2020.00250. eCollection 2020.
Kanahara N, Nakata Y, Iyo M.
A preliminary exome sequence in three patients with tardive dystonia Psychiatr Genet.2020 Apr;30(2):57-59. doi: 10.1097/YPG.0000000000000248.
Higuchi T, Ishigooka J, Iyo M, Hagi K.
Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study Asia Pac Psychiatry. 2020 Mar;12(1):e12377. doi: 10.1111/appy.12377. Epub 2019 Dec 13.
Kanahara N, Nakata Y, Iyo M.
A preliminary exome sequence in three patients with tardive dystonia. Psychiatr Genet. 2020 Apr;30(2):57-59. doi: 10.1097/YPG.0000000000000248.
Kusui Y, Nishizawa D, Hasegawa J, Uno K, Miyanishi H, Ujike H, Ozaki N, Inada T, Iwata N, Sora I, Iyo M, Yamada M, Kondo N, Won MJ, Naruse N, Uehara-Aoyama K, Ikeda K, Nitta A.
A Medical Marker for Diagnosis of Methamphetamine Addiction - DNA Methylation of SHATI/NAT8L Promoter Sites from Patient Blood. Curr Pharm Des. 2020;26(2):260-264. doi: 10.2174/138161282666620010111703.
Oishi K, Niitsu T, Kanahara N, Hashimoto T, Komatsu H, Sasaki T, Takase M, Sato Y, Iyo M.
Genetic combination risk for schizophrenia Schizophr Res. 2020 Jan;215:473-474. doi: 10.1016/j.schres.2019.08.021. Epub 2019 Aug 30.
伊豫 雅臣
統合失調症薬物治療におけるドパミン過感受性(DSP)を考える(解説) 精神科Resident (2435-8762)1巻1号 Page58-60(2020.10)
伊豫 雅臣
【新規抗精神病薬blonanserinテープ製剤とは】統合失調症治療におけるblonanserinテープ製剤の可能性　薬物治療最適化の観点から(解説/特集) 臨床精神薬理 (1343-3474)23巻3号 Page261-266(2020.03)

2019年開く閉じる

Ogawa M, Hashimoto T, Tanaka M, Tachibana M, Seki R, Sato A, Okayama J, Endo M, Saito N, Sato Y, Watanabe H, Nakazato M, Mori E, Shozu M, Iyo M.
The Effect of Grandmothers' Presence on the Provision of Multidisciplinary Perinatal Support for Pregnant and Postpartum Women with Psychosocial Problems. J Multidiscip Healthc. 2019 Dec 11;12:1033-1041. doi: 10.2147/JMDH.S228320. eCollection 2019.
Shiina A, Sato A, Iyo M, Fujii C.
Outcomes of administrative involuntary hospitalization: A national retrospective cohort study in Japan. World J Psychiatry. 2019 Nov 19;9(7):99-106. doi: 10.5498/wjp.v9.i7.99. eCollection 2019 Nov 19.
Asada T, Kotani T, Nakayama K, Sasaki T, Fujii K, Sunami T, Sakuma T, Iijima Y, Akazawa T, Minami S, Ohtori S, Koda M, Yamazaki M.
Japanese adaptation of the Bad Sobernheim Stress Questionnaire-Brace for patients with adolescent idiopathic scoliosis. J Orthop Sci. 2019 Nov;24(6):1010-1014. doi: 10.1016/j.jos.2019.08.003. Epub 2019 Sep 10.
Oishi K, Niitsu T, Kanahara N, Hashimoto T, Komatsu H, Sasaki T, Takase M, Sato Y, Iyo M.
Genetic combination risk for schizophrenia. Schizophr Res. 2019 Aug 30. pii: S0920-9964(19)30376-7. doi: 10.1016/j.schres.2019.08.021. [Epub ahead of print] No abstract available.
Yoshinaga N, Kubota K, Yoshimura K, Takanashi R, Ishida Y, Iyo M, Fukuda T, Shimizu E.
Long-Term Effectiveness of Cognitive Therapy for Refractory Social Anxiety Disorder: One-Year Follow-Up of a Randomized Controlled Trial. Psychother Psychosom. 2019;88(4):244-246. doi: 10.1159/000500108. Epub 2019 May 23.
Higuchi T, Iyo M, Kwon JS, Chou YH, Chen HK, Chen JY, Chen TT, Huang SY, Lee JS, Saeki Y, Tanaka H, Wang TS, Wu BJ, Katoh T, Ishigouoka J.
Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial. Asia Pac Psychiatry. 2019 Sep;11(3):e12354. doi: 10.1111/appy.12354. Epub 2019 Mar 25.
Higuchi T, Ishigooka J, Iyo M, Yeh CB, Ebenezer EG, Liang KY, Lee JS, Lee SY, Lin SK, Yoon BH, Nakamura M, Hagi K, Sato T.
Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients. Asia Pac Psychiatry. 2019 Jun;11(2):e12352. doi: 10.1111/appy.12352. Epub 2019 Apr 4.
Kotajima-Murakami H, Takano A, Ogai Y, Tsukamoto S, Murakami M, Funada D, Tanibuchi Y, Tachimori H, Maruo K, Sasaki T, Matsumoto T, Ikeda K.
Study of effects of ifenprodil in patients with methamphetamine dependence: Protocol for an exploratory, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacol Rep. 2019 Jun;39(2):90-99. doi: 10.1002/npr2.12050. Epub 2019 Feb 12.
Kanahara N, Yoshimura K, Nakamura M, Oda Y, Watanabe M, Iyo M.
Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia. Int Clin Psychopharmacol. 2019 May;34(3):124-130. doi: 10.1097/YIC.0000000000000257.
Kanahara N, Yoshimura K, Nakamura M, Oda Y, Watanabe M, Iyo M.
Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia. Int Clin Psychopharmacol. 2019 May;34(3):124-130. doi: 10.1097/YIC.0000000000000257.
Tanemura N, Asawa M , Kuroda M, Sasaki T, Iwane Y, Urushihara H.
Pediatric off-label use of psychotropic drugs approved for adult use in Japan in the light of approval information regarding pediatric patients in the United States: a study of a pharmacy prescription database. World J Pediatr. 2019 Feb;15(1):92-99. doi: 10.1007/s12519-018-0213-z. Epub 2018 Nov 30.
伊豫 雅臣
【精神科救急における、長期予後を考慮した統合失調症薬物療法】統合失調症の長期予後とドパミン過感受性精神病(解説/特集) 精神科救急 (1345-7837)22巻 Page33-35(2019.08)
太田 貴代光, 新津 富央, 伊豫 雅臣
【精神医学における様々な仮説とモデルの今I】ドパミン過感受性　その概念と予防・治療(解説/特集) 精神科治療学 (0912-1862)34巻9号 Page1017-1022(2019.09)

2018年開く閉じる

Oishi K, Kanahara N, Takase M, Oda Y, Nakata Y, Niitsu T, Ishikawa M, Sato Y, Iyo M.
Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia. PLoS One. 2018 Nov 8;13(11):e0207133. doi: 10.1371/journal.pone.0207133. eCollection 2018.
Shiina A, Ojio Y, Sato A, Sugiyama N, Iyo M, Fujii C.
The recognition and expectations of ex-inpatients of mental health services: A web-based questionnaire survey in Japan. PLoS One. 2018 Oct 15;13(10):e0197639. doi: 10.1371/journal.pone.0197639. eCollection 2018.
Kanahara N, Yamanaka H, Suzuki T, Takase M, Iyo M.
First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort. BMC Psychiatry. 2018 Sep 3;18(1):274. doi: 10.1186/s12888-018-1853-1.
Hasegawa T, Hashimoto T, Kanahara N, Yamanaka H, Ishige M, Sato Y, Iyo M.
Identifying improvable employment-related factors in schizophrenia patients. Psychiatry Res. 2018 Aug;266:199-205. doi: 10.1016/j.psychres.2018.05.064. Epub 2018 May 28.
Kudo N, Yamamori H, Ishima T, Nemoto K, Yasuda Y, Fujimoto M, Azechi H, Niitsu T, Numata S, Ikeda M, Iyo M, Ohmori T, Fukunaga M, Watanabe Y, Hashimoto K, Hashimoto R.
Plasma Levels of Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2) are Associated with Hippocampal Volume and Cognitive Performance in Patients with Schizophrenia. Int J Neuropsychopharmacol. 2018 Jul 1;21(7):631-639. doi: 10.1093/ijnp/pyy013.
Kanahara N, Hirabayashi M, Mamada T, Nishimoto M, Iyo M.
Combination therapy of electroconvulsive therapy and aripiprazole for dopamine supersensitivity psychosis. Schizophr Res. 2018 Jun 21. pii: S0920-9964(18)30373-6. doi: 10.1016/j.schres.2018.06.038. [Epub ahead of print] No abstract available.
Kuno M, Hirano Y, Nakagawa A, Asano K, Oshima F, Nagaoka S, Matsumoto K, Masuda Y, Iyo M, Shimizu E.
White Matter Features Associated With Autistic Traits in Obsessive-Compulsive Disorder. Front Psychiatry. 2018 May 29;9:216. doi: 10.3389/fpsyt.2018.00216. eCollection 2018.
Sato A, Hashimoto T, Kimura A, Niitsu T, Iyo M.
Psychological Distress Symptoms Associated With Life Events in Patients With Bipolar Disorder: A Cross-Sectional Study. Front Psychiatry. 2018 May 23;9:200. doi: 10.3389/fpsyt.2018.00200. eCollection 2018.
Yamaki T, Suzuki K, Sudo Y, Niitsu T, Okai M, Oka N, Odaki M.
Association between uncooperativeness and the glucose metabolism of patients with chronic behavioral disorders after severe traumatic brain injury: a cross-sectional retrospective study. Biopsychosoc Med. 2018 Apr 23;12:6. doi: 10.1186/s13030-018-0125-0. eCollection 2018.
Setsu R, Asano K, Numata N, Tanaka M, Ibuki H, Yamamoto T, Uragami R, Matsumoto J, Hirano Y, Iyo M, Shimizu E, Nakazato M.
A single-arm pilot study of guided self-help treatment based cognitive behavioral therapy for bulimia nervosa in Japanese clinical settings. BMC Res Notes. 2018 Apr 25;11(1):257. doi: 10.1186/s13104-018-3373-y.
Okato A, Hashimoto T, Tanaka M, Tachibana M, Machizawa A, Okayama J, Endo M, Senda M, Saito N, Iyo M.
Hospital-based child protection teams that care for parents who abuse or neglect their children recognize the need for multidisciplinary collaborative practice involving perinatal care and mental health professionals: a questionnaire survey conducted in Japan. J Multidiscip Healthc. 2018 Feb 22;11:121-130. doi: 10.2147/JMDH.S155352. eCollection 2018.
Matsuura A, Ishima T, Fujita Y, Iwayama Y, Hasegawa S, Kawahara-Miki R, Maekawa M, Toyoshima M, Ushida Y, Suganuma H, Kida S, Yoshikawa T, Iyo M, Hashimoto K.
Dietary glucoraphanin prevents the onset of psychosis in the adult offspring after maternal immune activation. Sci Rep. 2018 Feb 1;8(1):2158. doi: 10.1038/s41598-018-20538-3.
Nagata S, Seki Y, Shibuya T, Yokoo M, Murata T, Hiramatsu Y, Yamada F, Ibuki H, Minamitani N, Yoshinaga N, Kusunoki M, Inada Y, Kawasoe N, Adachi S, Oshiro K, Matsuzawa D, Hirano Y, Yoshimura K, Nakazato M, Iyo M, Nakagawa A, Shimizu E.
Does cognitive behavioral therapy alter mental defeat and cognitive flexibility in patients with panic disorder? BMC Res Notes. 2018 Jan 12;11(1):23. doi: 10.1186/s13104-018-3130-2.
金原 信久, 伊豫 雅臣
【精神科薬物療法の実践と治療哲学】 (第II章)<統合失調症>　抗精神病薬持効性注射剤導入の工夫(解説/特集) 臨床精神医学 (0300-032X)47巻増刊 Page73-78(2018.12)
仲田 祐介, 金原 信久, 伊豫 雅臣
治療抵抗性統合失調症患者に対するドパミン過感受性を考慮した長半減期型非定型抗精神病薬の効果検証　千葉大学精神神経科における後方視研究(原著論文) 臨床精神薬理 (1343-3474)21巻10号 Page1391-1402(2018.10)
伊豫 雅臣
治療抵抗性統合失調症とドパミン過感受性精神病　病態と予防および治療法(総説) 精神医学 (0488-1281)60巻3号 Page291-299(2018.03)
金原 信久, 伊豫 雅臣
【統合失調症の研究最前線】 統合失調症とドパミン過感受性(解説/特集) 精神科 (1347-4790)32巻3号 Page227-233(2018.03)

2017年開く閉じる

Shiina A, Niitsu T, Sato A, Omiya S, Nagata T, Tomoto A, Watanabe H, Igarashi Y, Iyo M.
Effect of educational intervention on attitudes toward the concept of criminal responsibility. World J Psychiatry. 2017 Dec 22;7(4):197-206. doi: 10.5498/wjp.v7.i4.197. eCollection 2017 Dec 22.
Shirayama Y, Takahashi M, Oda Y, Yoshino K, Sato K, Okubo T, Iyo M.
rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine. Brain Imaging Behav. 2017 Dec 15. doi: 10.1007/s11682-017-9803-y. [Epub ahead of print]
Asano K, Koike H, Shinohara Y, Kamimori H, Nakagawa A, Iyo M, Shimizu E.
Group cognitive behavioural therapy with compassion training for depression in a Japanese community: a single-group feasibility study. BMC Res Notes. 2017 Dec 4;10(1):670. doi: 10.1186/s13104-017-3003-0.
Takase M, Kanahara N, Oda Y, Niitsu T, Watanabe H, Iyo M.
The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia. Schizophr Res. 2017 Dec;190:182-183. doi: 10.1016/j.schres.2017.03.014. Epub 2017 Mar 9. No abstract available.
Setsu R, Hirano Y, Tokunaga M, Takahashi T, Numata N, Matsumoto K, Masuda Y, Matsuzawa D, Iyo M, Shimizu E, Nakazato M.
Increased Subjective Distaste and Altered Insula Activity to Umami Tastant in Patients with Bulimia Nervosa. Front Psychiatry. 2017 Sep 25;8:172. doi: 10.3389/fpsyt.2017.00172. eCollection 2017.
Nakata Y, Kanahara N, Iyo M.
Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice. J Psychopharmacol. 2017 Sep 1:269881117728428. doi: 10.1177/0269881117728428. Epub 2017 Sep 19.
Tsuchiyagaito A, Hirano Y, Asano K, Oshima F, Nagaoka S, Takebayashi Y, Matsumoto K, Masuda Y, Iyo M, Shimizu E, Nakagawa A.
Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder with and without Autism Spectrum Disorder: Gray Matter Differences Associated with Poor Outcome. Front Psychiatry. 2017 Aug 15;8:143. doi: 10.3389/fpsyt.2017.00143. eCollection 2017.
Okuda T, Asano K, Numata N, Hirano Y, Yamamoto T, Tanaka M, Matsuzawa D, Shimizu E, Iyo M, Nakazato M.
Feasibility of cognitive remediation therapy for adults with autism spectrum disorders: a single-group pilot study. Neuropsychiatr Dis Treat. 2017 Aug 16;13:2185-2191. doi: 10.2147/NDT.S141555. eCollection 2017.
Oda Y, Fujita Y, Oishi K, Nakata Y, Takase M, Niitsu T, Kanahara N, Shirayama Y, Hashimoto K, Iyo M.
Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats. Psychopharmacology (Berl). 2017 Jul 25. doi: 10.1007/s00213-017-4695-5.Epub 2017 Jul 25.
Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, Iyo M.
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy. Psychother Psychosom. 2017;86(4):189-219. doi: 10.1159/000477313. Epub 2017 Jun 24.
Nakata Y, Kanahara N, Kimura H, Watanabe H, Iyo M.
Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia. Int Clin Psychopharmacol. 2017 May;32(3):169-173. doi: 10.1097/YIC.0000000000000160.
Shiina A, Tomoto A, Omiya S, Sato A, Iyo M, Igarashi Y.
Differences between British and Japanese perspectives on forensic mental health systems: A preliminary study. World J Psychiatry. 2017 Mar 22;7(1):8-11. doi: 10.5498/wjp.v7.i1.8. eCollection 2017 Mar 22.
Seki Y, Nagata S, Shibuya T, Yoshinaga N, Yokoo M, Ibuki H, Minamitani N, Kusunoki M, Inada Y, Kawasoe N, Adachi S, Yoshimura K, Nakazato M, Iyo M, Nakagawa A, Shimizu E.
Erratum to: A feasibility study of the clinical effectiveness and cost-effectiveness of individual cognitive behavioral therapy for panic disorder in a Japanese clinical setting: an uncontrolled pilot study. BMC Res Notes. 2017 Feb 6;10(1):86. doi: 10.1186/s13104-017-2398-y. No abstract available.
Tadokoro S, Nonomura N, Kanahara N, Hashimoto K, Iyo M.
Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report. Clin Psychopharmacol Neurosci. 2017 Feb 28;15(1):79-81. doi: 10.9758/cpn.2017.15.1.79.
Matsumoto J, Hirano Y, Hashimoto K, Ishima T, Kanahara N, Niitsu T, Shiina A, Hashimoto T, Sato Y, Yokote K, Murano S, Kimura H, Hosoda Y, Shimizu E, Iyo M, Nakazato M.
Altered serum level of matrix metalloproteinase-9 and its association with decision-making in eating disorders. 2017 Feb;71(2):124-134. doi: 10.1111/pcn.12490. Epub 2017 Jan 14.
Ikeda M, Takahashi A, Kamatani Y, Okahisa Y, Kunugi H, Mori N, Sasaki T, Ohmori T, Okamoto Y, Kawasaki H, Shimodera S, Kato T, Yoneda H, Yoshimura R, Iyo M, Matsuda K, Akiyama M, Ashikawa K, Kashiwase K, Tokunaga K, Kondo K, Saito T, Shimasaki A, Kawase K, Kitajima T, Matsuo K, Itokawa M, Someya T, Inada T, Hashimoto R, Inoue T, Akiyama K, Tanii H, Arai H, Kanba S, Ozaki N, Kusumi I, Yoshikawa T, Kubo M, Iwata N.
A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder. Mol Psychiatry. 2017 Jan 24. doi: 10.1038/mp.2016.259.Epub 2017 Jan 24.
伊豫 雅臣
【子どもと親のこころに今何がおきているのか。～いじめ・虐待・発達障害～】 成人精神分野としての虐待の背景　親の双極性障害・ADHD・虐待の連鎖(解説/特集) 心と社会 (0023-2807)48巻4号 Page27-34(2017.12)
金原 信久, 伊豫 雅臣
【精神医学症候群(第2版)[III]-物質関連障害および嗜癖性障害群からてんかんまで-】 医薬品誘発性運動症群および他の医薬品有害作用　薬剤性ジストニア(急性、遅発性)(解説/特集) 日本臨床 (0047-1852)別冊精神医学症候群III Page347-351(2017.09)
佐々木 剛, 橋本 謙二, 伊豫 雅臣
【精神神経疾患と興奮性アミノ酸受容体】 思春期の心的外傷後ストレス障害(PTSD)患者を対象にしたイフェンプロジル酒石酸塩の有効性を検討するためのプラセボ対照二重盲検比較試験(解説/特集) 日本生物学的精神医学会誌 (2186-6619)28巻2号 Page95-99(2017.06)
高瀬 正幸, 金原 信久, 伊豫 雅臣
【精神医学症候群(第2版)-発達障害・統合失調症・双極性障害・抑うつ障害-】 統合失調症スペクトラム障害および他の精神病性障害群　抗精神病薬による薬物療法　抗精神病薬　概論(解説/特集) 日本臨床 (0047-1852)別冊精神医学症候群I Page368-372(2017.03)
伊豫 雅臣
【精神医学症候群(第2版)-発達障害・統合失調症・双極性障害・抑うつ障害-】 統合失調症スペクトラム障害および他の精神病性障害群　統合失調症総論　統合失調症の経過、転帰、予後(解説/特集) 日本臨床 (0047-1852)別冊精神医学症候群I Page246-249(2017.03)
伊豫 雅臣
司法精神保健に関わる精神疾患の診断と治療(解説) 司法精神医学 (1881-0330)12巻1号 Page47-50(2017.03)

2016年開く閉じる

Tachibana M, Niitsu T, Watanabe M, Hashimoto T, Kanahara N, Ishikawa M, Iyo M.
Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis. Asian J Psychiatr. 2016 Dec;24:28-32. doi: 10.1016/j.ajp.2016.08.014.
Hashimoto T, Shiina A, Hasegawa T, Kimura H, Oda Y, Niitsu T, Ishikawa M, Tachibana M, Muneoka K, Matsuki S, Nakazato M, Iyo M.
Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial. Ann Gen Psychiatry. 2016 Oct 19;15:27.
Hirose M, Hirano Y, Nemoto K, Sutoh C, Asano K, Miyata H, Matsumoto J, Nakazato M, Matsumoto K, Masuda Y, Iyo M, Shimizu E, Nakagawa A.
Relationship between symptom dimensions and brain morphology in obsessive-compulsive disorder. Brain Imaging Behav. 2017 Oct;11(5):1326-1333. doi: 10.1007/s11682-016-9611-9.
Seki Y, Nagata S, Shibuya T, Yoshinaga N, Yokoo M, Ibuki H, Minamitani N, Kusunoki M, Inada Y, Kawasoe N, Adachi S, Yoshimura K, Nakazato M, Iyo M, Nakagawa A, Shimizu E.
A feasibility study of the clinical effectiveness and cost-effectiveness of individual cognitive behavioral therapy for panic disorder in a Japanese clinical setting: an uncontrolled pilot study. BMC Res Notes. 2016 Oct 7;9(1):458.
Sasaki T, Hashimoto K, Oda Y, Ishima T, Yakita M, Kurata T, Kunou M, Takahashi J, Kamata Y, Kimura A, Niitsu T, Komatsu H, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shimizu E, Iyo M.
Increased Serum Levels of Oxytocin in 'Treatment Resistant Depression in Adolescents (TRDIA)' Group. PLoS One. 2016 Aug 18;11(8):e0160767. doi: 10.1371/journal.pone.0160767. eCollection 2016.
Kimura H, Kanahara N, Sasaki T, Komatsu N, Ishige M, Muneoka K, Ino H, Yoshimura K, Yamanaka H, Suzuki T, Komatsu H, Watanabe H, Shimizu E, Iyo M.
Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up. J Psychopharmacol. 2016 Aug;30(8):795-802. doi: 10.1177/0269881116655978. Epub 2016 Jul 1.
Kimura H, Kanahara N, Takase M, Yoshida T, Watanabe H, Iyo M.
A randomized, sham-controlled study of high frequency rTMS for auditory hallucination in schizophrenia. Psychiatry Res. 2016 Jul 30;241:190-4. doi: 10.1016/j.psychres.2016.04.119. Epub 2016 May 6.
Yagi M, Hirano Y, Nakazato M, Nemoto K, Ishikawa K, Sutoh C, Miyata H, Matsumoto J, Matsumoto K, Masuda Y, Obata T, Iyo M, Shimizu E, Nakagawa A.
Relationship between symptom dimensions and white matter alterations in obsessive-compulsive disorder. Acta Neuropsychiatr. 2017 Jun;29(3):153-163. doi: 10.1017/neu.2016.45. Epub 2016 Sep 13.
Yoshinaga N, Matsuki S, Niitsu T, Sato Y, Tanaka M, Ibuki H, Takanashi R, Ohshiro K, Ohshima F, Asano K, Kobori O, Yoshimura K, Hirano Y, Sawaguchi K, Koshizaka M, Hanaoka H, Nakagawa A, Nakazato M, Iyo M, Shimizu E.
Cognitive Behavioral Therapy for Patients with Social Anxiety Disorder Who Remain Symptomatic following Antidepressant Treatment: A Randomized, Assessor-Blinded, Controlled Trial. Psychother Psychosom. 2016;85(4):208-17. doi: 10.1159/000444221. Epub 2016 May 27.
Kanahara N, Kimura H, Iyo M.
Reply to "concern over your recent paper on risperidone long-acting injectable for treatment-resistant schizophrenia". Schizophr Res. 2016 May;173(1-2):118. doi: 10.1016/j.schres.2016.03.004. Epub 2016 Mar 9. No abstract available.
Yamanaka H, Kanahara N, Suzuki T, Takase M, Moriyama T, Watanabe H, Hirata T, Asano M, Iyo M.
Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis. Schizophr Res. 2016 Feb;170(2-3):252-8. doi: 10.1016/j.schres.2016.01.013. Epub 2016 Jan 13.
Takako Nagata, Atsuo Nakagawa, Satoko Matsumoto, Akihiro Shina, Masaomi Iyo, Naotsugu Hirabayashi, Yoshito Igarashi.
Characteristics of Female Mentally Disordered Offenders Culpable under the New Legislation inJapan: A Gender Comparison Study. Crim Behav Ment Health. 2016 Feb;26(1):50-8. doi: 10.1002/cbm.1949. Epub 2015 Mar 10.
Sutoh C, Koga Y, Kimura H, Kanahara N, Numata N, Hirano Y, Matsuzawa D, Iyo M, Nakazato M, Shimizu E.
Repetitive Transcranial Magnetic Stimulation Changes Cerebral Oxygenation on the Left Dorsolateral Prefrontal Cortex in Bulimia Nervosa: A Near-Infrared Spectroscopy Pilot Study. Eur Eat Disord Rev. 2016 Jan;24(1):83-8. doi: 10.1002/erv.2413. Epub 2015 Oct 20.
Hashimoto K, Yoshida T, Ishikawa M, Fujita Y, Niitsu T, Nakazato M, Watanabe H, Sasaki T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M.
Increased serum levels of serine enantiomers in patients with depression. Acta Neuropsychiatr. 2016 Jun;28(3):173-8. doi: 10.1017/neu.2015.59. Epub 2015 Oct 29.
伊豫 雅臣
【[改訂版]精神科・わたしの診療手順】(第3章)統合失調症スペクトラム障害および他の精神病性障害群 治療抵抗性の統合失調症(解説/特集) 臨床精神医学 (0300-032X)45巻増刊号 Page113-116(2016.12)
小松 英樹, 伊豫 雅臣
【統合失調症のベストプラクティス】 (第II部)各論　心理社会的治療　モバイル機器を用いた再発予防プログラム(解説/特集) 精神科治療学 (0912-1862)31巻増刊 Page220-224(2016.10)
金原 信久, 伊豫 雅臣
【統合失調症のベストプラクティス】 (第II部)各論　薬物療法の進歩と課題　ドパミン過感受性精神病　概念と治療アプローチ(解説/特集) 精神科治療学 (0912-1862)31巻増刊 Page127-131(2016.10)
高瀬 正幸, 金原 信久, 伊豫 雅臣
【向精神薬の初期用量・最大用量・維持用量】 第2世代抗精神病薬持効性注射剤の用量設定および病状変化への急性対応　ドパミン感受性を考慮した検討の重要性(解説/特集) 臨床精神薬理 (1343-3474)19巻5号 Page585-595(2016.05)
内田 亜由美, 田邊 恭子, 椎名 明大, 伊豫 雅臣
青年期広汎性発達障害患者に対する集団認知行動療法の就労支援効果に関する試み 臨床精神医学 (0300-032X)45巻3号 Page357-365(2016.03)
沖田 麻優子, 小堀 修, 沖田 恭治, 長谷川 直, 白石 哲也, 伊豫 雅臣
健康不安患者の再保証を求める行動の動機と特徴　日本人のサンプルにおける質的研究(The motivations and characteristics of seeking reassurance in health anxiety: A qualitative study of Japanese samples)(英語) 千葉医学雑誌 (0303-5476)92巻1号 Page1-9(2016.02)

2015年開く閉じる

Oda Y, Kanahara N, Iyo M.
Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia. Int J Mol Sci. 2015 Dec 17;16(12):30144-63. doi: 10.3390/ijms161226228. Review.
Hashimoto T, Sakurai D, Oda Y, Hasegawa T, Kanahara N, Sasaki T, Komatsu H, Takahashi J, Oiwa T, Sekine Y, Watanabe H, Iyo M.
Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study. Neuropsychiatr Dis Treat. 2015 Dec 10;11:3031-40. doi: 10.2147/NDT.S95067. eCollection 2015.
Oda Y, Tadokoro S, Takase M, Kanahara N, Watanabe H, Shirayama Y, Hashimoto K, Iyo M.
G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis. J Psychopharmacol. 2015 Dec;29(12):1308-13. doi: 10.1177/0269881115593903. Epub 2015 Jul 14.
Nishizawa D, Kasai S, Hasegawa J, Sato N, Yamada H, Tanioka F, Nagashima M, Katoh R, Satoh Y, Tagami M, Ujike H, Ozaki N, Inada T, Iwata N, Sora I, Iyo M, Yamada M, Kondo N, Won MJ, Naruse N, Uehara-Aoyama K, Itokawa M, Ohi K, Hashimoto R, Tanisawa K, Arai T, Mori S, Sawabe M, Naka-Mieno M, Yamada Y, Yamada M, Sato N, Muramatsu M, Tanaka M, Irukayama-Tomobe Y, Saito YC, Sakurai T, Hayashida M, Sugimura H, Ikeda K.
Associations between the orexin (hypocretin) receptor 2 gene polymorphism Val308Ile and nicotine dependence in genome-wide and subsequent association studies. Mol Brain. 2015 Aug 20;8:50. doi: 10.1186/s13041-015-0142-x.
Oda Y, Kanahara N, Kimura H, Watanabe H, Hashimoto K, Iyo M.
Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia. Neuropsychiatr Dis Treat. 2015 Jul 29;11:1845-51. doi: 10.2147/NDT.S86042. eCollection 2015.
Niitsu T, Fabbri C, Serretti A.
Predictors of switch from depression to mania in bipolar disorder. J Psychiatr Res. 2015 Jul-Aug;66-67:45-53.
Sasaki T, Hashimoto K, Oda Y, Ishima T, Kurata T, Takahashi J, Kamata Y, Kimura H, Niitsu T, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M.
Decreased levels of serum oxytocin in pediatric patients with Attention Deficit/Hyperactivity Disorder. Psychiatry Res. 2015 Jun 15. pii: S0165-1781(15)00304-2. doi: 10.1016/j.psychres.2015.05.029.Epub 2015 Jun 15.
Shiina A, Iyo M, Hirata T, Igarashi Y.
Audit study of the new hospitalization for assessment scheme for forensic mental health in Japan. World J Psychiatry. 2015 Jun 22;5(2):234-42. doi: 10.5498/wjp.v5.i2.234.
Sasaki T, Iyo M.
Treatment of puberty trichotillomania with low-dose aripiprazole. Ann Gen Psychiatry. 2015 Jun 17;14:18. doi: 10.1186/s12991-015-0056-0. eCollection 2015.
Matsuura A, Fujita Y, Iyo M, Hashimoto K.
Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine. Acta Neuropsychiatr. 2015 Jun;27(3):159-67. doi: 10.1017/neu.2015.1. Epub 2015 Feb 4.
Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, Iyo M.
Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res. 2015 Jun 30;227(2-3):278-82. doi: 10.1016/j.psychres.2015.02.021. Epub 2015 Mar 31.
Shirayama Y, Ishima T, Oda Y, Okamura N, Iyo M, Hashimoto K.
Opposite roles for neuropeptide S in the nucleus accumbens and bed nucleus of the stria terminalis in learned helplessness rats. Behav Brain Res. 2015 May 16;291:67-71. doi: 10.1016/j.bbr.2015.05.007. Epub 2015 May 16.
Shiina A, Kanahara N, Sasaki T, Oda Y, Hashimoto T, Hasegawa T, Yoshida T, Iyo M, Hashimoto K.
An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia. Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):62-7. doi: 10.9758/cpn.2015.13.1.62.
Matsumoto J, Hirano Y, Numata N, Matzuzawa D, Murano S, Yokote K, Iyo M, Shimizu E, Nakazato M.
Comparison in decision-making between bulimia nervosa, anorexia nervosa, and healthy women: influence of mood status and pathological eating concerns. J Eat Disord. 2015 Apr 2;3:14. doi: 10.1186/s40337-015-0050-6. eCollection 2015.
Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, Iyo M.
Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol. 2015 Apr;29(4):383-9. doi: 10.1177/0269881115570083. Epub 2015 Mar 3.
Kimura A, Hashimoto T, Niitsu T, Iyo M.
Presence of psychological distress symptoms associated with onset-related life events in patients with treatment-refractory depression. J Affect Disord. 2015 Apr 1;175:303-9. doi: 10.1016/j.jad.2015.01.027. Epub 2015 Jan 22.
Miyaoka T, Furuya M, Horiguchi J, Wake R, Hashioka S, Thoyama M, Murotani K, Mori N, Minabe Y, Iyo M, Ueno S, Ezoe S, Hoshino S, Seno H.
Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, multicenter, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med. 2015;2015:201592. doi: 10.1155/2015/201592. Epub 2015 Apr 14.
Uno K, Nishizawa D, Seo S, Takayama K, Matsumura S, Sakai N, Ohi K, Nabeshima T, Hashimoto R, Ozaki N, Hasegawa J, Sato N, Tanioka F, Sugimura H, Fukuda KI, Higuchi S, Ujike H, Inada T, Iwata N, Sora I, Iyo M, Kondo N, Won MJ, Naruse N, Uehara-Aoyama K, Itokawa M, Yamada M, Ikeda K, Miyamoto Y, Nitta A.
The Piccolo Intronic Single Nucleotide Polymorphism rs13438494 Regulates Dopamine and Serotonin Uptake and Shows Associations with Dependence-Like Behavior in Genomic Association Study. Curr Mol Med. 2015;15(3):265-74.
Ishigooka J, Nakamura J, Fujii Y, Iwata N, Kishimoto T, Iyo M, Uchimura N, Nishimura R, Shimizu N; ALPHA Study Group.
Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: A multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res. 2015 Feb;161(2-3):421-8. doi: 10.1016/j.schres.2014.12.013. Epub 2014 Dec 31.
Shiina A, Iyo M, Igarashi Y.
Defining outcome measures of hospitalization for assessment in the Japanese forensic mental health scheme: a Delphi study. Int J Ment Health Syst. 2015 Jan 28;9:7.
原口 正(心の風クリニック), 清水 栄司, 中里 道子, 小堀 修, 伊豫 雅臣
千葉県精神科医療機関のスタッフに認知行動療法は広まっているか　質問紙調査　認知行動療法のアンケート調査(原著論文) 精神療法 (0916-8710)41巻6号 Page887-895(2015.12)
伊豫 雅臣
【精神科救急における薬物療法のあり方】 精神科救急における薬物療法の在り方　長期予後を考えた統合失調症の精神科救急薬物療法(解説/特集) 精神科救急 (1345-7837)18巻 Page27-29(2015.11)
吉村 健佑, 金原 信久, 伊豫 雅臣
【精神科治療における処方ガイドブック】 (第18章)とくに注意すべき副作用について　ジストニア(解説/特集) 精神科治療学 (0912-1862)30巻増刊 Page393-395(2015.10)
原口 正(心の風クリニック), 清水 栄司, 中里 道子, 小堀 修, 伊豫 雅臣
千葉県における認知行動療法の実態　質問紙調査(原著論文) 千葉医学雑誌 (0303-5476)91巻4号 Page177-184(2015.08)
古関 麻衣子, 橋本 佐, 金原 信久, 櫻井 大路, 築地 茉莉子, 長谷川 直, 伊豫 雅臣
双極性障害における治療薬調査および世界的ガイドラインと実臨床の比較研究(原著論文) Bipolar Disorder 13巻 Page29-35(2015.06)
金原 信久, 木村 大, 渡邉 博幸, 伊豫 雅臣
【持効性注射製剤のベネフィットとリスク】 治療抵抗性統合失調症に対する非定型抗精神病薬持効性注射剤の有用性(総説/特集) 臨床精神薬理 (1343-3474)18巻6号 Page747-755(2015.06)
原口 正(心の風クリニック), 山内 直人, 伊豫 雅臣, 清水 栄司
心の健康問題のある人々が復職に重要とみなす因子は何か?　パイロット研究(What factors do people with mental health problems consider important for return to work?: A pilot study)(英語)(原著論文) 千葉医学雑誌 (0303-5476)91巻2号 Page7-12(2015.04)

2014年開く閉じる

Astushi Imai, Naoki Hayashi, Akihiro Shiina, Noriko Sakikawa, Yoshito Igarashi.
Factors associated with violence among Japanese patients with schizophrenia prior to psychiatric emergency hospitalization: A case-controlled study. Schizophr Res. 2014 Dec;160(1-3):27-32.
金原 信久(千葉大学社会精神保健教育研究センター), 木村 大, 山中 浩嗣, 渡邉 博幸, 伊豫 雅臣
【治療抵抗性統合失調症への挑戦】 ドパミンD2受容体過感受性からみた治療抵抗性統合失調症の理解と治療戦略(解説/特集) 臨床精神薬理 (1343-3474)17巻12号 Page1617-1623(2014.12)
伊豫 雅臣(千葉大学 大学院医学研究院精神医学)
今さら聞けないこの言葉　ドパミン過感受性精神病(解説) 精神科臨床サービス (1883-0463)14巻4号 Page444-445(2014.11)
宮田 久嗣(東京慈恵会医科大学 精神医学講座), 樋口 進, 廣中 直行, 池田 和隆, 伊豫 雅臣, 小宮山 徳太郎, 松本 俊彦, 鈴木 勉, 高田 孝二, 和田 清, 齋藤 利和
DSM-5を理解するための基礎知識(第10回)　物質関連障害および嗜癖性障害群(解説) 精神神経学雑誌 (0033-2658)116巻11号 Page950-954(2014.11)
Matsuzawa D, Shirayama Y, Niitsu T, Hashimoto K, Iyo M.
Deficits in emotion based decision-making in schizophrenia; a new insight based on the Iowa Gambling Task. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3;57:52-9. doi: 10.1016/j.pnpbp.2014.10.007. Epub 2014 Oct 24.
Okamoto H, Iyo M, Ueda K, Han C, Hirasaki Y, Namiki T.
Yokukan-san: a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions. Neuropsychiatr Dis Treat. 2014 Sep 12;10:1727-42. doi: 10.2147/NDT.S65257. eCollection 2014. Review.
山本 徹也, 渡邉 博幸, 伊豫 雅臣
「【精神科における困難事例にどう対処するか?I】 強迫性障害および自閉症スペクトラム障害の併存が想定された治療抵抗性統合失調症のコンビネーションセラピー　Clozapine治療にSSRIおよび認知行動療法を組み合わせる(解説/特集)」 精神科治療学 (0912-1862)29巻9号 Page1105-1112(2014.09)
Miyaoka T, Furuya M, Horiguchi J, Wake R, Hashioka S, Tohyama M, Mori N, Minabe Y, Iyo M, Ueno S, Ezoe S, Murotani K, Hoshino S, Seno H.
Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis). Psychopharmacology (Berl). 2015 Jan;232(1):155-64. doi: 10.1007/s00213-014-3645-8. Epub 2014 Jun 13.
Kobori O, Sawamiya Y, Iyo M, Shimizu E.
A Comparison of Manifestations and Impact of Reassurance Seeking among Japanese Individuals with OCD and Depression. Behav Cogn Psychother. 2014 Jun 3:1-12. [Epub ahead of print]
Okita K, Kanahara N, Nishimura M, Yoshida T, Yasui-Furukori N, Niitsu T, Yoshida T, Ishikawa M, Kimura H, Nomura F, Iyo M.
Second-generation antipsychotics and bone turnover in schizophrenia. Schizophr Res. 2014 Aug;157(1-3):137-41. doi: 10.1016/j.schres.2014.05.009. Epub 2014 Jun 2.
Niitsu T, Shirayama Y, Matsuzawa D, Shimizu E, Hashimoto K, Iyo M.
Association between serum levels of glial cell-line derived neurotrophic factor and attention deficits in schizophrenia. Neurosci Lett. 2014 Jul 11;575:37-41. doi: 10.1016/j.neulet.2014.05.034. Epub 2014 May 24.
高瀬 正幸, 金原 信久, 伊豫 雅臣
「長期予後を見据えた統合失調症の薬物療法　非定型抗精神病薬持効性注射剤の可能性　アドヒアランス維持とドパミン過感受性精神病の予防・改善(解説)」 臨床精神薬理 (1343-3474)17巻5号 Page635-641(2014.05)
中里 道子(千葉大学大学院医学研究院子どものこころの発達研究センター), 木村 大, 金原 信久, 伊豫 雅臣
【摂食障害難治例の治療の工夫】 摂食障害に対する反復性経頭蓋磁気刺激法の効果　難治例への適応について(解説/特集) 総合病院精神医学 (0915-5872)26巻2号 Page145-153(2014.04)
Akihiro Shiina, Masaomi Iyo, Akira Yoshizumi, Naotsugu Hirabayashi.
Recognition of change in the reform of forensic mental health by clinical practitioners: a questionnaire survey in Japan. Ann Gen Psychiatry. 2014 Mar 29;13(1):9.
Hiroshi Kimura, Nobuhisa Kanahara,Hideki Komatsu, Ishige M, Muneoka K, Yoshimura M, Yamanaka H, Suzuki T, Komatsu H, Tsuyoshi Sasaki, Tasuku Hashimoto, Tadashi Hasegawa, Akihiro Shiina, Ishikawa M, Yoshitomo Sekine,Tetsuya Shiraishi, Hiroyuki Watanabe, Eiji Shimizu, Kenji Hashimoto, Masaomi Iyo.
A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr Res. 2014 May;155(1-3):52-8
Tsuyoshi Sasaki, Kenji Hashimoto, Masumi Tachibana, Tsutomu Kurata, Hiroshi Kimura, Hideki Komatsu, Masatomo Ishikawa, Tadashi Hasegawa, Akihiro Shiina, Tasuku Hashimoto, Nobuhisa Kanahara, Tetsuya Shiraishi, Masaomi Iyo.
Tipepidine in adolescent patients with depression: a 4 week,open-label, preliminary study. Neuropsychiatr Dis Treat. 2014 May 5;10:719-22.
椎名 明大, 五十嵐 禎人, 伊豫 雅臣
「精神障害者の司法精神医学の認識に関する研究(原著論文)」 司法精神医学 (1881-0330)9巻1号 Page2-13(2014.03)
松木 悟志, 薛 陸景, 清水 栄司, 伊豫 雅臣
「【認知行動療法の研修体制】 大学病院で認知行動療法を学ぶということ　千葉大学の場合(解説/特集)」 認知療法研究 (1883-2296)7巻1号 Page18-28(2014.02)
金原 信久, 鈴木 智崇, 伊豫 雅臣
「Clozapineのより具体的な適応症例　治療抵抗性統合失調症の評価に際して(総説)」 臨床精神薬理 (1343-3474)17巻2号 Page261-275(2014.02)
Niitsu T, Ishima T, Yoshida T, Hashimoto T, Matsuzawa D, Shirayama Y, Nakazato M, Shimizu E, Hashimoto K, Iyo M.
A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res. 2014 Feb 28;215(2):268-73. doi: 10.1016/j.psychres.2013.12.009. Epub 2013 Dec 14.
伊豫 雅臣, 中込 和幸, 若松 昭秀, 高橋 清久
「精神科看護師及び統合失調症患者における持効性注射剤(デポ剤)への構え及び使用状況についての実態調査結果　統合失調症再発予防研究会アンケート調査の結果より(原著論文)」 最新精神医学 (1342-4300)19巻1号 Page55-62(2014.01)
金原 信久, 宗岡 克政, 木村 大, 伊豫 雅臣
「【統合失調症の退院支援の進め方-17の視点と工夫-】 非定型持効性注射剤による統合失調症難治例への取り組み(解説/特集)」 精神科治療学 (0912-1862)29巻1号 Page37-43(2014.01)
Tsuyoshi Sasaki, Kenji Hashimoto, Masumi Tachibana, Tsutomu Kurata, Keiko Okawada, Maki Ishikawa, Hiroshi Kimura, Hideki Komatsu,Masatomo Ishikawa, Tadashi hasegawa, Akihiro Shiina, Tasuku Hashimoto, Nobuhisa Kanahara, Tetsuya Shiraishi, Masaomi Iyo.
Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-labe, preliminary study. Neuropsychiatr Dis Treat. 2014 Jan 24;10:147-51.
Nishizawa D, Fukuda K, Kasai S, Hasegawa J, Aoki Y, Nishi A, Saita N, Koukita Y, Nagashima M, Katoh R, Satoh Y, Tagami M, Higuchi S, Ujike H, Ozaki N, Inada T, Iwata N, Sora I, Iyo M, Kondo N, Won MJ, Naruse N, Uehara-Aoyama K, Itokawa M, Koga M, Arinami T, Kaneko Y, Hayashida M, Ikeda K.
Genome-wide association study identifies a potent locus associated with human opioid sensitivity. Mol Psychiatry. 2014 Jan;19(1):55-62. doi: 10.1038/mp.2012.164. Epub 2012 Nov 27.

2013年開く閉じる

佐々木剛、山内俊雄、横山富士男、杉本篤言
「Adult ADHD Expert Meeting (座談会)」 ストラテラ全国座談会(2013.12.7)
中込 和幸, 伊豫 雅臣, 若松 昭秀, 高橋 清久, 統合失調症再発予防研究会
「精神科看護師及び統合失調症患者における再発予防に対する認識と取り組みの実態調査結果　統合失調症再発予防研究会アンケート調査の結果より(原著論文)」 最新精神医学 (1342-4300)18巻6号 Page615-624(2013.11)
高橋 道宏, 藤越 慎治, 中原 直博, 伊豫 雅臣
「急性期統合失調症患者におけるolanzapine単剤治療およびその他の抗精神病薬単剤治療の治療継続率についての検討　日常診療下における1年間の観察試験(原著論文)」 臨床精神薬理 (1343-3474)16巻11号 Page1649-1660(2013.11)
伊豫 雅臣, 金原 信久, 山中 浩嗣
「【統合失調症治療における新時代】 統合失調症の薬物療法の最適化　新たな剤型とその意義　非定型抗精神病薬持効性注射製剤を中心に(解説/特集)」 Progress in Medicine (0287-3648)33巻11号 Page2335-2340(2013.11)
Komatsu H, Sekine Y, Okamura N, Kanahara N, Okita K, Matsubara S, Hirata T, Komiyama T, Watanabe H, Minabe Y, Iyo M.
Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: a randomized controlled trial. Schizophr Res. 2013 Oct;150(1):240-4. doi: 10.1016/j.schres.2013.08.007. Epub 2013 Aug 31.
佐々木剛、志津雄一郎、大塚芳克
「成人期ADHDの診断と治療における現状と課題（座談会）」 ストラテラ全国座談会 in 千葉(2013.9.12)
Ikeda M, Okahisa Y, Aleksic B, Won M, Kondo N, Naruse N, Aoyama-Uehara K, Sora I, Iyo M, Hashimoto R, Kawamura Y, Nishida N, Miyagawa T, Takeda M, Sasaki T, Tokunaga K, Ozaki N, Ujike H, Iwata N.
Evidence for shared genetic risk between methamphetamine-induced psychosis and schizophrenia. Neuropsychopharmacology. 2013 Sep;38(10):1864-70. doi: 10.1038/npp.2013.94. Epub 2013 Apr 12.
Muneoka K, Shirayama Y, Horio M, Iyo M, Hashimoto K.
Differential levels of brain amino acids in rat models presenting learned helplessness or non-learned helplessness. Psychopharmacology (Berl). 2013 Sep;229(1):63-71. doi: 10.1007/s00213-013-3080-2. Epub 2013 Apr 9.
Kenji Hashimoto, Tsuyoshi Sasaki, Akira Kishimoto
Old drug ifenprodil, new hope for PTSD with a history of childhood abuse Psychopharmacology (2013) 227:375–376
Tsuyoshi Sasaki, Kenji Hashimoto, Keiko Okawada, Junko Tone, Akira Machizawa, Aya Tano, Michiko Nakazato, Masaomi Iyo
Ifenprodil for the Treatment of Flashbacks in Adolescent Female Posttraumatic Stress Disorder Patients with a History of Abuse Psychother Psychosom 2013;82:344–345
田野彩、岡和田景子、佐々木剛（千葉大学医学部附属病院こどものこころ診療部）田邊恭子（千葉大学医学部附属病院精神神経科）浅野憲一、永岡紗和子、中里道子（千葉大学医学研究院子どものこころの発達研究センター）
「思春期女児の疼痛性障害に対する認知行動療法」 第53回日本児童青年精神医学会総会
焼田まどか、橘真澄、岡東歩美、佐々木剛（千葉大学医学部附属病院　こどものこころ診療部•精神神経科）
「社会恐怖を合併した思春期統合失調症男児に対する認知行動療法的アプローチ」 第53回日本児童青年精神医学会総会
伊豫 雅臣, 木村 真人, 信田 広晶, 肥田 裕久
「うつ病治療における薬物療法のあり方(座談会)」 Pharma Medica (0289-5803)31巻7号 Page93-98(2013.07)
Niitsu T, Okamoto H, Iyo M.
Behavioural and psychological symptoms of dementia in an Alzheimer's disease case successfully treated with natural medicine: association with gonadotropins. Psychogeriatrics. 2013 Jun;13(2):124-7. doi: 10.1111/psyg.12010.
Kanahara N, Yoshida T, Oda Y, Yamanaka H, Moriyama T, Hayashi H, Shibuya T, Nagaushi Y, Sawa T, Sekine Y, Shimizu E, Asano M, Iyo M.
Onset Pattern and Long-Term Prognosis in Schizophrenia: 10-Year Longitudinal Follow-Up Study. PLoS One. 2013 Jun 26;8(6):e67273. Print 2013.
Iyo M, Tadokoro S, Kanahara N, Hashimoto T, Niitsu T, Watanabe H, Hashimoto K.
Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol. 2013 Jun;33(3):398-404. doi: 10.1097/JCP.0b013e31828ea95c. Review.
Taisuke Yoshida
Serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in healthy subjects. Curr. Psychiatry Rev.
Taisuke Yoshida
Recent advances in the potential therapeutic drugs for cognitive deficits in schizophrenia. Open Clin. Chem. J.
長谷川直
「妊娠に伴う精神疾患の急性期における不安への配慮」 （特集）精神科治療学　28 (6);791-796, 2013
A.Shiina, M. Iyo, A. Yoshizumi, N. Hirabayashi
Involuntary hospitalization for offenders with mental disorders in Japan The 8th European Congress on Violence in Clinical Psychiatry 10/2013 Ghent, Belgie.
椎名明大・阿部宏史・川畑俊貴・澤潔・村上直人・吉岡眞吾・平田豊明・五十嵐禎人
医療観察法における鑑定入院に関する実態調査とその運用面の改善に関する研究 　第8回日本司法精神医学会 2013年5月　東京。
Kimura H, Kanahara N, Komatsu N, Ishige M, Muneoka K, Yoshimura M, Yamanaka H, Suzuki T, Komatsu H, Sekine Y, Watanabe H, Iyo M.
[Effectiveness of long-acting injectable risperidone for patients with treatment refractory schizophrenia]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2013 Apr;33(2):85-7. Japanese. No abstract available.
Ishima T, Iyo M, Hashimoto K.
[Aripiprazol potentiates NGF-induced neurite outgrowth]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2013 Apr;33(2):59-60. Japanese. No abstract available.
Kimura H, Kanahara N, Watanabe H, Iyo M.
Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophr Res. 2013 Apr;145(1-3):130-1. doi: 10.1016/j.schres.2013.01.008. Epub 2013 Feb 8. No abstract available.
木村 大, 金原 信久, 小松 尚也, 石毛 稔, 宗岡 克政, 吉村 政之, 山中 浩嗣, 鈴木 智崇, 小松 英樹, 関根 吉統, 渡邉 博幸, 伊豫 雅臣
「治療抵抗性統合失調症に対するリスペリドン持効性注射剤の効果(中間報告)(原著論文)」 日本神経精神薬理学雑誌 (1340-2544)33巻2号 Page85-87(2013.04)
Hagiwara H, Iyo M, Hashimoto K.
Neonatal disruption of serine racemase causes schizophrenia-like behavioral abnormalities in adulthood: clinical rescue by d-serine. PLoS One. 2013 Apr 22;8(4):e62438. doi: 10.1371/journal.pone.0062438. Print 2013.
A. Shiina, T. Yamamoto, Y. Higuchi, Y. Yamanaka, S. Hirano, M. Asahina
Risk Factors of Psychiatric Complication after Deep Brain Stimulation for the Patients with Parkinson’s Disease: A Case Controlled Study. International Congress on mental dysfunction and other non-motor features in Parkinson's disease 9th 4/2013 Seoul.
Kyoji Okita, Osamu Kobori, Tsuyoshi Sasaki, Michiko Nakazato, Eiji Shimizu, Masaomi Iyo
Cognitive behavioural therapy for somatoform pain disorder in adolescents: a case study. Asia Pacific Journal of Counselling and Psychotherapy, 2013
Kyoji Okita, Osamu Kobori, Tsuyoshi Sasaki, Michiko Nakazato, Eiji Shimizu, Masaomi Iyo.
Cognitive behavioural therapy for somatoform pain disorder in adolescents: a case study. Asia Pacific Journal of Counselling and Psychotherapy. 18-Mar 2013
Chihiro Sutoh, Michiko Nakazato, Daisuke Matsuzawa, Kadushi Tsuru, Tomihisa Niitsu, Masaomi Iyo, Eiji Shimizu
Changes in Self-Regulation-Related Prefrontal Activities in Eating Disorders: A Near Infrared Spectroscopy Study. PLoS ONE 8(3): e59324. 2013
Nakazato M, Arakawa S, Takase M, Suzuki M, Shiina A, Hashimoto T, Kanahara N, Kimura H, Niitsu T, Yoshida T, Shiraishi T, Watanabe H, Ishima T, Fujita Y, Hashimoto K, Shimizu E and Iyo M.
Effectiveness of Enteral Formula with Enriched Polyunsaturated Fatty Acids in the Treatment of Anorexia Nervosa: A Pilot Open Case Study The Open Nutrition Journal,6, 89-92. 2012
Sutoh C, Nakazato M, Matsuzawa D, Tsuru K, Niitsu T, Iyo M, Shimizu E.
[Changes in self-regulation-related prefrontal activities in eating disorders: a near infrared spectroscopy study.] PLoS One. 2013;8(3):e59324. doi: 10.1371/journal.pone.0059324. Epub 2013 Mar 19.
Okita K, Shiina A, Nakazato M, Iyo M.
[Tandospirone, a 5-HT1A partial agonist is effective in treating anorexia nervosa: a case series.] Ann Gen Psychiatry. 2013 Mar 9;12(1):7. doi: 10.1186/1744-859X-12-7.
Yoshinaga N, Niitsu T, Hanaoka H, Sato Y, Ohshima F, Matsuki S, Kobori O, Nakazato M, Nakagawa A, Iyo M, Shimizu E.
Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting: a randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment. BMJ Open 13;3(2). 2/2013
Yoshinaga N, Ohshima F, Matsuki S, Tanaka M, Kobayashi T, Ibuki H, Asano K, Kobori O, Shiraishi T, Ito E, Nakazato M, Nakagawa A, Iyo M, Shimizu E.
A preliminary study of individual cognitive behavior therapy for social anxiety disorder in Japanese clinical settings: a single-arm, uncontrolled trial. BMC Res Notes. 28;6:74.2/2013
Kanahara N, Sekine Y, Haraguchi T, Uchida Y, Hashimoto K, Shimizu E, Iyo M.
Orbitofrontal cortex abnormality and deficit schizophrenia. Schizophr Res. 2013 Feb;143(2-3):246-52. doi: 10.1016/j.schres.2012.11.015. Epub 2012 Dec 8.
Okamoto H, Chino A, Hirasaki Y, Ueda K, Iyo M, Namiki T.
Orengedoku-to augmentation in cases showing partial response to yokukan-san treatment: a case report and literature review of the evidence for use of these Kampo herbal formulae. Neuropsychiatr Dis Treat. 2013;9:151-5. doi: 10.2147/NDT.S38318. Epub 2013 Jan 18.
Yamamoto T, Kanahara N, Hirai A, Watanabe H, Iyo M.
Lamotrigine in binge-eating disorder associated with bipolar II depression and treatment-resistant type 2 diabetes mellitus: a case report. Clin Neuropharmacol. 2013 Jan-Feb;36(1):34-5. doi: 10.1097/WNF.0b013e31827dbd3d.

2012年開く閉じる

A. Shiina, Y. Igarashi, M. Iyo
A Research of Recognition about Forensic Psychiatry of Patients with Mental Disorders. Together Against Stigma: Changing how we see mental illness 5th International Stigma Conference 6/2012 Ottawa, Canada.
Kenji Hashimoto, Tsuyoshi Sasaki , Akira Kishimoto
Old drug ifenprodil, new hope for PTSD with a history of childhood abuse Psychopharmacology (in Press)
Tsuyoshi Sasaki, Kenji Hashimoto, Keiko Okawada,Junko Tone, Akira Machizawa, Aya Tano, Michiko Nakazato, Masaomi Iyo
Ifenprodil for the Treatment of Flashbacks in Adolescent Female Posttraumatic Stress Disorder Patients with a History of Abuse Psychother Psychosom (in Press)
Sasaki T, Hashimoto T, Niitsu T, Kanahara N, Iyo M.
Treatment of refractory catatonic schizophrenia with low dose aripiprazole. Ann Gen Psychiatry. 2012 May 3;11(1):12
Nakazato M, Hashimoto K, Shimizu E, Niitsu T, Iyo M.
Possible involvement of brain-derived neurotrophic factor in eating disorders. IUBMB Life 64(5):355-61. 5/2012
Tchanturia K, Davies H, Roberts M, Harrison A, Nakazato M, Schmidt U, Treasure J, Morris R.
Poor Cognitive Flexibility in Eating Disorders: Examining the Evidence using the Wisconsin Card Sorting Task. PLoS ONE 7(1) 10/2012
Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M, Hashimoto K.
Decreased Serum Levels of Mature Brain-Derived Neurotrophic Factor (BDNF), but Not Its Precursor proBDNF, in Patients with Major Depressive Disorder PLoS One 7(8):e42676. 2012
金原信久, 渡邉博幸,　伊豫雅臣
疫学的知見からみた急性精神病へのアプローチ. 精神科治療学 2012; 28: 29-34.
宮澤惇宏,　榎原雅代,　金原信久,　藤崎美久,　伊豫雅臣
Clozapineによって頻回の解離症状・自傷行為が消失した治療抵抗性統合失調症の１例. 臨床精神薬理 2012;15(9): 1551-1557.
Kanahara N, Shimizu E, Sekine Y, Iyo M.
Resting state blood flow andglucose metabolism in psychiatric disorders. Neuroimaging, ed. P Bright.Rijeka, Croatia: Intech Press.
Omiya S, Kobori O, Tomoto A, Igarashi Y, Iyo M.
[Substance use risk personality trait for adolescents] Nihon Arukoru Yakubutsu Igakkai Zasshi. 2012 Dec;47(6):287-97. Japanese.
Yoshinaga N, Ohshima F, Matsuki S, Tanaka M, Kobayashi T, Ibuki H, Asano K, Kobori O, Shiraishi T, Ito E, Nakazato M, Nakagawa A, Iyo M, Shimizu E.
A preliminary study of individual cognitive behavior therapy for social anxiety disorder in Japanese clinical settings: a single-arm, uncontrolled trial BMC Res Notes. 2013 Feb 28;6:74. doi: 10.1186/1756-0500-6-74.
Yoshinaga N, Niitsu T, Hanaoka H, Sato Y, Ohshima F, Matsuki S, Kobori O, Nakazato M, Nakagawa A, Iyo M, Shimizu E
Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting: a randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment. BMJ Open. 2013 Feb 13;3(2). doi:pii: e002242. 10.1136/bmjopen-2012-002242. Print 2013
Kimura H, Kanahara N, Watanabe H, Iyo M.
Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophr Res. 2013 Apr;145(1-3):130-1. doi: 10.1016/j.schres.2013.01.008. Epub 2013 Feb 8. No abstract available.
Okamoto H, Chino A, Hirasaki Y, Ueda K, Iyo M, Namiki T.：
Orengedoku-to augmentation in cases showing partial response to yokukan-san treatment: a case report and literature review of the evidence for use of these Kampo herbal formulae.： Neuropsychiatr Dis Treat. 2013;9:151-5. doi: 10.2147/NDT.S38318. Epub 2013 Jan 18
Yamamoto T, Kanahara N, Hirai A, Watanabe H, Iyo M：
Lamotrigine in binge-eating disorder associated with bipolar II depression and treatment-resistant type 2 diabetes mellitus: a case report.： Clin Neuropharmacol. 2013 Jan-Feb;36(1):34-5. doi: 10.1097/WNF.0b013e31827dbd3d
Kanahara N, Sekine Y, Haraguchi T, Uchida Y, Hashimoto K, Shimizu E, Iyo M.：
Orbitofrontal cortex abnormality and deficit schizophrenia.： Schizophr Res. 2013 Feb;143(2-3):246-52. doi: 10.1016/j.schres.2012.11.015. Epub 2012 Dec 8
Nishizawa D, Fukuda K, Kasai S, Hasegawa J, Aoki Y, Nishi A, Saita N, Koukita Y, Nagashima M, Katoh R, Satoh Y, Tagami M, Higuchi S, Ujike H, Ozaki N, Inada T, Iwata N, Sora I, Iyo M, Kondo N, Won MJ, Naruse N, Uehara-Aoyama K, Itokawa M, Koga M, Arinami T, Kaneko Y, Hayashida M, Ikeda K.：
Genome-wide association study identifies a potent locus associated with human opioid sensitivity.： Mol Psychiatry. 2012 Nov 27. doi: 10.1038/mp.2012.164. [Epub ahead of print]
Ishima T, Iyo M, Hashimoto K.：
Neurite outgrowth mediated by the heat shock protein Hsp90α: a novel target for the antipsychotic drug aripiprazole.： Transl Psychiatry. 2012 Oct 16;2:e170. doi: 10.1038/tp.2012.97.
Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M.：
A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study.： J Clin Psychopharmacol. 2012 Oct;32(5):593-601. doi: 10.1097/JCP.0b013e3182664cfc
Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M, Hashimoto K.：
Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder.： PLoS One. 2012;7(8):e42676. doi: 10.1371/journal.pone.0042676. Epub 2012 Aug 3.
Sasaki T, Hashimoto T, Niitsu T, Kanahara N, Iyo M.：
Treatment of refractory catatonic schizophrenia with low dose aripiprazole.： Ann Gen Psychiatry. 2012 May 3;11(1):12. doi: 10.1186/1744-859X-11-12.
Nakazato M, Hashimoto K, Shimizu E, Niitsu T, Iyo M.：
Possible involvement of brain-derived neurotrophic factor in eating disorders.： IUBMB Life. 2012 May;64(5):355-61. doi: 10.1002/iub.1012. Epub 2012 Apr 4. Review
Niitsu T, Iyo M, Hashimoto K.：
Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases.： Curr Pharm Des. 2012;18(7):875-83. Review.
Fujita Y, Kunitachi S, Iyo M, Hashimoto K：
The antibiotic minocycline prevents methamphetamine-induced rewarding effects in mice.： Pharmacol Biochem Behav. 2012 Apr;101(2):303-6. doi: 10.1016/j.pbb.2012.01.005. Epub 2012 Jan 12
Ishikawa M, Sakata M, Toyohara J, Oda K, Ishii K, Wu J, Yoshida T, Iyo M, Ishiwata K, Hashimoto K：
Occupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [(11)C]CHIBA-1001 in Healthy Human Subjects.： Clin Psychopharmacol Neurosci. 2011 Dec;9(3):111-6. doi: 10.9758/cpn.2011.9.3.111. Epub 2011 Dec 31.
Okita K, Shiina A, Shiraishi T, Watanabe H, Igarashi Y, Iyo M：
The Effect of a New Educational Model on the Motivation of Novice Japanese Psychiatrists to enter Forensic Psychiatry. ： MedEdWorld Epub 2012
Nakazato M, Arakawa S, Takase M, Suzuki M, Shiina A, Hashimoto T, Kanahara N, Kimura H, Niitsu T, Yoshida T, Shiraishi T, Watanabe H, Ishima T, Fujita Y, Hashimoto K, Shimizu E, Iyo M：
Effetiveness of enteral formula with enriched polyunsaturated fatty acids in the treatment of anorexia nervosa: a pilot open case study. The Open Nutrition Journal, 2012, 6, 104-107
Shiina A, Fujisaki M, Iyo M：
Beyond Binder: Determination of Criminal Responsibility while in a State of Drunkenness by Japanese Courts.： J Forensic Res 2013 S11:005
Arai E, Arai M, Uchiyama T, Higuchi Y, Aoyagi K, Yamanaka Y, Yamamoto T, Nagano O, Shiina A, Maruoka D, Matsumura T, Nakagawa T, Katsuno T, Imazeki F, Saeki N, Kuwabara S, Yokosuka O：
Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease. Brain. 2012 May;135(Pt 5):1478-85. doi: 10.1093/brain/aws086. Epub 2012 Apr 19.

2011年開く閉じる

吉田泰介(千葉大学社会精神保健教育研究センター 病態解析研究部門), 伊豫雅臣, 橋本謙二
【統合失調症の予後改善に向けての新たな戦略】薬物療法による予後改善　認知改善薬を中心に(解説/特集) 精神医学(0488-1281)53巻2号 Page127-134(2011.02)
伊豫雅臣(千葉大学 大学院医学研究院精神医学)
うつ病・不安障害におけるベンゾジアゼピンの臨床的位置づけ(解説) 臨床精神薬理(1343-3474)14巻1号 Page141-150(2011.01)
橋本佐(千葉大学医学部附属病院 精神神経科), 吉村健佑, 三田朋美, 椎名明大, 岡村斉恵, 渡邉博幸, 伊豫雅臣
Quetiapineへの切り替えにより有害事象の改善が見られた統合失調症の4症例(原著論文/症例報告) 臨床精神薬理(1343-3474)14巻1号 Page93-101(2011.01)
Chen H, Wu J, Zhang J, Fujita Y, Ishima T, Iyo M, Hashimoto K.：
Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine.： Psychopharmacology (Berl). 2011 Dec 27. [Epub ahead of print]
Arakawa S, Shirayama Y, Fujita Y, Ishima T, Horio M, Muneoka K, Iyo M, Hashimoto K.：
Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline.： Pharmacol Biochem Behav. 2011 Sep 24. [Epub ahead of print]
Niitsu T, Shirayama Y, Matsuzawa D, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Shiina A, Fukami G, Fujisaki M, Watanabe H, Nakazato M, Asano M, Kimura S, Hashimoto K, Iyo M.
Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia.： Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1836-40. Epub 2011 Sep 10.
Okahisa Y, Kodama M, Takaki M, Inada T, Uchimura N, Yamada M, Iwata N, Iyo M, Sora I, Ozaki N, Ujike H.
Association between the Regulator of G-protein Signaling 9 Gene and Patients with Methamphetamine Use Disorder and Schizophrenia.： Curr Neuropharmacol. 2011 Mar;9(1):190-4.
Okahisa Y, Kodama M, Takaki M, Inada T, Uchimura N, Yamada M, Iwata N, Iyo M, Sora I, Ozaki N, Ujike H.：
Association Study of Two Cannabinoid Receptor Genes, CNR1 and CNR2, with Methamphetamine Dependence.： Curr Neuropharmacol. 2011 Mar;9(1):183-9.
Kobayashi H, Ujike H, Iwata N, Inada T, Yamada M, Sekine Y, Uchimura N, Iyo M, Ozaki N, Itokawa M, Sora I.：
Association analysis of the tryptophan hydroxylase 2 gene polymorphisms in patients with methamphetamine dependence/psychosis.： Curr Neuropharmacol. 2011 Mar;9(1):176-82.
Yokobayashi E, Ujike H, Kotaka T, Okahisa Y, Takaki M, Kodama M, Inada T, Uchimura N, Yamada M, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S.
Association study of serine racemase gene with methamphetamine psychosis. Curr Neuropharmacol. 2011 Mar;9(1):169-75.
Ujike H, Kishimoto M, Okahisa Y, Kodama M, Takaki M, Inada T, Uchimura N, Yamada M, Iwata N, Iyo M, Sora I, Ozaki N.
Association Between 5HT1b Receptor Gene and Methamphetamine Dependence. Curr Neuropharmacol. 2011 Mar;9(1):163-8.
Tsunoka T, Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Okumura T, Inada T, Ujike H, Yamada M, Uchimura N, Sora I, Iyo M, Ozaki N, Iwata N.：
No Association Between GRM3 and Japanese Methamphetamine-Induced Psychosis.： Curr Neuropharmacol. 2011 Mar;9(1):160-2.
Okumura T, Okochi T, Kishi T, Ikeda M, Kitajima T, Kinoshita Y, Kawashima K, Tsunoka T, Fukuo Y, Inada T, Yamada M, Uchimura N, Iyo M, Sora I, Ozaki N, Ujike H, Iwata N.
Genetic Association Analysis of NOS1 and Methamphetamine-Induced Psychosis Among Japanese.： Curr Neuropharmacol. 2011 Mar;9(1):155-9.
Okochi T, Kishi T, Ikeda M, Kitajima T, Kinoshita Y, Kawashima K, Okumura T, Tsunoka T, Fukuo Y, Inada T, Yamada M, Uchimura N, Iyo M, Sora I, Ozaki N, Ujike H, Iwata N.：
Genetic Association Analysis of NOS3 and Methamphetamine-Induced Psychosis Among Japanese.： Curr Neuropharmacol. 2011 Mar;9(1):151-4.
Kobayashi H, Ujike H, Iwata N, Inada T, Yamada M, Sekine Y, Uchimura N, Iyo M, Ozaki N, Itokawa M, Sora I.：
Association analysis of the adenosine A1 receptor gene polymorphisms in patients with methamphetamine dependence/psychosis.： Curr Neuropharmacol. 2011 Mar;9(1):137-42.
Kishi T, Kitajima T, Tsunoka T, Okumura T, Kawashima K, Okochi T, Yamanouchi Y, Kinoshita Y, Ujike H, Inada T, Yamada M, Uchimura N, Sora I, Iyo M, Ozaki N, Iwata N.
Lack of association between prokineticin 2 gene and Japanese methamphetamine dependence.： Curr Neuropharmacol. 2011 Mar;9(1):133-6.
Kishi T, Kitajima T, Kawashima K, Okochi T, Yamanouchi Y, Kinoshita Y, Ujike H, Inada T, Yamada M, Uchimura N, Sora I, Iyo M, Ozaki N, Iwata N.
Association Analysis of Nuclear Receptor Rev-erb Alpha Gene (NR1D1) and Japanese Methamphetamine Dependence.： Curr Neuropharmacol. 2011 Mar;9(1):129-32.
Kishi T, Fukuo Y, Okochi T, Kitajima T, Ujike H, Inada T, Yamada M, Uchimura N, Sora I, Iyo M, Ozaki N, Correll CU, Iwata N.：
No significant association between SIRT1 gene and methamphetamine-induced psychosis in the Japanese population.： Hum Psychopharmacol. 2011 Oct;26(7):445-50. doi: 10.1002/hup.1223. Epub 2011 Aug 31.
Kishi T, Okochi T, Kitajima T, Ujike H, Inada T, Yamada M, Uchimura N, Sora I, Iyo M, Ozaki N, Correll CU, Iwata N.：
Lack of association between translin-associated factor X gene (TSNAX) and methamphetamine dependence in the Japanese population.： Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1618-22. Epub 2011 Jun 13.
Yoshida T, Suga M, Arima K, Muranaka Y, Tanaka T, Eguchi S, Lin C, Yoshida S, Ishikawa M, Higuchi Y, Seo T, Ueoka Y, Tomotake M, Kaneda Y, Darby D, Maruff P, Iyo M, Kasai K, Higuchi T, Sumiyoshi T, Ohmori T, Takahashi K, Hashimoto K.：
Criterion and Construct Validity of the CogState Schizophrenia Battery in Japanese Patients with Schizophrenia.： PLoS One. 2011;6(5):e20469. Epub 2011 May 26.
Yoshimura T, Usui H, Takahashi N, Yoshimi A, Saito S, Aleksic B, Ujike H, Inada T, Yamada M, Uchimura N, Iwata N, Sora I, Iyo M, Ozaki N.：
Association analysis of the GDNF gene with methamphetamine use disorder in a Japanese population.： Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jul 1;35(5):1268-72. Epub 2011 Apr 14.
Shiina A, Fujisaki M, Nagata T, Oda Y, Suzuki M, Yoshizawa M, Iyo M, Igarashi Y.：
Expert consensus on hospitalization for assessment: a survey in Japan for a new forensic mental health system.： Ann Gen Psychiatry. 2011 Apr 8;10:11.
Haraguchi T, Fujisaki M, Shiina A, Igarashi Y, Okamura N, Fukami G, Shiraishi T, Nakazato M, Iyo M.：
Attitudes of Japanese psychiatrists toward forensic mental health as revealed by a national survey.： Psychiatry Clin Neurosci. 2011 Mar;65(2):150-7.
Tadokoro S, Okamura N, Sekine Y, Kanahara N, Hashimoto K, Iyo M.：
Chronic Treatment With Aripiprazole Prevents Development of Dopamine Supersensitivity and Potentially Supersensitivity Psychosis.： Schizophr Bull. 2011 Mar 14. [Epub ahead of print].
Haraguchi T, Shimizu E, Ogura H, Fukami G, Fujisaki M, Iyo M.：
Alterations of Responsibility Beliefs Through Cognitive-Behavioural Group Therapy for Obsessive-Compulsive Disorder.： Behav Cogn Psychother. 2011 Feb 22:1-6. [Epub ahead of print]
Okamoto H, Sekiya N, Chino A, Iyo M, Terasawa K.：
A suspected case of somatoform disorder successfully treated with an herbal medicine.： J Altern Complement Med. 2011 Feb;17(2):171-3. Epub 2011 Feb 7

2010年開く閉じる

谷渕由布子(千葉大学社会精神保健教育研究センター 病態解析研究部門), 伊豫雅臣, 橋本謙二
薬物依存症の末梢血バイオマーカーに関する最新知見　神経栄養因子およびサイトカインを中心に(総説) 日本アルコール・薬物医学会雑誌(1341-8963)45巻6号 Page515-524(2010：12)
中里道子(千葉大学医学部附属病院 こどものこころ診療部), 橋本謙二, 伊豫雅臣
【精神疾患の免疫異常】 摂食障害と脳由来神経栄養因子(解説/特集) 日本生物学的精神医学会誌(0915-7328)21巻4号 Page237-244(2010.12)
小堀修(千葉大学社会精神保健教育研究センター), 清水栄司, 伊豫雅臣, 中里道子
うつ病からの回復とリハビリテーション】 嵐の後のさわやかな風になる　認知行動療法のひろがりとつながり(解説/特集) こころのりんしょうa・la・carte(0288-0512)29巻4号 Page522-526(2010.12)
伊豫雅臣(千葉大学 大学院医学研究院精神医学), 小石川比良来, 青木勉, 白山幸彦
うつ病治療の現状と今後の展望　NaSSAを中心として(座談会) Progress in Medicine(0287-3648)30巻10号 Page2589-2596(2010.10)
伊豫雅臣(千葉大学 大学院医学研究院精神医学)
【救急場面での状態像からみた精神疾患の診断と初期対応】 総論 月刊レジデント3巻10号 Page6-9(2010.10)
田所重紀(千葉大学医学部附属病院 精神神経科), 中里道子, 白石哲也, 伊豫雅臣
認知行動療法における「動機づけ」と「疾病の外在化」の変化について　神経性無食欲症患者に対する入院治療例に基づく考察 認知療法研究(1883-2296)3巻 Page98-106(2010.09)
伊豫雅臣(千葉大学 大学院医学研究院精神医学), 大田郁也, 宮岡剛, 吉川憲人
長期の治療ゴールを捉えた統合失調症治療とは　抗精神病薬の長期投与による社会復帰(リカバリー)例からの考察 Pharma Medica(0289-5803)28巻8号 Page171-180(2010.08)
高橋純平(千葉大学医学部附属病院 精神神経科・こどものこころ診療部), 久能勝, 東出香, 長谷川直, 白石哲也, 深見悟郎, 伊豫雅臣
小児・思春期の双極性障害に対する薬物療法 Bipolar Disorder8巻 Page102-110(2010.06)
鈴木純子(千葉大学医学部附属病院 こどものこころの診療部), 佐々木剛, 中里道子, 伊豫雅臣
児童思春期の社会不安障害に対する認知行動療法 精神科(1347-4790)16巻5号 Page473-478(2010.05)
伊豫雅臣(千葉大学 大学院医学研究院精神医学)
2009年における統合失調症研究のトピックス 精神薬療研究年報(1346-1702)42号 Page9-10(2010.03)
伊豫雅臣(千葉大学 大学院医学研究院精神医学)
社会不安障害の診断と治療 臨床精神薬理(1343-3474)13巻4号 Page699-704(2010.04)
Fukami G, Hashimoto T, Shirayama Y, Hasegawa T, Watanabe H, Fujisaki M, Hashimoto K, Iyo M.
Effects of etizolam and ethyl loflazepate on the P300 event-related potential in healthy subjects. Ann Gen Psychiatry. 2010 Nov 3
Tanibuchi Y, Shimagami M, Fukami G, Sekine Y, Iyo M, Hashimoto K.
A case of methamphetamine use disorder treated with the antibiotic drug minocycline. Gen Hosp Psychiatry. 2010 Sep-Oct;32(5):559.e1-3. Epub 2010 Jan 21
Kobayashi H, Ujike H, Iwata N, Inada T, Yamada M, Sekine Y, Uchimura N, Iyo M, Ozaki N, Itokawa M, Sora I.
The adenosine A2A receptor is associated with methamphetamine dependence/psychosis in the Japanese population. Behav Brain Funct. 2010 Aug 30
Kishi T, Fukuo Y, Okochi T, Kitajima T, Kawashima K, Naitoh H, Ujike H, Inada T, Yamada M, Uchimura N, Sora I, Iyo M, Ozaki N, Iwata N.
Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population. Drug Alcohol Depend. 2010 Aug 10.
Shirayama Y, Muneoka K, Fukumoto M, Tadokoro S, Fukami G, Hashimoto K, Iyo M.
Infusions of allopregnanolone into the hippocampus and amygdala, but not into the nucleus accumbens and medial prefrontal cortex, produce antidepressant effects on the learned helplessness rats. Hippocampus. 2010 Jul 9.
Niitsu T, Shirayama Y, Fujisaki M, Hashimoto K, Iyo M.
Fluvoxamine improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1345-6. Epub 2010 Jun 19
Kishi T, Kitajima T, Tsunoka T, Okumura T, Okochi T, Kawashima K, Inada T, Ujike H, Yamada M, Uchimura N, Sora I, Iyo M, Ozaki N, Iwata N.
PROKR2 is associated with methamphetamine dependence in the Japanese population. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):1033-6. Epub 2010 May 24
Nakazato M, Hashimoto K, Schmidt U, Tchanturia K, Campbell IC, Collier DA, Iyo M, Treasure J.
Serum glutamine, set-shifting ability and anorexia nervosa. Ann Gen Psychiatry. 2010 Jun 25
Shiina A, Shirayama Y, Niitsu T, Hashimoto T, Yoshida T, Hasegawa T, Haraguchi T, Kanahara N, Shiraishi T, Fujisaki M, Fukami G, Nakazato M, Iyo M, Hashimoto K.
A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry. 2010 Jun 24
Tanibuchi Y, Wu J, Toyohara J, Fujita Y, Iyo M, Hashimoto K.
Characterization of [(3)H]CHIBA-1001 binding to alpha7 nicotinic acetylcholine receptors in the brain from rat, monkey, and human. Brain Res. 2010 Aug 12;1348:200-8. Epub 2010 Jun 9
Arai M, Yuzawa H, Nohara I, Ohnishi T, Obata N, Iwayama Y, Haga S, Toyota T, Ujike H, Arai M, Ichikawa T, Nishida A, Tanaka Y, Furukawa A, Aikawa Y, Kuroda O, Niizato K, Izawa R, Nakamura K, Mori N, Matsuzawa D, Hashimoto K, Iyo M, Sora I, Matsushita M, Okazaki Y, Yoshikawa T, Miyata T, Itokawa M.
Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry. 2010 Jun
Matsuda S, Matsuzawa D, Nakazawa K, Sutoh C, Ohtsuka H, Ishii D, Tomizawa H, Iyo M, Shimizu E.
d-serine enhances extinction of auditory cued fear conditioning via ERK1/2 phosphorylation in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16
Tsunoka T, Kishi T, Kitajima T, Okochi T, Okumura T, Yamanouchi Y, Kinoshita Y, Kawashima K, Naitoh H, Inada T, Ujike H, Yamada M, Uchimura N, Sora I, Iyo M, Ozaki N, Iwata N.
Association analysis of GRM2 and HTR2A with methamphetamine-induced psychosis and schizophrenia in the Japanese population. Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30;34(4):639-44. Epub 2010 Mar 6
Ishii D, Matsuzawa D, Kanahara N, Matsuda S, Sutoh C, Ohtsuka H, Nakazawa K, Kohno M, Hashimoto K, Iyo M, Shimizu E.
Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway. Neurosci Lett. 2010 Feb 26;471(1):53-7. Epub 2010 Jan 18

2009年開く閉じる

椎名明大(千葉大学医学部附属病院 精神神経科), 小田靖典, 鈴木正利, 吉澤雅弘, 原口正, 藤崎美久, 五十嵐禎人, 伊豫雅臣
心神喪失者等医療観察法と地域サポート 医療観察法の現状と課題 日本社会精神医学会雑誌(0919-1372)18巻2号 Page252-258(2009.11)
橋本謙二(千葉大学社会精神保健教育研究センター 病態解析研究部門), 伊豫雅臣
【精神医学Update　最新研究動向】最新・疾患研究動向【重要疾患・研究トピックス】薬物依存症の脳画像研究と新しい治療法 医学のあゆみ(0039-2359)231巻10号 Page1079-1082(2009.12)
伊豫雅臣( 千葉大学大学院医学研究院精神医学), 椎名明大, 松原三郎, 川田和人, 吉川明弘, 三邉義雄, 畠稔, 福島秀行, 岩崎弥生, 小宮浩美, 小宮山徳太郎, 南風原泰, 篠田守, 佐々木一, 羽間京子, 佐竹直子
退院促進に関する精神医療の質的実態把握と最適化 精神神経学雑誌(0033-2658)111巻9号 Page1165-1170(2009.09)
原口正( 千葉大学大学院医学研究院精神医学), 清水栄司, 山内直人, 伊豫雅臣
うつ病治療後に職場復帰が成功するための条件因子についてのアンケート調査 産業医学ジャーナル(0388-337X)32巻6号 Page88-93(2009.11)
橋本謙二(千葉大学社会精神保健教育研究センター 病態解析研究部門), 三村將
シグマ受容体リガンドとしてのFluvoxamineの臨床的有用性を考える Progress in Medicine(0287-3648)29巻9号 Page2229-2234(2009.09)
椎名明大(千葉大学医学部附属病院 精神神経科)
ブロナンセリンが著効した統合失調症の1例 Pharma Medica(0289-5803)27巻8号 Page96-98(2009.08)
橋本謙二(千葉大学社会精神保健教育研究センター 病態解析研究部問), 林輝男
うつ病をはじめとする精神疾患におけるシグマ1受容体アゴニストの役割と抗うつ薬の新たな可能性 臨床精神薬理(1343-3474)12巻9号 Page2067-2074(2009.09)
小堀修(イギリス), 清水栄司, 伊豫雅臣
体性感覚障害に対するMirror TherapyとfMRI evidence(会議録/症例報告)
イギリスの認知行動療法セラピストを7年で10,000人養成する計画 千葉医学雑誌(0303-5476)85巻2号 Page93-95(2009.04)
関根吉統( 千葉大学社会精神保健教育研究センター), 橋本謙二, 伊豫雅臣
【依存症の生物学　薬物やアルコールへの依存メカニズムを解く】依存の脳画像解析 Medical Bio(1881-9354)6巻4号 Page36-41(2009.07)
椎名明大(千葉大学医学部附属病院 精神神経科)
【心神喪失者等医療観察法の改正をめぐって】医療観察法の今後　医療観察法で精神科医療は「底上げ」されるか 臨床精神医学(0300-032X)38巻5号 Page739-745(2009.05)
渡邉博幸(総合病院国保旭中央病院 神経精神科)
【統合失調症薬物治療のエッセンス】新規薬剤の臨床的有用性　アリピプラゾールの臨床的有用性(総説/特集) Progress in Medicine(0287-3648)29巻5号 Page1335-1339(2009.05)
橋本謙二(千葉大学社会精神保健教育研究センター 病態解析研究部門)
【統合失調症とうつ病のための新しい生物学的マーカー】脳由来神経栄養因子とうつ病(解説/特集) 脳と精神の医学(0915-7328)20巻1号 Page55-60(2009.03)
中里道子(千葉大学医学部附属病院 こころの診療部), 阿部哲也, 林秀紀, 伊豫雅臣
【心理療法　update】コグニティブ・レメディエイション・セラピー 心療内科(1342-9892)13巻2号 Page122-129(2009.03)
伊豫雅臣( 千葉大学大学院医学研究院精神医学), 浅野誠, 早川達郎, 石毛稔
精神科救急における患者像およびその治療技法　薬物療法を中心に
橋本謙二(千葉大学社会精神保健教育研究センター 病態解析研究部門), ZoharJoseph, 福田正人
強迫性障害に対する薬物療法　シグマ受容体を介したSSRIの新たな可能性 臨床精神薬理(1343-3474)12巻4号 Page781-790(2009.04)
橋本謙二(千葉大学社会精神保健教育研究センター 病態解析研究部門)
うつ病治療におけるシグマ1受容体の働き　その最新知見(解説) 臨床精神薬理(1343-3474)12巻3号 Page597-603(2009.03)
橋本謙二(千葉大学社会精神保健教育研究センター 病態解析研究部門)
「身体表現性障害に対するSSRIの有用性について　Fluvoxamineを用いて」の論文に対するコメント 臨床精神薬理(1343-3474)12巻3号 Page521-522(2009.03)
Nanbu M, Kurayama T, Nakazawa K, Matsuzawa D, Komiya Z, Haraguchi T, Ogura H, Hashimoto T, Yoshida S, Iyo M, Shimizu E.
Impaired P50 suppression in fear extinction in obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Dec 24.
Ishii D, Matsuzawa D, Fujita Y, Sutoh C, Ohtsuka H, Matsuda S, Kanahara N, Hashimoto K, Iyo M, Shimizu E.
Enhancement of acoustic prepulse inhibition by contextual fear conditioning in mice is maintained even after contextual fear extinction. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):183-8. Epub 2009 Nov 14.
Shirayama Y, Obata T, Matsuzawa D, Nonaka H, Kanazawa Y, Yoshitome E, Ikehira H, Hashimoto K, Iyo M.
Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage. 2010 Feb 1;49(3):2783-90.
Hagiwara H, Iyo M, Hashimoto K.
Mithramycin protects against dopaminergic neurotoxicity in the mouse brain after administration of methamphetamine. Brain Res. 2009 Dec 8;1301:189-96. Epub 2009 Sep 11.
Kishi T, Tsunoka T, Ikeda M, Kitajima T, Kawashima K, Okochi T, Okumura T, Yamanouchi Y, Kinoshita Y, Ujike H, Inada T, Yamada M, Uchimura N, Sora I, Iyo M, Ozaki N, Iwata N.
Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. Neuropharmacology. 2010 Feb;58(2):452-6. Epub 2009 Sep 10.
Tanibuchi Y, Fujita Y, Kohno M, Ishima T, Takatsu Y, Iyo M, Hashimoto K.
Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of alpha1-adrenoceptors. Eur Neuropsychopharmacol. 2009 Dec;19(12):861-7. Epub 2009 Aug 4.
Okamura N, Reinscheid RK, Ohgake S, Iyo M, Hashimoto K.
Neuropeptide S attenuates neuropathological, neurochemical and behavioral changes induced by the NMDA receptor antagonist MK-801. Neuropharmacology. 2010 Jan;58(1):166-72. Epub 2009 Jul 2.
Ishikawa M, Sakata M, Ishii K, Kimura Y, Oda K, Toyohara J, Wu J, Ishiwata K, Iyo M, Hashimoto K.
High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. Int J Neuropsychopharmacol. 2009 Sep;12(8):1127-31. Epub 2009 Jul 2.
Okahisa Y, Ujike H, Kotaka T, Morita Y, Kodama M, Inada T, Yamada M, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S.
Association between neuropeptide Y gene and its receptor Y1 gene and methamphetamine dependence. Psychiatry Clin Neurosci. 2009 Jun;63(3):417-22.
Iwayama Y, Hattori E, Maekawa M, Yamada K, Toyota T, Ohnishi T, Iwata Y, Tsuchiya KJ, Sugihara G, Kikuchi M, Hashimoto K, Iyo M, Inada T, Kunugi H, Ozaki N, Iwata N, Nanko S, Iwamoto K, Okazaki Y, Kato T, Yoshikawa T.
Association analyses between brain-expressed fatty-acid binding protein (FABP) genes and schizophrenia and bipolar disorder. Prog J Med Genet B Neuropsychiatr Genet. 2009 Jun 24.
Kotaka T, Ujike H, Okahisa Y, Takaki M, Nakata K, Kodama M, Inada T, Yamada M, Uchimura N, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S.
G72 gene is associated with susceptibility to methamphetamine psychosis. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):1046-9. Epub 2009 May 29.
Matsuzawa D, Shirayama Y, Shimizu E, Hashimoto K, Iyo M.
Evaluating the cognitive decline in early-stage frontotemporal dementia. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):1077-9. Epub 2009 May 15.
Kunitachi S, Fujita Y, Ishima T, Kohno M, Horio M, Tanibuchi Y, Shirayama Y, Iyo M, Hashimoto K.
Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res. 2009 Jul 7;1279:189-96. Epub 2009 May 9.
Okochi T, Kishi T, Ikeda M, Kitajima T, Kinoshita Y, Kawashima K, Okumura T, Tsunoka T, Inada T, Yamada M, Uchimura N, Iyo M, Sora I, Ozaki N, Ujike H, Iwata N.
Genetic association analysis of NRG1 with methamphetamine-induced psychosis in a Japanese population. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 1;33(5):903-5. Epub 2009 Apr 24.
Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Tsunoka T, Okumura T, Inada T, Ujike H, Yamada M, Uchimura N, Sora I, Iyo M, Ozaki N, Iwata N.
A functional polymorphism in estrogen receptor alpha gene is associated with Japanese methamphetamine induced psychosis. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 1;33(5):895-8. Epub 2009 Apr 19.
Nakamura K, Sekine Y, Takei N, Iwata Y, Suzuki K, Anitha A, Inada T, Harano M, Komiyama T, Yamada M, Iwata N, Iyo M, Sora I, Ozaki N, Ujike H, Mori N.
An association study of monoamine oxidase A (MAOA) gene polymorphism in methamphetamine psychosis. Neurosci Lett. 2009 May 15;455(2):120-3. Epub 2009 Feb 26.
Toyohara J, Sakata M, Wu J, Ishikawa M, Oda K, Ishii K, Iyo M, Hashimoto K, Ishiwata K.
Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping alpha7 nicotinic receptors by positron emission tomography. Ann Nucl Med. 2009 May;23(3):301-9. Epub 2009 Apr 1.
Ujike H, Katsu T, Okahisa Y, Takaki M, Kodama M, Inada T, Uchimura N, Yamada M, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S.
Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jun 15;33(4):625-9. Epub 2009 Mar 10.
Hattori E, Toyota T, Ishitsuka Y, Iwayama Y, Yamada K, Ujike H, Morita Y, Kodama M, Nakata K, Minabe Y, Nakamura K, Iwata Y, Takei N, Mori N, Naitoh H, Yamanouchi Y, Iwata N, Ozaki N, Kato T, Nishikawa T, Kashiwa A, Suzuki M, Shioe K, Shinohara M, Hirano M, Nanko S, Akahane A, Ueno M, Kaneko N, Watanabe Y, Someya T, Hashimoto K, Iyo M, Itokawa M, Arai M, Nankai M, Inada T, Yoshida S, Kunugi H, Nakamura M, Iijima Y, Okazaki Y, Higuchi T, Yoshikawa T.
Preliminary genome-wide association study of bipolar disorder in the Japanese population. Prog J Med Genet B Neuropsychiatr Genet. 2009 Dec 5;150B(8):1110-7.
Ohgake S, Shimizu E, Hashimoto K, Okamura N, Koike K, Koizumi H, Fujisaki M, Kanahara N, Matsuda S, Sutoh C, Matsuzawa D, Muramatsu H, Muramatsu T, Iyo M.
Dopaminergic hypofunctions and prepulse inhibition deficits in mice lacking midkine. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):541-6. Epub 2009 Feb 13.
Hashimoto K, Fujita Y, Horio M, Kunitachi S, Iyo M, Ferraris D, Tsukamoto T.
Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry. 2009 Jun 15;65(12):1103-6. Epub 2009 Feb 12.
Kanahara N, Shimizu E, Sekine Y, Uchida Y, Shibuya T, Yamanaka H, Hashimoto T, Asaka T, Sasaki T, Miyatake R, Ohkami T, Fukami G, Fujisaki M, Watanabe H, Shirayama Y, Hayashi H, Hashimoto K, Asano M, Iyo M.
Does hypofrontality expand to global brain area in progression of schizophrenia?: a cross-sectional study between first-episode and chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):410-5. Epub 2009 Jan 6.

2008年開く閉じる

深見悟郎(千葉大学医学部附属病院 精神神経科・こどものこころ診療部)
【精神科医の仕事】Q&A集　「気分はどうですか?」というような診療で交わす会話も精療法なのでしょうか? こころのりんしょうa・la・carte(0288-0512)27巻4号 Page514(2008.12)
深見悟郎(千葉大学医学部附属病院 精神神経科・こどものこころ診療部)
【精神科医の仕事】 Q&A集　外来での診察時間は、何分くらいほしいですか? こころのりんしょうa・la・carte(0288-0512)27巻4号 Page513(2008.12)
伊豫雅臣( 千葉大学大学院医学研究院精神医学)
覚せい剤関連精神障害におけるドパミン神経傷害と酸化ストレス 北陸神経精神医学雑誌(0913-7378)22巻2号 Page1-4(2008.12)
橋本謙二(千葉大学社会精神保健教育研究センター 病態解析研究部門)
うつ病治療におけるシグマ1受容体とその臨床的意義　シグマ1受容体に関する基礎的および臨床的知見 臨床精神薬理(1343-3474)12巻2号 Page355-361(2009.02)
渡邉博幸( 千葉大学大学院医学研究院精神医学)
薬の使い方シリーズ　Quetiapineを使いこなす　切り替え　前薬からの切り替えにquetiapineの効果が期待できるのはどのような臨床場面か? 臨床精神薬理(1343-3474)12巻2号 Page337-344(2009.02)
木村大( 千葉大学大学院医学研究院精神医学教室), 白山幸彦, 新津富央, 高田護, 椎名明大, 伊豫雅臣
双極性障害の患者が寛解後に高齢になって呈した躁状態に対する考察　脳血管障害の関与について Bipolar Disorder6巻 Page21-25(2008.05)
渡邉博幸( 千葉大学大学院医学研究院精神医学)
エビデンスの読み方・使い方　千葉大学精神科統合失調症薬物治療手順2007　エビデンスに基づく治療アルゴリズムはユーザーの役に立つのか? 臨床薬理(0388-1601)39巻5号 Page225-230(2008.09)
橋本謙二( 千葉大学社会精神保健教育センター病態解析研究部門)
【こころのお薬】仮説の矛盾点 こころのりんしょうa・la・carte(0288-0512)27巻3号 Page484-488(2008.09)
橋本謙二( 千葉大学社会精神保健教育センター病態解析研究部門)
【こころのお薬】今後期待される抗精神病薬と、その作用メカニズム こころのりんしょうa・la・carte(0288-0512)27巻3号 Page469-472(2008.09)
倉山太一( 千葉大学大学院医学研究院神経情報統合生理学), 橋本佐, 織田泰寛, 鈴木智嵩, 南部誠, 松澤大輔, 中澤健, 吉田晋, 伊豫雅臣, 清水栄司
強迫性障害における事象関連電位の異常 強迫性障害の研究9巻 Page73-78(2008.05)
伊豫雅臣( 千葉大学大学院医学研究院精神医学)
高力価短時間作用型ベンゾジアゼピン系薬のinterdose rebound anxiety,insomniaが長時間作用型への切り替えによって軽快したパニック障害の1例 臨床精神薬理(1343-3474)11巻9号 Page1735-1740(2008.09)
萩原裕子(千葉大学社会精神保健教育研究センター 病態解析研究部門), 橋本謙二
末梢血因子を用いた精神疾患診断法の進歩　薬物依存症における脳-末梢関連に関する最新知見 日本アルコール・薬物医学会雑誌(1341-8963)43巻2号 Page77-86(2008.04)
伊豫雅臣( 千葉大学大学院医学研究院精神医学), 渡邊衡一郎
服薬アドヒアランスによる統合失調症再発予防 臨床精神薬理(1343-3474)11巻8号 Page1607-1615(2008.08)
村崎光邦(CNS薬理研究所), 小山司, 伊豫雅臣, 石郷岡純, 上島国利, 八木剛平, 尾崎紀夫, 福居顯二, 武田雅俊, 米田博, 木下利彦, 神庭重信, 前田久雄
Perospironeの初発統合失調症に対する市販後調査　有効性と安全性の検討 臨床精神薬理(1343-3474)11巻8号 Page1531-1550(2008.08)
新津富央( 千葉大学大学院医学研究院精神医学), 渡邉博幸, 伊豫雅臣
【向精神薬をどう使い分けるか】統合失調症治療に非定型抗精神病薬をどう使い分けるか 精神科(1347-4790)12巻6号 Page478-484(2008.06)
橋本謙二(千葉大学社会精神保健教育研究センター 病態解析研究部門), HindmarchIan, 笠井清登
うつ病・不安障害治療とシグマ受容体　Dr. Ian Hindmarchをお招きして 臨床精神薬理(1343-3474)11巻7号 Page1407-1417(2008.07)
渡邉博幸( 千葉大学大学院医学研究院精神医学)
【最強のエビデンスをめざして　今後の臨床試験への提言】CATIE試験は統合失調症薬物治療にどんな臨床知をもたらすか? 臨床精神薬理(1343-3474)11巻7号 Page1267-1274(2008.07)
上島国利(国際医療福祉大学 医療福祉学部), 伊豫雅臣, 大下隆司, 岡田俊, 中山誠, 三浦宗克
Aripiprazoleをどう使いこなすか 臨床精神薬理(1343-3474)11巻5号 Page995-1011(2008.05)
伊豫雅臣( 千葉大学大学院医学研究院精神医学), 小川嘉正, 橋元佐代子, 宮越久孝, 伏見史久, 今村恭子
Risperidone内用液1mg/mLの使用成績調査　Risperidone内用液の安全性と服薬アドヒアランスの確保に向けて 臨床精神薬理(1343-3474)11巻5号 Page929-945(2008.05)
荒川志保( 千葉大学大学院医学研究院精神医学教室), 伊豫雅臣
【いまremissionを考える　統合失調症治療の新たなゴール】Remissionの基準　その妥当性と展望 Schizophrenia Frontier(1345-8639)8巻4号 Page274-277(2008.01)
伊豫雅臣( 千葉大学大学院医学研究院精神医学), 中込和幸, 渡邊衡一郎, 上島国利
「第2回うつ病の薬物療法についての考え方」実態調査結果　より適切な薬物療法の推進を目的として 臨床精神薬理(1343-3474)11巻4号 Page683-697(2008.04)
橋本謙二(千葉大学社会精神保健教育研究センター 病態解析研究部門)
覚せい剤関連精神障害の治療薬としてのミノサイクリン 日本神経精神薬理学雑誌(1340-2544)28巻1号 Page19-22(2008.02)
Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K, Inada T, Harano M, Komiyama T, Hori T, Yamada M, Iyo M, Sora I, Sekine Y, Ozaki N, Ujike H, Iwata N.
Prostate apoptosis response 4 gene is not associated with methamphetamine-use disorder in the Japanese population. Ann N Y Acad Sci. 2008 Oct;1139:83-8.
Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K, Inada T, Harano M, Komiyama T, Hori T, Yamada M, Iyo M, Sora I, Sekine Y, Ozaki N, Ujike H, Iwata N.
Alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes are not associated with methamphetamine-use disorder in the Japanese population. Ann N Y Acad Sci. 2008 Oct;1139:70-82.
Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K, Inada T, Harano M, Komiyama T, Hori T, Yamada M, Iyo M, Sora I, Sekine Y, Ozaki N, Ujike H, Iwata N.
Glutamate cysteine ligase modifier (GCLM) subunit gene is not associated with methamphetamine-use disorder or schizophrenia in the Japanese population. Ann N Y Acad Sci. 2008 Oct;1139:63-9.
Kinoshita Y, Ikeda M, Ujike H, Kitajima T, Yamanouchi Y, Aleksic B, Kishi T, Kawashima K, Ohkouchi T, Ozaki N, Inada T, Harano M, Komiyama T, Hori T, Yamada M, Sekine Y, Iyo M, Sora I, Iwata N.
Association study of the calcineurin A gamma subunit gene (PPP3CC) and methamphetamine-use disorder in a Japanese population. Ann N Y Acad Sci. 2008 Oct;1139:57-62.
Ezaki N, Nakamura K, Sekine Y, Thanseem I, Anitha A, Iwata Y, Kawai M, Takebayashi K, Suzuki K, Takei N, Iyo M, Inada T, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Mori N.
Short allele of 5-HTTLPR as a risk factor for the development of psychosis in Japanese methamphetamine abusers. Ann N Y Acad Sci. 2008 Oct;1139:49-56.
Kotaka T, Ujike H, Morita Y, Kishimoto M, Okahisa Y, Inada T, Harano M, Komiyama T, Hori T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S.
Association study between casein kinase 1 epsilon gene and methamphetamine dependence. Ann N Y Acad Sci. 2008 Oct;1139:43-8.
Hashimoto K, Nishiyama S, Ohba H, Matsuo M, Kobashi T, Takahagi M, Iyo M, Kitashoji T, Tsukada H.
[11C]CHIBA-1001 as a novel PET ligand for alpha7 nicotinic receptors in the brain: a PET study in conscious monkeys. PLoS One. 2008 Sep 18;3(9):e3231.
Nakazato M, Tchanturia K, Schmidt U, Campbell IC, Treasure J, Collier DA, Hashimoto K, Iyo M.
Brain-derived neurotrophic factor (BDNF) and set-shifting in currently ill and recovered anorexia nervosa (AN) patients. Psychol Med. 2009 Jun;39(6):1029-35. Epub 2008 Aug 28.
Kishimoto M, Ujike H, Okahisa Y, Kotaka T, Takaki M, Kodama M, Inada T, Yamada M, Uchimura N, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S.
The Frizzled 3 gene is associated with methamphetamine psychosis in the Japanese population. Behav Brain Funct. 2008 Aug 15;4:37.
Isono S, Iizuka K, Fukami G, Shinozuka N, Iyo M, Nishino T.
Ubretid (distigmine bromide) taken to treat urinary retention prolongs the effect of suxamethonium. J Anesth. 2008;22(3):337. Epub 2008 Aug 7.
Ishima T, Nishimura T, Iyo M, Hashimoto K.
Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Oct 1;32(7):1656-9. Epub 2008 Jul 2.
Kanahara N, Iyo M, Hashimoto K.
Failure to confirm the association between the PIK4CA gene and schizophrenia in a Japanese population. Prog J Med Genet B Neuropsychiatr Genet. 2009 Apr 5;150B(3):450-2.
Nishimura T, Ishima T, Iyo M, Hashimoto K.
Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One. 2008 Jul 2;3(7):e2558.
Kanahara N, Miyatake R, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iyo M, Hashimoto K.
Association study between the PIK4CA gene and methamphetamine use disorder in a Japanese population. Prog J Med Genet B Neuropsychiatr Genet. 2009 Mar 5;150B(2):233-8.
Matsuzawa D, Hashimoto K, Hashimoto T, Shimizu E, Watanabe H, Fujita Y, Iyo M.
Association study between the genetic polymorphisms of glutathione-related enzymes and schizophrenia in a Japanese population. Prog J Med Genet B Neuropsychiatr Genet. 2009 Jan 5;150B(1):86-94.
Kanahara N, Shimizu E, Ohgake S, Fujita Y, Kohno M, Hashimoto T, Matsuzawa D, Shirayama Y, Hashimoto K, Iyo M.
Glycine and D: -serine, but not D: -cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology (Berl). 2008 Jun;198(3):363-74. Epub 2008 Apr 24.
Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, Takanashi J, Matsuda T, Shimizu E, Ikehira H, Iyo M, Hashimoto K.
Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One. 2008 Apr 9;3(4):e1944.
Uhl GR, Drgon T, Liu QR, Johnson C, Walther D, Komiyama T, Harano M, Sekine Y, Inada T, Ozaki N, Iyo M, Iwata N, Yamada M, Sora I, Chen CK, Liu HC, Ujike H, Lin SK.
Genome-wide association for methamphetamine dependence: convergent results from 2 samples. Arch Gen Psychiatry. 2008 Mar;65(3):345-55.
Otani K, Ujike H, Sakai A, Okahisa Y, Kotaka T, Inada T, Harano M, Komiyama T, Hori T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S.
Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence. Neurosci Lett. 2008 Mar 21;434(1):88-92. Epub 2008 Jan 19.
Iyo M, Shirayama Y, Watanabe H, Fujisaki M, Miyatake R, Fukami G, Shiina A, Nakazato M, Shiraishi T, Ookami T, Hashimoto K.
Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):1072-3. Epub 2008 Jan 16.
Hashimoto T, Hashimoto K, Miyatake R, Matsuzawa D, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iyo M.
Association study between polymorphisms in glutathione-related genes and methamphetamine use disorder in a Japanese population. Prog J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1040-6.
Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K.
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol. 2008 Jun;18(6):448-54. Epub 2007 Dec 31.
Fujita Y, Ishima T, Kunitachi S, Hagiwara H, Zhang L, Iyo M, Hashimoto K.
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):336-9. Epub 2007 Aug 29.

2007年開く閉じる

伊豫雅臣
【期待される新規作用機序の精神科治療薬】期待される新規作用機序の抗精神病薬　ドパミン仮説からグルタミン酸仮説へ 臨床精神薬理　VO:10:1979-1985，2007.11
伊豫雅臣
【スローガン:守ること育むこと】摂食障害に関する最近の知見　脳由来神経成長因子と認知行動療法について 児童青年精神医学とその近接領域VO:48:480，2007.08
松澤大輔, 福本誠, 田中優子, 藤崎美久, 渡邉博幸, 白山一彦, 清水栄司, 伊豫雅臣
高齢者に対するロフラゼプ酸エチル(メイラックス)の有効性、安全性の検討 新薬と臨床　VO:56:1079-1085，2007.07
伊豫雅臣
自立生活を支える統合失調症薬物治療　服薬アドヒアランスに関する「千葉県の精神科臨床医による、統合失調症の薬物療法コンセンサス」からの考察 臨床精神薬理VO:10:1327-1339，2007.07
石川雅智, 橋本謙二, 伊豫雅臣
【精神疾患におけるシグマ受容体の役割】PETによるシグマ1受容体測定の意義 臨床精神薬理VO:10:1229-1236，2007.07
伊豫雅臣
【統合失調症の認知機能障害】病態と治療 臨床精神薬理VO:10:1147-1152，2007.07
伊豫雅臣
森田療法と認知療法の対話 不安障害に対する認知行動療法と森田療法について 日本森田療法学会雑誌VO:18:35-38，2007.04
橋本謙二, 澤明, 伊豫雅臣
ヒト死後脳を用いた精神疾患の病態研究　死後脳におけるアミノ酸濃度に関する研究 精神薬療研究年報　39:185-189，2007.03
清水栄司, 大掛真太郎, 白山幸彦, 橋本謙二, 伊豫雅臣
ミドカイン欠損マウスにおけるプレパルス抑制障害機構と抗精神病薬の改善効果 精神薬療研究年報39:89-93，2007.03
Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K.
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol. 2008 Jun;18(6):448-54. Epub 2007 Dec 31.
Takeshita M, Yamada K, Hattori E, Iwayama Y, Toyota T, Iwata Y, Tsuchiya KJ, Sugihara G, Hashimoto K, Watanabe H, Iyo M, Kikuchi M, Okazaki Y, Yoshikawa T.
Genetic examination of the PLXNA2 gene in Japanese and Chinese people with schizophrenia. Schizophr Res. 2008 Feb;99(1-3):359-64. Epub 2007 Dec 11.
Fujita Y, Ishima T, Kunitachi S, Hagiwara H, Zhang L, Iyo M, Hashimoto K.
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):336-9. Epub 2007 Aug 29.
Hashimoto T, Shimizu E, Koike K, Orita Y, Suzuki T, Kanahara N, Matsuzawa D, Fukami G, Miyatake R, Shinoda N, Fujisaki M, Shirayama Y, Hashimoto K, Iyo M.
Deficits in auditory P50 inhibition in obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):288-96. Epub 2007 Aug 24.
Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M.
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacol. 2008 Jun;18(6):414-21. Epub 2007 Sep 4.
Okamura N, Hashimoto K, Iyo M, Shimizu E, Dempfle A, Friedel S, Reinscheid RK.
Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1444-8. Epub 2007 Jul 3.
Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K.
High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry. 2007 Oct 15;62(8):878-83. Epub 2007 Jul 30.
Matsuzawa D, Hashimoto K, Miyatake R, Shirayama Y, Shimizu E, Maeda K, Suzuki Y, Mashimo Y, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Hata A, Sawa A, Iyo M.
Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry. 2007 Jul;164(7):1105-14.
Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, Tsukada H, Iyo M.
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol Psychiatry. 2008 Jan 1;63(1):92-7. Epub 2007 Jun 28.
Morita Y, Ujike H, Tanaka Y, Kishimoto M, Okahisa Y, Kotaka T, Harano M, Inada T, Komiyama T, Hori T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S.
The glycine transporter 1 gene (GLYT1) is associated with methamphetamine-use disorder. Am J Med Genet B Neuropsychiatr Genet. 2008 Jan 5;147B(1):54-8.
Hashimoto K, Sawa A, Iyo M.
Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. 2007 Dec 1;62(11):1310-6. Epub 2007 Jun 15.
Kishimoto M, Ujike H, Motohashi Y, Tanaka Y, Okahisa Y, Kotaka T, Harano M, Inada T, Yamada M, Komiyama T, Hori T, Sekine Y, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S.
The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biol Psychiatry. 2008 Jan 15;63(2):191-6. Epub 2007 Jun 6.
Tsuchiya KJ, Hashimoto K, Iwata Y, Tsujii M, Sekine Y, Sugihara G, Matsuzaki H, Suda S, Kawai M, Nakamura K, Minabe Y, Yagi A, Iyo M, Takei N, Mori N.
Decreased serum levels of platelet-endothelial adhesion molecule (PECAM-1) in subjects with high-functioning autism: a negative correlation with head circumference at birth. Biol Psychiatry. 2007 Nov 1;62(9):1056-8. Epub 2007 May 23.
Tomiya M, Fukushima T, Watanabe H, Fukami G, Fujisaki M, Iyo M, Hashimoto K, Mitsuhashi S, Toyo'oka T.
Alterations in serum amino acid concentrations in male and female schizophrenic patients. Clin Chim Acta. 2007 May 1;380(1-2):186-90. Epub 2007 Feb 15.
Ikeda M, Ozaki N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y, Kishi T, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Inada T, Iwata N.
Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia. Genes Brain Behav. 2007 Feb;6(1):107-12.
Zhang L, Shirayama Y, Iyo M, Hashimoto K.
Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology. 2007 Sep;32(9):2004-10. Epub 2007 Jan 17.
Shimizu E, Imai M, Fujisaki M, Shinoda N, Handa S, Watanabe H, Nakazato M, Hashimoto K, Iyo M.
Maintenance electroconvulsive therapy (ECT) for treatment-resistant disorganized schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):571-3. Epub 2006 Dec 20.
Fukushima T, Mitsuhashi S, Tomiya M, Iyo M, Hashimoto K, Toyo'oka T.
Determination of kynurenic acid in human serum and its correlation with the concentration of certain amino acids. Clin Chim Acta. 2007 Feb;377(1-2):174-8. Epub 2006 Sep 30.
Nakajima M, Hattori E, Yamada K, Iwayama Y, Toyota T, Iwata Y, Tsuchiya KJ, Sugihara G, Hashimoto K, Watanabe H, Iyo M, Hoshika A, Yoshikawa T.
Association and synergistic interaction between promoter variants of the DRD4 gene in Japanese schizophrenics. J Hum Genet. 2007;52(1):86-91. Epub 2006 Nov 7.
Related Articles Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, Sekine Y, Suzuki K, Minabe Y, Takei N, Iyo M, Mori N.
Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1529-31. Epub 2006 Jul 28. Erratum in: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):592.
Shimizu E, Watanabe H, Kojima T, Hagiwara H, Fujisaki M, Miyatake R, Hashimoto K, Iyo M.
Combined intoxication with methylone and 5-MeO-MIPT. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):288-91. Epub 2006 Jul 28.
Shinohe A, Hashimoto K, Nakamura K, Tsujii M, Iwata Y, Tsuchiya KJ, Sekine Y, Suda S, Suzuki K, Sugihara G, Matsuzaki H, Minabe Y, Sugiyama T, Kawai M, Iyo M, Takei N, Mori N.
Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1472-7. Epub 2006 Jul 24. Erratum in: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):590.

2006年開く閉じる

伊豫雅臣
【今日の精神科治療指針2006】精神障害の治療指針 精神作用物質依存 臨床精神医学　2006年増刊:59-63，:2006.12
伊豫雅臣, 足立嘉樹, 小羽俊士, 柴田勳, 三浦宗克, IqbalNaveed
米国でのaripiprazoleの臨床経験から 臨床精神薬理VO:9:2512-2522，2006.12
伊豫雅臣, 稲田俊也, 小松尚也, 早川達郎, 渡邉博幸
統合失調症の治療戦略　アルゴリズムをどのように活用するか 臨床精神薬理VO:9:2333-2348，2006.11
小泉裕紀, 伊豫雅臣
【肥満・摂食のニューロサイエンス】摂食調節系　神経栄養因子による摂食調節 C ical Neuroscience　VO:24:893-895，2006.08
渡邉博幸, 吉村政之, 中里道子, 清水栄司, 伊豫雅臣
社会不安障害(SAD)への取り組みの現状　認知モデルの援用により,診断治療が可能となった社会不安障害の2症例 臨床精神薬理VO:9:1474-1478，2006.07
深見悟郎, 伊豫雅臣
【統合失調症　診断と治療の今日】診断,病態と治療 入院治療 カレントテラピー　VO:24:605-610，2006.06
藤崎美久, 伊豫雅臣, 橋本謙二
千葉県における精神鑑定,措置入院治療等の実態に関する調査研究 千葉医学雑誌　VO:82:163-169，2006.06
深見悟郎, 中里道子, 谷渕由布子, 渡邊博幸, 小松尚也, 伊豫雅臣:大学病院における精神科救急 自傷行為を繰り返す身体合併症患者への危機回避的介入 精神科救急VO:9:109-115，2006.05
倉田健一, 田村達辞, 近藤直樹, 成瀬暢也, 伊豫雅臣, 尾崎茂, 小沼杏坪
【薬物関連精神障害に対する治療的対応】薬物(アルコールを含む)関連精神障害に関する精神科医師の意識調査結果について 精神科救急　VO:9:102-106，2006.05
榎原雅代, 渡辺博幸, 伊豫雅臣
【抗精神病薬のスイッチング】スイッチングの基礎知識 臨床精神薬理VO:9:829-833，2006.05
橋本謙二, 張琳, 北市清幸, 藤本洋平, 中山寛尚, 清水栄司, 伊豫雅臣
覚せい剤投与による行動異常およびドパミン神経系の障害におけるミノサイクリンの改善作用 精神薬療研究年報38:221-225，2006.03
伊豫雅臣
【Aripiprazoleのすべて】Aripiprazoleの薬理と脳内ドパミンD2受容体占拠率 臨床精神薬理VO:9:191-196，2006.02
橋本謙二, 伊豫雅臣
【グルタミン酸受容体　分子機構から治療戦略へ】グルタミン酸受容体拮抗薬・作用薬の神経保護作用　mGluR GroupII作動薬の神経保護作用 Clinical Neuroscience VO:24:197-199，2006.02
Hashimoto K, Fujita Y, Ishima T, Hagiwara H, Iyo M.
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: Role of a7 nicotinic receptors. Eur J Pharmacol. 2006 Dec 28; 553(1-3): 191-195.
Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, Sekine Y, Suzuki K, Minabe Y, Takei N, Iyo M, Mori N.
Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. Prog Neuropharmacol Biol Psychiatry. 2006 Dec 30; 30(8): 1529-1531.
Shinohe A, Hashimoto K, Nakamura K, Tsujii M, Iwata Y, Tsuchiya KJ, Sekine Y, Suda S, Suzuki K, Sugihara G, Matsuzaki H, Minabe Y, Sugiyama T, Kawai M, Iyo M, Takei N, Mori N.
Increased serum levels of glutamate in adult patients with autism. Prog Neuropharmacol Biol Psychiatry. 2006 Dec 30; 30(8): 1472-1477.
Zhang L, Kitaichi K, Fujimoto Y, Nakayama H, Shimizu E, Iyo M, Hashimoto K.
Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropharmacol Biol Psychiatry. 2006 Dec 30; 30(8): 1381-1393.
Koizumi H, Hashimoto K, Iyo M.
Dietary restriction changes behaviors in brain-derived neurotrophic factor heterozygous mice: role of serotonergic system. Eur J Neurosci. 2006 Oct; 24(8): 2335-2344.
Hashimoto K.
The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs. Clin Psychopharmacol Neurosci. 2006 Aug; 4 (1): 3-10.
Zhang L, Shirayama Y, Shimizu E, Iyo M, Hashimoto K.
Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur J Pharmacol. 2006 Aug 21; 544(1-3): 1-9.
Nakazato M, Hashimoto K, Yoshimura K, Hashimoto T, Shimizu E, Iyo M.
No change between the serum brain-derived neurotrophic factor in female patients with anorexia nervosa before and after partial weight recovery. Prog Neuropharmacol Biol Psychiatry. 2006 Aug; 30(6): 1117-1121.
Tatsumi R, Fujio M, Takanashi S, Numata A, Katayama J, Satoh H, Shiigi Y, Maeda J, Kuriyama M, Horikawa T, Murozono T, Hashimoto K, Tanaka, H.
(R)-3’-(3-Methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5’-oxazolidin]-2’-one, a novel and potent a7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties. J Med Chem. 2006 Jul 13; 49(14): 4374-4383.
Hashimoto K, Ishiwata K.
Sigma receptor ligands: Possible applications as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des. 2006; 12(30): 3857-3876.
Hayashi Y, Ishibashi H, Hahimoto K, Nakanishi H.
Potentiation of the NMDA receptor-mediated responses through the activation of the glycine site by microglia secreting soluble factors. Glia. 2006 Apr 15; 53(6): 660-668.
Ozawa K,Hahimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M.
Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry. 2006 Mar 15; 59(6): 546-554.
Iwayama Y,Hahimoto K, Nakajima M, Toyota T, Yamada K, Shimizu E, Itokawa M, Hoshika A, Iyo M, Yoshikawa T.
Analysis of correlation between serum D-serine levels and functional promoter polymorphisms of GRIN2A and GRIN2B genes. Neurosci Lett. 2006 Feb 13; 394(2): 101-104.
Shimizu E,Hashimoto K, Ohgake S, Koizumi H, Okamura N, Koike K, Fujisaki M, Iyo M.
Association between angiotensin I-converting enzyme insertion/deletion gene functional polymorphism and novelty seeking personality in healthy females. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan; 30(1): 99-103.
Hashimoto K.
Glycine transporter inhibitors as therapeutic agents for schizophrenia. Recent Patents on CNS Drug Discovery. 2006 Jan; 1: 43-53.
Morio A, Ujike H, Nomura A, Tanaka Y, Morita Y, Otani K, Kishimoto M, Harano M, Inada T, Komiyama T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S.
No association between CART (cocaine- and amphetamine-regulated transcript) gene and methamphetamine dependence. Ann N Y Acad Sci. 2006 Aug;1074:411-7. PMID: 17105939 [PubMed - indexed for MEDLINE]
Nomura A, Ujike H, Tanaka Y, Kishimoto M, Otani K, Morita Y, Morio A, Harano M, Inada T, Yamada M, Komiyama T, Hori T, Sekine Y, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S.
Association study of the tumor necrosis factor-alpha gene and its 1A receptor gene with methamphetamine dependence. Ann N Y Acad Sci. 2006 Aug;1074:116-24. PMID: 17105909 [PubMed - indexed for MEDLINE]
Ujike H, Sakai A, Nakata K, Tanaka Y, Kodaka T, Okahisa Y, Harano M, Inada T, Yamada M, Komiyama T, Hori T, Sekine Y, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S.
Association study of the dihydropyrimidinase-related protein 2 gene and methamphetamine psychosis. Ann N Y Acad Sci. 2006 Aug;1074:90-6. PMID: 17105906 [PubMed - indexed for MEDLINE]
Nakajima M, Hattori E, Yamada K, Iwayama Y, Toyota T, Iwata Y, Tsuchiya KJ, Sugihara G, Hashimoto K, Watanabe H, Iyo M, Hoshika A, Yoshikawa T.
Association and synergistic interaction between promoter variants of the DRD4 gene in Japanese schizophrenics. J Hum Genet. 2007;52(1):86-91. Epub 2006 Nov 7. PMID: 17089069 [PubMed - indexed for MEDLINE]
Aoyama N, Takahashi N, Kitaichi K, Ishihara R, Saito S, Maeno N, Ji X, Takagi K, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iwata N, Inada T, Ozaki N.
Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin Exp Res. 2006 Oct;30(10):1644-9. PMID: 17010131 [PubMed - indexed for MEDLINE]
Shinohe A, Hashimoto K, Nakamura K, Tsujii M, Iwata Y, Tsuchiya KJ, Sekine Y, Suda S, Suzuki K, Sugihara G, Matsuzaki H, Minabe Y, Sugiyama T, Kawai M, Iyo M, Takei N, Mori N.
Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1472-7. Epub 2006 Jul 24. Erratum in: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):590. PMID: 16863675 [PubMed - indexed for MEDLINE]
Suzuki A, Nakamura K, Sekine Y, Minabe Y, Takei N, Suzuki K, Iwata Y, Kawai M, Takebayashi K, Matsuzaki H, Iyo M, Ozaki N, Inada T, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Mori N.
An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder. Psychiatr Genet. 2006 Aug;16(4):133-8. PMID: 16829779 [PubMed - indexed for MEDLINE]
Nakamura K, Chen CK, Sekine Y, Iwata Y, Anitha A, Loh el-W, Takei N, Suzuki A, Kawai M, Takebayashi K, Suzuki K, Minabe Y, Tsuchiya K, Yamada K, Iyo M, Ozaki N, Inada T, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Ball DM, Yoshikawa T, Lin SK, Mori N.
Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations. Hum Genet. 2006 Sep;120(2):243-52. Epub 2006 Jun 29. PMID: 16807759 [PubMed - indexed for MEDLINE]
Kobayashi H, Hata H, Ujike H, Harano M, Inada T, Komiyama T, Yamada M, Sekine Y, Iwata N, Iyo M, Ozaki N, Itokawa M, Naka M, Ide S, Ikeda K, Numachi Y, Sora I.
Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis. Am J Med Genet B Neuropsychiatr Genet. 2006 Jul 5;141(5):482-6. PMID: 16741914 [PubMed - indexed for MEDLINE]
Suyama E, Iyo M, Taira K.
siRNAs generated by recombinant human Dicer induce specific and significant but target site-independent gene silencing in human cells. Nucleic Acids Res. 2006 May 2;34(8):2153. Print 2006. No abstract available. PMID: 16670428 [PubMed - indexed for MEDLINE]
Nomura A, Ujike H, Tanaka Y, Otani K, Morita Y, Kishimoto M, Morio A, Harano M, Inada T, Yamada M, Komiyama T, Sekine Y, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S.
Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence. Neurosci Lett. 2006 May 29;400(1-2):158-62. Epub 2006 Mar 9. PMID: 16529859 [PubMed - indexed for MEDLINE]
Hattori K, Uchino S, Isosaka T, Maekawa M, Iyo M, Sato T, Kohsaka S, Yagi T, Yuasa S.
Fyn is required for haloperidol-induced catalepsy in mice. J Biol Chem. 2006 Mar 17;281(11):7129-35. Epub 2006 Jan 10. PMID: 16407246 [PubMed - indexed for MEDLINE]
Ide S, Kobayashi H, Ujike H, Ozaki N, Sekine Y, Inada T, Harano M, Komiyama T, Yamada M, Iyo M, Iwata N, Tanaka K, Shen H, Iwahashi K, Itokawa M, Minami M, Satoh M, Ikeda K, Sora I.
Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms. Pharmacogenomics J. 2006 May-Jun;6(3):179-88. PMID: 16402083 [PubMed - indexed for MEDLINE]

2005年開く閉じる

原口正, 渡邉博幸, 浅香琢也, 橋本佐, 佐藤康一, 清水栄司, 小松尚也, 伊豫雅臣
【Clozapine症例集】Clozapineにより無顆粒球症を呈し,G-CSF製剤により回復した1例 臨床精神薬理，VO:8:2066-2070，2005.12
井貫正彦, 中里道子, 野々村司, 熊切力, 西澤馨, 清水栄司, 伊豫雅臣
【Clozapine症例集】Clozapineのtherapeutic window(有効血中濃度域)の存在が示された治療抵抗性統合失調症の1例 臨床精神薬理VO:8:2060-2065，2005.12
清水栄司, 今井逸雄, 藤崎美久, 篠田直之, 半田聡, 中里道子, 渡邊博幸, 米澤洋介, 木村章, 橋本謙二, 伊豫雅臣
【Clozapine症例集】Clozapineが無効であったため,ECTへ切り替えた薬物治療抵抗性の慢性解体型統合失調症の1例 臨床精神薬理VO:8:2057-2059，2005.12
原野睦生, 内村直尚, 上野雄文, 安陪等思, 石橋正彦, 飯田信夫, 田中得雄, 前田久雄, 曽良一郎, 伊豫雅臣, 橋本謙二, 小宮山徳太郎, 山田光彦, 関根吉統, 稲田俊也, 尾崎紀夫, 岩田仲生, 氏家寛
覚せい剤関連精神障害の分子生物学的研究の進歩　覚せい剤精神病におけるドパミンレセプターD2遺伝子Taq I A多型と脳MRI 日本アルコール精神医学雑誌VO:12:33-41，2005.08
平幸司, 長谷川直, 藤崎美久, 伊豫雅臣
困難な症例から学ぶ 抗精神病薬により強い錐体外路症状と遷延する排尿障害をきたした統合失調症の一症例 Schizophrenia Frontier　VO:6:143-146，2005.05
小林圭介, 清水栄司, 三森真実, 伊豫雅臣
【認知行動療法】認知行動療法の実際 パニック障害 こころの科学121:62-68，2005.05
橋本佐, 橋本謙二, 松澤大輔, 清水栄司, 関根吉統, 稲田俊也, 尾崎紀夫, 岩田仲生, 原野睦夫, 小宮山徳太郎, 山田光彦, 曽良一郎, 氏家寛, 伊豫雅臣
覚醒剤精神病とGlutathione S-transferase P1機能的遺伝子多型との関連について 精神薬療研究年報37:100-107，2005.03
Hashimoto K.
Neonatal signs following exposure to SSRIs. Hum Psychopharmacol. 2005 Nov; 20(7): 522.
Hashimoto K, Iyo M, Freedman R, Stevens KE.
Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of a7 nicotinic acetylcholine receptors. Psychopharmacology (Berl). 2005 Nov; 183(1): 13-19.
Yamamoto T, Sakakibara R,Hahimoto K, Nakazawa K, Uchiyama T, Liu Z, Ito T, Hattori T.
Striatal dopamine level increases in the urinary storage phase in cats: an in vivo microdialysis study. Neuroscience. 2005; 135(1): 299-303.
Hashimoto K, Fujita Y, Shimizu E, Iyo M.
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol. 2005 Sep 5; 519(1-2): 114-117.
Hashimoto K, Koike K, Shimizu E, Iyo M.
a7 Nicotinic receptor agonists as potential therapeutic drugs for schizophrenia. Curr Med Chem-CNS Agents. 2005 September; 5: 171-184.
Hashimoto K, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Takei N, Iyo M.
No changes in serum epidermal growth factor levels in patients with schizophrenia. Psychiatry Res. 2005 June 30; 135: 257-260.
Ohgake S, Hashimoto K, Shimizu E, Koizumi H, Okamura N, Koike K, Matsuzawa D, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Shirayama Y, Iyo M.
Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis. Addiction Biol. 2005 June; 10(2): 145-148.
Matsuzawa D, Hashimoto K, Shimizu E, Fujisaki M, Iyo M.
Functional polymorphism of the glutathione peroxidase 1 gene is associated with personality traits in healthy subjects. Neuropsychobiology. 2005 June 29; 52: 68-70.
Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M.
Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropharmacol Biol Psychiatry. 2005 June; 29: 767-769.
Shimizu E, Hashimoto K, Itoh K, Kobayashi K, Mitsumori M, Koizumi H, Ohgake S, Okamura N, Koike K, Matsuzawa D, Kumakiri C, Nakazato M, Komatsu N, Iyo M.
No association of the brain-derived neurotrophic factor (BDNF) gene polymorphisms with panic disorder. Prog Neuropharmacol Biol Psychiatry. 2005 June; 29: 708-712.
Kobayashi K, Shimizu E, Hashimoto K, Mitsumori M, Koike K, Okamura N, Koizumi H, Ohgake S, Matsuzawa D, Zhang L, Nakazato M, Iyo M.
Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: As a biological predictor of response to group cognitive behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2005 June; 29: 658-663.
Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Takao H, Toyota T, Minabe Y, Nakamura K, Shimizu E, Itokawa M, Mori N, Iyo M, Yoshikawa T.
Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry. 2005 June 15; 57(12): 1493-1503 (*equal contribution).
Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H, Nakazato M, Okamura N, Stevens KE, Freedman R, Iyo M.
Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophrenia Res. 2005 Jul 1;76(1):67-72.
Hashimoto K, Shimizu E, Iyo M.
Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatry Rev. 2005 1(2): 151-163.
Salama RH, Muramatsu H, Shimizu E, Hashimoto K, Ohgake S, Watanabe H, Komatsu N, Okamura N, Koike K, Shinoda N, Okada S, Iyo M, Muramatsu T.
Increased midkine levels in sera from patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2005 May; 29(4): 611-6.
Hashimoto K, Koizumi H, Nakazato M, Shimizu E, Iyo M.
Role of brain-derived neurotrophic factor in eating disorders: Recent findings and its pathophysiological implications. Prog Neuropsychopharmacol Biol Psychiatry. 2005 May; 29(4): 499-504.
Tatsumi R, Fujio M, Satoh H, Katayama J, Takanashi S, Hashimoto K, Tanaka H.
Discovery of the alpha7 nicotinic acetylcholine receptor agonists. (R)-3'-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one as a novel, potent, selective, and orally bioavailable ligand. J Med Chem. 2005 Apr 7; 48(7): 2678-86.
Koizumi H, Hashimoto K, Shimizu E, Iyo M, Mashimo Y, Hata A.
Further analysis of microsatellite marker in the BDNF gene. Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 23; 135B(1): 103.
Hashimoto T, Hashimoto K, Matsuzawa D, Shimizu E, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iyo M.
A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 23; 135B(1): 5-9.
Koike K, Hashimoto K, Fukami G, Okamura N, Zhang L, Ohgake S, Koizumi H, Matsuzawa D, Kawamura N, Shimizu E, Iyo M.
The immunophilin ligand FK506 protects against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Neuropharmacology. 2005 Mar; 48(3): 391-7.
Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom L, Iyo M.
Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry. 2005 Jan 31; 5(1): 6
Okamoto H, Shimizu E, Ozawa K, Hashimoto K, Iyo M.
Lithium augmentation in milnacipran-refractory depression for the prevention of relapse following electroconvulsive therapy. Aust N Z J Psychiatry. 2005 Jan; 39(1-2): 108.
Itoh K, Hashimoto K, Shimizu E, Sekine Y, Ozaki N, Inada T, Harano M, Iwata N, Komiyama T, Yamada M, Sora I, Nakata K, Ujike H, Iyo M.
Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan. Am J Med Genet B Neuropsychiatr Genet. 2005 Jan; 132B(1): 70-73
Shiina A, Nakazato M, Mitsumori M, Koizumi H, Shimizu E, Fujisaki M, Iyo M.
An open trial of outpatient group therapy for bulimic disorders: combination program of cognitive behavioral therapy with assertive training and self-esteem enhancement. Psychiatry Clin Neurosci. 2005 Dec;59(6):690-6. PMID: 16401245 [PubMed - indexed for MEDLINE]

2004年開く閉じる

氏家寛, 稲田俊也, 原野睦生, 小宮山徳太郎, 山田光彦, 関根吉統, 曽良一郎, 岩田仲生, 伊豫雅臣, 尾崎紀夫
遺伝子研究によってどこまで精神疾患の病態は解明されたか　薬物依存と遺伝子関連研究 精神神経学雑誌VO:106:1598-1603，2004.12
清水栄司, 橋本謙二, 伊豫雅臣
【うつ病　診断と治療の最前線】Key words　BDNF　抗うつ薬の効果発現機序を含めて カレントテラピー　VO:23:86-87，2004.12
藤崎美久, 清水栄司, 橋本謙二, 伊豫雅臣
【脳の深部を探る】恐怖条件付けにおける扁桃体海馬移行領域の役割 生体の科学VO:55:590-597，2004.12
伊豫雅臣, 渡邉博幸
第二世代抗精神病薬の効果 千葉大アルゴリズムの経験から 臨床精神薬理VO:7:1836-1844，2004.11
橋本謙二, 伊豫雅臣
統合失調症の仮説とそのモデル検証　海馬障害モデル 分子精神医学VO:4:238-241，2004.07
清水栄司, 橋本謙二, 伊豫雅臣
うつ病とBDNF(脳由来神経栄養因子) 日本神経精神薬理学雑誌VO:24:147-150，2004.06
伊豫雅臣, 関根吉統, 森則夫
【依存症のニューロサイエンス】主要な薬物依存症のニューロサイエンス的側面　覚醒剤関連精神障害のPET画像 Clinical NeuroscienceVO:22:696-698，2004.06
伊豫雅臣
ベンゾジアゼピン系薬の臨床薬理 分子精神医学VO:4:182-186，2004.04
椎名明大, 松澤大輔, 野間利昌, 今井逸雄, 渡辺博幸, 野田慎吾, 古関啓二郎, 小河直之, 大塚芳克, 伊豫雅臣
【向精神薬のスイッチング&減量・単剤化】　統合失調症治療における従来型抗精神病薬からrisperidone単剤への切り替えに関する研究　ハイブリッド型スイッチングプロトコルによるパイロットスタディ 臨床精神薬理VO:7:503-510，2004.04
渡邉博幸, 伊豫雅臣
【統合失調症の治療における合理的な薬物療法とは？】急性期治療効果の観点からみた統合失調症の合理的な薬物療法 精神科VO:4:148-157，2004.03
三辺義雄, 関根吉統, 尾内康臣, 吉川悦次, 中村和彦, 武井教使, 二ツ橋昌実, 岡田裕之, 鈴木勝昭, 岩田泰秀, 塚田秀夫, 伊豫雅臣, 森則夫
覚醒剤使用者のセロトニン・トランスポーター脳内密度と精神症状との関連に関する研究 精神薬療研究年報36:219-223，2004.03
橋本謙二, 塚田秀夫, 西山新吾, 福元大, 垣内岳春, 清水栄司, 伊豫雅臣
覚せい剤投与によるサル脳内ドーパミントランスポーターの減少に及ぼす抗酸化物質NACの保護作用 精神薬療研究年報36:215-218，2004.03
伊豫雅臣:抗精神病薬単剤処方の意義　抗精神病薬の単剤化　大学病院での統合失調症急性期治療の経験から 臨床精神薬理VO:7:407-417，2004.03
尾崎紀夫, 北島剛司, 岩田仲生, 前野信久, 鈴木竜世, 池田匡志, 西山毅, 稲田俊也, 氏家寛, 原野睦生, 小宮山徳太郎, 山田光彦, 関根吉統, 伊豫雅臣, 曽良一郎
5-HT3受容体遺伝子上多型による統合失調症・覚醒剤使用障害・人格傾向との関連解析 厚生労働省精神・神経疾患研究総括研究報告新しい診断・治療法の開発に向けた精神疾患の分子メカニズム解明に関する研究　平成12～14年:41-46，2004.03
伊豫雅臣
【新規抗精神病薬の登場によって薬物療法はどう変わるべきか】PET,SPECTによる抗精神病薬の受容体占拠率の立場から 臨床精神薬理VO:7PG:15-21，2004.01
Nakazato M, Hashimoto K, Shiina A, Koizumi H, Mitsumori M, Imai M, Shimizu E, Iyo M.
No changes in serum ghrelin levels in female patients with bulimia nervosa. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov; 28(7): 1181-4.
Hashimoto K, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Shimizu E, Iyo M.
Effects of N-Acetyl-L-Cysteine on the Reduction of Brain Dopamine Transporters in Monkey Treated with Methamphetamine. Ann N Y Acad Sci. 2004 Nov; 1025: 231-5.
Kubota O, Hattori K, Hashimoto K, Yagi T, Sato T, Iyo M, Yuasa S.
Auditory-conditioned-fear-dependent c-Fos expression is altered in the emotion-related brain structures of Fyn-deficient mice. Brain Res Mol Brain Res. 2004 Nov 4; 130(1-2): 149-60.
Hashimoto K, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Shimizu E, Iyo M.
Protective Effects of N-acetyl-L-cysteine on the Reduction of Dopamine Transporters in the Striatum of Monkeys Treated with Methamphetamine. Neuropsychopharmacology. 2004 Nov; 29(11): 2018-23.
Shimizu E, Otsuka A, Hashimoto K, Iyo M.
Blepharospasm associated with olanzapine: a case report. Eur Psychiatry. 2004 Sep; 19(6): 389.
Fukami G, Hashimoto K, Koike K, Okamura N, Shimizu E, Iyo M.
Effect of antioxidant N-acetyl-l-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res. 2004 Jul 30; 1016(1): 90-95.
Tatsumi R, Seio K, Fujio M, Katayama J, Horikawa T, Hashimoto K, Tanaka H.
(+)-3-[2-(Benzo[b]thiephen-2-yl)-2-oxoethyl]-1-azabicyclo[2.2.2]-octane as potent agonists for the a7 nicotinic acetylcholine receptor. Bioorg Med Chem Lett. 2004 14: 3781-3784.
Hashimoto K, Okamura N, Shimizu E, Iyo M.
Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr Med Chem - CNS Agents. 2004 4 (2): 147-154.
Shimizu E, Hashimoto K, Kobayashi K, Mitsumori M, Ohgake S, Koizumi H, Okamura N, Koike K, Kumakiri C, Nakazato M, Komatsu N, Iyo M.
Lack of association between angiotensin I-converting enzyme insertion/deletion gene functional polymorphism and panic disorder in humans. Neurosci Lett. 2004 Jun 3; 363(1): 81-3.
Hashimoto K, Shimizu E, Iyo M.
Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev. 2004 May; 45(2): 104-14.
Yanahashi S, Hashimoto K, Hattori K, Yuasa S, Iyo M.
Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol. Brain Res. 2004 Jun 11; 1011(1): 84-93.
Koizumi H, Hashimoto K, Itoh K, Nakazato M, Shimizu E, Ohgake S, Koike K, Okamura N, Matsushita S, Suzuki K, Murayama M, Higuchi S, Iyo M.
Association between the brain-derived neurotrophic factor 196G/A polymorphism and eating disorders. Am J Med Genet. 2004 May 15; 127B(1): 125-7.
Koike K, Hashimoto K, Okamura N, Ohgake S, Shimizu E, Koizumi H, Komatsu N, Iyo M.
Decreased cell proliferation in the dentate gyrus of alpha7 nicotinic acetylcholine receptor heterozygous mice. Prog Neuropsychopharmacol Biol Psychiatry. 2004 May; 28(3): 517-20.
Shimizu E, Hashimoto K, Iyo M.
Ethnic difference of the BDNF 196G/A (val66met) polymorphism frequencies: The possibility to explain ethnic mental traits. Am J Med Genet. 2004 Apr 1; 126B(1): 122-3.
Koizumi H, Hashimoto K, Kumakiri C, Shimizu E, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Takei N, Iyo M.
Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers. Am J Med Genet. 2004 Apr 1; 126B(1): 43-5.
Fujisaki M, Hashimoto K, Iyo M, Chiba T.
Role of the amygdalo-hippocampal transition area in the fear expression: evaluation by behavior and immediate early gene expression. Neuroscience. 2004; 124(1): 247-60.
Minabe Y, Shirayama Y, Hashimoto K, Routledge C, Hagan JJ, Ashby CR Jr.
Effect of the acute and chronic administration of the selective 5-HT6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study. Synapse. 2004 Apr; 52(1): 20-8.
Okamura N, Hashimoto K, Shimizu E, Kumakiri C, Komatsu N, Iyo M.
Adenosine A1 Receptor Agonists Block the Neuropathological Changes in Rat Retrosplenial Cortex after Administration of the NMDA Receptor Antagonist Dizocilpine. Neuropsychopharmacology. 2004 Mar; 29(3): 544-50.
Hashimoto K, Fukushima T, Shimizu E, Okada S, Komatsu N, Okamura N, Koike K, Koizumi H, Kumakiri C, Imai K, Iyo M.
Possible role of D-serine in the pathophysiology of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar; 28(2): 385-8.
Itoh K, Hashimoto K, Kumakiri C, Shimizu E, Iyo M.
Association between brain-derived neurotrophic factor 196 G/A polymorphism and personality traits in healthy subjects. Am J Med Genet. 2004 Jan 1; 124B(1): 61-3.
Minabe Y, Hashimoto K, Shirayama Y, Ashby CR Jr.
Effect of the acute and chronic administration of the putative atypical antipsychotic drug Y-931 (8-fluoro-12- (4-methylpiperazin-1-yl)-6H-[1]benzothieno[2,3b][1,5] benzodiazepine maleate) on spontaneously active rat midbrain dopamine neurons: an in vivo electrophysiological study. Synapse. 2004 Jan; 51(1): 19-26.

2003年開く閉じる

伊豫雅臣, 関根吉統
【精神医学症候群　器質・症状性精神障害など】物質関連精神障害　精神刺激薬(アンフェタミン系薬物)関連精神障害　覚せい剤関連精神障害 日本臨床VO:別冊:精神医学症候群III:507-512，2003.10
篠田直之, 伊豫雅臣
「こどものこころ診療部」の開設について 精神科治療学VO:18:1224-1225，2003.10
野村文夫, 曽川一幸, 朝長毅, 大橋建也, 糸賀栄, 根津雅彦, 須永雅彦, 伊豫雅臣, 近藤直樹
プロテインチップテクノロジーによる新たな飲酒マーカーの探索 アルコールと医学生物学VO:23:11-14，2003.09
伊豫　雅臣
【新・必修精神科研修プログラム　主要病院における研修プラン】千葉大学医学部附属病院における精神科神経科研修プログラム 精神科VO:3:182-184，2003.08
野々村司, 伊豫雅臣
【精神医学症候群　統合失調症と周縁疾患など】感情障害と周縁疾患　抗うつ薬による副作用　ラピッド・サイクラー誘発 日本臨床VO:別冊:精神医学症候群I:381-384，2003.06
大掛真太郎, 伊豫雅臣
【精神医学症候群　統合失調症と周縁疾患など】感情障害と周縁疾患　抗うつ薬による副作用　躁転 日本臨床VO:別冊:精神医学症候群I:379-380，2003.06
深見悟郎, 橋本謙二, 小池香, 岡村斉恵, 清水栄司, 伊豫雅臣
覚せい剤による神経毒性に対する抗酸化物質N-acetylcysteineの効果 精神薬療研究年報35:134-137，2003.03
河野稔明, 稲田俊也, 高国子, 山之内芳雄, 野畑綾子, 栗田廣, 上島国利, 尾崎紀夫, 伊豫雅臣, 樋口輝彦
DIGS日本語版信頼性確立のための予備的検討 脳と精神の医学VO:14:51-58，2003.03
Minabe Y, Schechter L, Hashimoto K, Shirayama Y, Ashby CR Jr.
Acute and chronic administration of the selective 5-HT1A receptor antagonist WAY-405 significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse. 2003 Dec 1; 50(3): 181-90.
Okamura N, Hashimoto K, Shimizu E, Koike K, Ohgake S, Koizumi H, Kumakiri C, Komatsu N, Iyo M.
Protective effect of LY379268, a selective group II metabotropic glutamate receptor agonist, on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. Brain Res. 2003 Nov 28; 992(1): 114-9.
Shimizu E, Hashimoto K, Watanabe H, Komatsu N, Okamura N, Koike K, Shinoda N, Nakazato M, Kumakiri C, Okada S, Iyo M.
Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett. 2003 Nov 13; 351(2): 111-4.
Hashimoto K, Shimizu E, Komatsu N, Nakazato M, Okamura N, Watanabe H, Kumakiri C, Shinoda N, Okada S, Takei N, Iyo M.
Increased levels of serum basic fibroblast growth factor in schizophrenia. Psychiatry Res. 2003 Oct 15; 120(3): 211-8.
Nakazato M, Hashimoto K, Shimizu E, Kumakiri C, Koizumi H, Okamura N, Mitsumori M, Komatsu N, Iyo M.
Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders. Biol Psychiatry. 2003 Aug 15; 54(4): 485-90.
Okamoto H, Shino Y, Hashimoto K, Kumakiri C, Shimizu E, Shirasawa H, Iyo M.
Dynamic changes in AP-1 transcription factor DNA binding activity in rat brain following administration of antidepressant amitriptyline and brain-derived neurotrophic factor. Neuropharmacology. 2003 Aug; 45(2): 251-9.
Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003 Jul 1; 54(1): 70-5.
Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M.
Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003 Jun; 60(6): 572-6.
Shimizu E, Hashimoto K, Salama RH, Watanabe H, Komatsu N, Okamura N, Koike K, Shinoda N, Nakazato M, Kumakiri C, Okada S, Muramatsu H, Muramatsu T, Iyo M.
Two clusters of serum midkine levels in drug-naive patients with schizophrenia. Neurosci Lett. 2003 Jun 26; 344(2): 95-8.
Okamura N, Hashimoto K, Kanahara N, Shimizu E, Kumakiri C, Komatsu N, Iyo M.
Protective effect of the antipsychotic drug zotepine on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. Eur J Pharmacol. 2003 Feb 14; 461(2-3): 93-8.

2002年開く閉じる

伊豫雅臣
統合失調症薬物療法の新しい展開　非定型抗精神病薬を中心にして　統合失調症治療における定型抗精神病薬，非定型抗精神病薬 臨床医薬VO:18:1303-1308，2002.12
伊豫雅臣
薬物依存症を考える　薬物依存　その成立と予防,初期治療 日本臨床麻酔学会誌VO:22:311-313，2002.11
清水栄司, 橋本謙二, 伊豫雅臣
強迫性障害の神経生物学的研究　最近の動向 日本神経精神薬理学雑誌VO:22:111-119，2002.08
伊豫雅臣
精神分裂病治療における非定型抗精神病薬 ファルマシアVO:38:742-746，2002.08
伊豫雅臣, 清水栄司, 尾崎茂
【メンタルヘルスをめぐる諸問題】メンタルヘルスに関連した心の病態　薬物依存の疫学と中枢機構 Clinical Neuroscience　VO:20:571-574，2002.05
橋本謙二, 伊豫雅臣
アルツハイマー病のアミロイド・カスケード仮説とα7ニコチン受容体 日本神経精神薬理学雑誌VO:22:49-53，2002.04
橋本謙二, 伊豫雅臣
依存性薬物・麻薬の作用分子メカニズムの最先端　ヒトにおける薬物乱用の現況 分子精神医学VO:2:172-175，2002.04
橋本謙二, 伊豫雅臣
精神分裂病のグルタミン酸仮説と新しい治療薬の創製 日本神経精神薬理学雑誌VO:22PG:3-13，2002.02
渡邉博幸, 伊豫雅臣
【これだけは知っておきたい　診療・相談記録の書き方】様々な臨床場面における診療・相談記録の書き方　退院時サマリーと退院療養計画書の書き方 精神科臨床サービスVO:2:46-49，2002.01
関根吉統, 伊豫雅臣, 森則夫
【中毒性・依存性薬物の分子作用機序】覚せい剤依存者における脳内神経伝達系の変化 分子精神医学VO:2:55-61，2002.01
Shimizu E, Watanabe H, Iyo M.
Delayed-onset nocturnal akathisia due to risperidone and levomepromazine: a case report. Eur Psychiatry. 2002 Sep;17(5):294-5.
Shimizu E, Hashimoto K, Komatsu N, Iyo M.
Roles of endogenous glutathione levels on 6-hydroxydopamine-induced apoptotic neuronal cell death in human neuroblastoma SK-N-SH cells. Neuropharmacology. 2002 Sep;43(3):434-43.
Sekine Y, Minabe Y, Kawai M, Suzuki K, Iyo M, Isoda H, Sakahara H, Ashby CR Jr, Takei N, Mori N.
Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study. Neuropsychopharmacology. 2002 Sep;27(3):453-61.
Ando K, Takei N, Matsumoto H, Iyo M, Isoda H, Mori N.
Neural damage in the lenticular nucleus linked with tardive dyskinesia in schizophrenia: a preliminary study using proton magnetic resonance spectroscopy. Schizophr Res. 2002 Oct 1;57(2-3):273-9.
Namba H, Fukushi K, Nagatsuka S, Iyo M, Shinotoh H, Tanada S, Irie T.
Positron emission tomography: quantitative measurement of brain acetylcholinesterase activity using radiolabeled substrates. Methods. 2002 Jul;27(3):242-50.
Nakazato M, Iyo M, Sato M, Miyamoto S.
Two cases of diabetes mellitus type 1 accompanied by hallucinatory-delusional state. Pediatr Int. 2002 Apr;44(2):177-8.
Morimoto T, Hashimoto K, Yasumatsu H, Tanaka H, Fujimura M, Kuriyama M, Kimura K, Takehara S, Yamagami K.
Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H-[1]benzothieno[2,3-b][1,5] benzodiazepine maleate). Neuropsychopharmacology. 2002 Apr;26(4):456-67.
Shirayama Y, Hashimoto K, Suzuki Y, Higuchi T.
Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr Res. 2002 Nov 1;58(1):69-74.
Blackburn TP, Minabe Y, Middlemiss DN, Shirayama Y, Hashimoto K, Ashby CR Jr.
Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: An in vivo extracellular single cell study. Synapse. 2002 Dec 1;46(3):129-139.
Takano A, Suhara T, Sudo Y, Inoue M, Hashimoto K, Zhang MR, Ichimiya T, Yasuno F, Suzuki K.
Comparative evaluation of two serotonin transporter ligands in the human brain: [11C](+)McN5652 and [11C]cyanoimipramine. Eur J Nucl Med Mol Imaging. 2002 Oct;29(10):1289-97.

2001年開く閉じる

渡邉博幸, 伊豫雅臣
【ほんとうに困った症例集　精神科編】リスクの高いケース　リチウム中断後に生じた全身性ジストニア こころのりんしょうa・la・carte　VO:20 IP:増刊:196-198，2001.09
星野良一, 伊豫雅臣, 安藤勝久, 河合正好, 田中純二, 上田昌康, 野島陽子
神経性大食症の認知修正法としての森田療法の適用 メンタルヘルス岡本記念財団研究助成報告集12:115-120，2001.03
Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N.
Methamphetamine-Related Psychiatric Symptoms and Reduced Brain Dopamine Transporters Studied With PET. Am J Psychiatry 2001;158(8):1206-14.
Mody M, Cao Y, Cui Z, Tay KY, Shyong A, Shimizu E, Pham K, Schultz P, Welsh D, Tsien JZ.
Genome-wide gene expression profiles of the developing mouse hippocampus. Proc Natl Acad Sci U S A 2001;98(15):8862-7.
Minabe Y, Hashimoto K, Watanabe K, Ashby CR. (2001)
The acute and repeated administration of the selective 5-HT2A receptor antagonist M 100907 significantly alters the activity of midbrain dopamine neurons: an in vivo electrophysiological study. Synapse 40, 102-112.
Matsuki H, Shirayama Y, Hashimoto K, Tanaka A, Minabe Y. (2001)
Effects of age and gender on the expression of brain-derived neurotrophic factor mRNA in rat retrosplenial cortex following administration of dizocilpine. Neuropsychopharmacol. 25, 258-266.
Shirayama Y, Hashimoto K, Higuchi T, Minabe Y. (2001)
Subchronic treatment with methamphetamine and phencyclidine differentially alter the adenosine A1 and A2A receptors in the prefrontal cortex, hippocampus and striatum of the rat. Neurochemical Res. 26, 363-368.
Sekine Y, Takei N, Iyo M, Mori N, Minami M, Ohta T.
Effective risperidone treatment for simple deteriorative disorder (simple schizophrenia): a case report. Schizophr Res. 2001 ;50(3):213-4.
Tanaka N, Fukushi K, Shinotoh H, Nagatsuka S, Namba H, Iyo M, Aotsuka A, Ota T, Tanada S, Irie T.
Positron Emission Tomographic Measurement of Brain Acetylcholinesterase Activity Using N-[11C]Methylpiperidin-4-yl Acetate without Arterial Blood Sampling: Methodology of Shape Analysis and Its Diagnostic Power for Alzheimer's Disease. J Cereb Blood Flow Metab 2000; 21(3):295-306.
Matsunaga T, Tsukada H, Nishiyama S, Sekine Y, Kakiuchi T, Iyo M, Mori N.
Yohimbine increases the binding potential for [11C]flumazenil in the monkey brain. J Neural Transm. 2001;108(12):1375-82.
Tani K, Iyo M, Matsumoto H, Kawai M, Suzuki K, Iwata Y, Won T, Tsukamoto T, Sekine Y, Sakanoue M, Hashimoto K, Ohashi Y, Takei N, Mori N.
The effects of dentate granule cell destruction on behavioural activity and Fos protein expression induced by systemic methamphetamine in rats. Br J Pharmacol. 2001 Dec;134(7):1411-8.
Tsukamoto T, Iyo M, Tani K, Sekine Y, Hashimoto K, Ohashi Y, Suzuki K, Iwata Y, Mori N.
The effects of FK506, a specific calcineurin inhibitor, on methamphetamine-induced behavioral change and its sensitization in rats. Psychopharmacology (Berl). 2001 Nov;158(2):107-13.
Nagatsuka Si S, Fukushi K, Shinotoh H, Namba H, Iyo M, Tanaka N, Aotsuka A, Ota T, Tanada S, Irie T.
Kinetic analysis of [11C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. J Cereb Blood Flow Metab. 2001 Nov;21(11):1354-66.
Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M, Asahina M, Hattori T, Tanada S, Irie T.
In vivo mapping of brain cholinergic function in Parkinson's disease and progressive supranuclear palsy. Adv Neurol. 2001;86:249-55.
Kowalska A, Asada T, Arima K, Kumakiri C, Kozubski W, Takahashi K, Tabira T.
Genetic analysis in patients with familial and sporadic frontotemporal dementia: two tau mutations in only familial cases and no association with apolipoprotein epsilon4. Dement Geriatr Cogn Disord 2001 Nov-Dec;12(6):387-92.

2000年開く閉じる

Sekine Y, Iyo M, Tanaka K, Matsuyama K, Matsunaga T, Mori N.
Effective adjunctive use of low-dose methylphenidate with mianserin for major depression with silent cerebral infarction: a case report. J Clin Psychopharmacol 2000;20(5):584-5.
Iwata Y, Kotani Y, Hoshino R, Takei N, Iyo M, Mori N.
Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychiatry 2000;61(7):528-9.
Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M.
Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci. 2000;66(25):2455-64.
Shimizu E, Tang YP, Rampon C, Tsien JZ.
NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation. Science 2000; 290: 1170-1174.
Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, Blethrow J, Shimizu E, Tsien JZ, Schultz PG, Rose MD, Wood JL, Morgan DO, Shokat KM.
A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 2000;407(6802):395-401.
Rampon C, Tang YP, Goodhouse J, Shimizu E, Kyin M, Tsien JZ.
Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice. Nature Neurosci 2000;3(3):238-44.
Yasuno I, Kodama K, Kumakiri C, Shimizu E, Sato T.
Screening for point mutations of the RYR1 and SCN4AA genes in neuroleptic malignant syndrome. Chiba Igaku 2000. 76: 75-79.
Hashimoto K, Fujimura M, Yamagami K. (2000)
Dizocilpine-induced neuropathological changes in rat retrosplenial cortex are reversed by subsequent clozapine treatment. Life Sci 66, 1071-1078.
Fujimura M, Hashimoto K, Yamagami K. (2000)
Effects of antipsychotic drugs on neurotoxicity, expression of Fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine. Eur J Pharmacol 398, 1-10.
Shirayama Y, Hashimoto K, Iyo M, Watanabe K, Higuchi T, Minabe Y. (2000)
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)-induced egr-1 mRNA in rat brain: pharmacological manipulation. Eur J Pharmacol 402, 215-222.
Fujimura M, Hashimoto K, Yamagami K. (2000)
The effect of the antipsychotic drug mosapramine on the expression of Fos protein in the rat brain: comparison to haloperidol, clozapine and risperidone. Life Sci 67, 2865-2872.
Kodama K, Okada S, Komatsu N, Yamanouchi N, Noda S, Kumakiri C, Sato T. (2000)
Relationship between MRI findings and prognosis for patients with general paresis. J Neuropsychiatry Clin Neurosci 12(2):246-50
Kodama K, Okada S, Iseki E, Kowalska A, Tabira T, Hosoi N, Yamanouchi N, Noda S, Komatsu N, Nakazato M, Kumakiri C, Yazaki M, Sato T. (2000)
Familial frontotemporal dementia with a P301L tau mutation in Japan. J Neurol Sci 176(1):57-64.
Nakazato M, Kodama K, Miyamoto S, Sato M, Sato T.
Psychiatric disorders in juvenile patients with insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 2000;48(3):177-83.

1999年開く閉じる

Arase K, Saijo K, Watanabe H, Konno A, Arase H, Saito T.
Ablation of a specific cell population by the replacement of a uniquely expressed gene with a toxin gene Proc Natl Acad Sci USA 96: 9264-9268, (1999)
Shirayama Y, Hashimoto K, Shirayama M, Watanabe K, Ogawa T, Higuchi T, Minabe Y. (1999)
Effects of acute and subchronic administration with methamphetamine or phencyclidine on plasma levels of adrenocorticotropin, corticosterone and progesterone in rat. Addiction Biol 4:345-350.
Shirayama Y, Hashimoto K, Matsuki H, Tsunashima K, Iyo M, Higuchi T, Minabe Y. (1999)
Increased expression of zif268 mRNA in rat retrosplenial cortex following administration of phencyclidine. Brain Res 839:180-185.
Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ.
Genetic enhancement of learning and memory in mice. Nature 1999;401(6748):63-9.
Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, Tsien J, Ubersax J, Blethrow J, Morgan DO, Shokat KM.
Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 1999;6(9):671-8.
Kumakiri C, Kodama K, Shimizu E, Yamanouchi N, Okada S, Noda S, Okamoto H, Sato T, Shirasawa H.
Study of the association between the serotonin transporter gene regulatory region polymorphism and personality traits in a Japanese population. Neurosci Lett 1999;263(2-3):205-7.
Iyo M, Sekine Y, Matunaga T, Tsukamoto T, Takei N, Mori N.
Methamphetamine-associated obsessional symptoms and effective risperidone treatment: A case report. J Clin Psychiatry 60(5): 337-338, 1999.
Ohashi Y, Okamoto N, Uchida K, Iyo M, Mori N, Morita Y.
Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type. Biological Psychiatry 15;45(12):1646-52, 1999.
Namba H, Iyo M, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T.
Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age. Eur J Nucl Med 26(2):135-143, 1999.
Ouchi Y, Yoshikawa E, Okada H, Futatsubashi M, Sekine Y, Iyo M, Sakamoto M.
Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography. Ann Neurol 45(5):601-10, 1999.
Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M, Asahina M, Hattori T, Tanada S, Irie T
Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's Disease and Progressive Supranuclear Palsy. Ann Neurol 46:62-69, 1999.
Okada S, Yamanouchi N, Kodama K, Uchida Y, Hirai S, Sakamoto T, Noda S, Komatsu N, Sato T.
Regional cerebral blood flow abnormalities in chronic solvent abusers. Psychiatry Clin Neurosci 1999;53(3):351-6.
Komatsu N, Kodama K, Yamanouchi N, Okada S, Noda S, Nawata Y, Takabayashi K, Iwamoto I, Saito Y, Uchida Y, Ito H, Yoshikawa K, Sato T.
Decreased regional cerebral metabolic rate for glucose in systemic lupus erythematosus patients with psychiatric symptoms. Eur Neurol 1999 42(1):41-8.
Shinoda N, Kodama K, Sakamoto T, Yamanouchi N, Takahashi T, Okada S, Noda S, Komatsu N, Sato T.
Predictors of 1-year outcome for patients with panic disorder. Compr Psychiatry 1999;40(1):39-43.

1998年開く閉じる

Watanabe K, Hashimoto K, Nishimura T, Tsunashima K, Minabe Y. (1998)
Expression of Fos protein in rat brain following administration of a nicotinic acetylcholine receptor agonist epibatidine. Brain Res 797:135-142.
Hashimoto K, Watanabe K, Nishimura T, Iyo M, Shirayama Y, Minabe Y. (1998)
Behavioral changes and expression of heat shock protein hsp-70 mRNA, brain-derived neurotrophic factor mRNA, and cyclooxygenase-2 mRNA in rat brain following seizures induced by systemic administration of kainic acid. Brain Res 804, 212-223.
Hashimoto K, Hatano K, Minabe Y, Iyo M, Taniguchi M, Hoshino O, Kawasumi Y, Sakiyama Y. (1998)
Radiosynthesis of [18F]N-(4-phenylbutyl)-4-(fluorobenzoyl) piperidine for studying serotonin 5-HT2A receptor. J Labelled Compds Radiopharm XLI: 941-949.
Namba H, Iyo M, Shinotoh H, Nagatsuka S, Fukushi K, Irie T
Preserved acetylcholinesterase activity in aged cerebral cortex. Lancet 351(9106): 881-882, 1998.
Namba H, Iwadate Y, Iyo M, Fukushi K, Irie T, Sueyoshi K, Tagawa M, Sakiyama S.
Glucose and methionine uptake by rat brain tumor treated with prodrug-activated gene therapy. Nucl Med Biology 25: 247-250, 1998.
Kodama K, Noda S, Murakami A, Azuma Y, Takeda N, Yamanouchi N, Okada S, Komatsu N, Sato T, Miyazawa Y, Kawamura I.
Depressive disorders as psychiatric complications after obesity surgery. Psychiatry Clin Neurosci 1998;52(5):471-6.
Moriyama T, Yamanouchi N, Kodama K, Murakami A, Okada S, Noda S, Komatsu N, Sato T, Kusaka T, Kato K.
Activation of non-primary motor areas during a complex finger movement task revealed by functional magnetic resonance imaging. Psychiatry Clin Neurosci 1998;52(3):339-43.

1997年開く閉じる

Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T.
In vivo measurement using PET of acetylcholinesterase activity in the brains of patients with Alzheimer's disease and normal controls. Lancet 349: 1805-1809, 1997.
Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M.
Decreased prefrontal dopamine D1 receptor binding in schizophrenia revealed by PET. Nature 385(6617): 634-637, 1997.
Iyo M, Namba H, Hirai S, Yanagisawa M, Yui N, Fukui S.
Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99mTc-HMPAO and SPECT. Prog Neuro-Psych Biol Psych 21(5): 789-796, 1997.
Ohashi Y, Okamoto N, Uchida K, Iyo M, Mori N, Morita Y.
Differential pattern of the circadian rhythm of serum melatonin in young and elderly healthy subjects. Biol Signals 6(4-6): 301-306, 1997. (July)
Yamazaki T, Arase H, Ono S, Ohno H, Watanabe H, and Saito T.
A Shift from Negative to Positive Selection of Autoreactive T Cells by the Reduced Level of TCR Signal in TCR-Transgenic CD3?-Deficient Mice. J Immunology 158,1634-1640. (1997)
Watanabe H, Shiratori T, Shoji H, Miyatake S, Okazaki Y, Ikuta K, Sato T, and Saito T.
A Novel acyl-CoA Thioesterase Enhances its Enzymatic Activity by Direct Binding with HIV Nef. Biochem Biophysic Res Comm 238, 234-239. (1997)
Shimizu E, Kodama K, Sakamoto T, Komatsu N, Yamanouchi N, Okada S, Sato T.
Recovery from neuroendocrinological abnormalities and frontal hypoperfusion after remission in a case with rapid cycling bipolar disorder. Psychiatry Clin Neurosci 1997;51(4):207-12.
Shimizu E, Shirasawa H, Kodama K, Kuroyanagi H, Shirasawa T, Sato T, Simizu B.
Glutamate dehydrogenase mRNA is immediately induced after phencyclidine treatment in the rat brain. Schizophr Res 1997;25(3):251-8.
Narita, N., Hashimoto, K., Tomitaka, S., Minabe, Y. and Yamazaki, K. (1997)
YM90K, a selective a- amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonist, prevents induction of heat shock protein HSP-70 and hsp-70 mRNA in rat retrosplenial cortex by phencyclidine. Addiction Biol 2, 47-56.
Hashimoto, K., Narita, N., Tomitaka, S., Iyo, M. and Minabe, Y. (1997)
In vivo regulation of serotonin 5-HT2A receptor in rat brain by subchronic administration of s receptor ligand NE-100. Life Sci 60, 2245-2254.
Hashimoto, K., Tomitaka, S., Narita, N., Minabe, Y. and Iyo, M. (1997)
Inductions of Fos protein by 3,4-methylenedioxymethamphetamine in rat brain: regional differences by pharmacological manipulation. Addiction Biol 2: 317-326.
Tomitaka, S., Hashimoto, K., Narita, N., Minabe, Y. and Tamura, A. (1997)
Regionally different effects of scopolamine on NMDA antagonist-induced heat shock protein HSP-70. Brain Res 763, 255-258.
Katsumori, H., Hashimoto, K., Tomitaka, S., Osawa, M. and Minabe, Y. (1997)
Acute effect of c-fos antisense oligodeoxynucletide on hippocampal partial seizures elicited by electrical stimulation in rats. Neurosci Lett 225, 149-152.
Hashimoto, K., Tomitaka, S., Bi, Y., Narita, N., Minabe, Y. and Iyo M. (1997)
Rolipram, a potent and selective cyclic AMP phosphodiesterase type IV inhibitor, prevents the induction of heat shock protein HSP-70 and hsp-70 mRNA in rat retrosplenial cortex by NMDA receptor antagonist dizocilpine. Eur J Neurosci 9: 1891-1901.
Takahashi, H., Traystman, R.J., Hashimoto, K., London, E.D. and Kirsh, J.R. (1997)
Postischemic brain injury is affected stereospecifically by pentazocine in rats. Anesth Analg 85: 353-357.
Hashimoto, K., Minabe, Y. and Iyo, M. (1997)
Expression of cyclooxygenase-2 mRNA in rat retrosplenial cortex following administration of phencyclidine. Brain Res 762: 259-263.
Hashimoto, K., Minabe, Y. and Iyo, M. (1998)
Expression of brain-derived neurotrophic factor mRNA in rat retrosplenial cortex following administration of phencyclidine. Addiction Biol 3: 79-83.
Yamanouchi N, Okada S, Kodama K, Sakamoto T, Sekine H, Hirai S, Murakami A, Komatsu N, Sato T.
Effects of MRI abnormalities on WAIS-R performance in solvent abusers. Acta Neurol Scand 1997;96(1):34-9.

1996年開く閉じる

Hashimoto, K., Tomitaka, S., Narita, N., Minabe, Y., Iyo, M. and Fukui, S. (1996)
Induction of heat shock protein HSP-70 in posterior cingulate and retrosplenial cortex of rat brain by dizocilpine and phencyclidine: lack of protective effects of sigma receptor ligands. Addiction Biol 1: 61-70.
Hashimoto, K., Tomitaka, S., Narita, N., Minabe, Y., Iyo, M. and Fukui S. (1996)
Induction of heat shock protein HSP-70 in rat retrosplenial cortex following administration of dextromethorphan. Enviro Toxicol Pharmacol 35: 235-239.
Narita, N., Hashimoto, K., Tomitaka, S. and Minabe, Y. (1996)
Interactions of selective serotonin reuptake inhibitors with subtypes of s receptors in rat brain. Eur J Pharmacol 307: 117-119.
Takahashi, H., Kirsch, J.R., Hashimoto, K., London, E.D., Koehler, R.C. and Traystman, R.J. (1996)
PPBP [4-phenyl-1-(4-phenylbutyl)piperidine], decreases brain injury following transient focal ischemia in rats. Stroke 27: 2120-2123.
Tomitaka, S., Hashimoto, K., Narita, N., Sakamoto, S., Minabe, Y. and Tamura, A. (1996)
Memantine induces heat shock protein HSP-70 in the posterior cingulate cortex, retrosplenial cortex and dentate gyrus of rat brain. Brain Res 740: 1-5.
Shimizu E, Shirasawa H, Kodama K, Sato T, Simizu B.
Expression, regulation and polymorphism of the mxi1 genes. Gene 1996; 176(1-2):45-8.
Namba H., Irie T., Fukushi K., Iyo M., Hashimoto T., Ando K.
Time courses of changes in cerebral blood flow and blood-brain barrier integrity by focal proton radiation in the rat. Neurological Res 18(1): 83-56, 1996.
Irie T., Fukushi K., Namba H., Iyo M., Tamagami H., Nagatsuka S., Ikota N.
Brain acetylcholinesterase activity: Validation of a PET tracer in a rat model of Alzheimer's Disease. J Nucl Med 37(4): 649-655, 1996.
Urata J., Uchiyama M., Iyo M., Enomoto T., Hayakawa T., Tomiyama M., Nakajima T., Sasaki H., Shirakawa S., Wada K., Fukui S., Yamadera H., Okawa M.
Effects of a small dose of triazolam on P300 and resting EEG. Psychopharmacology 125(2): 179-184, 1996.
Kitao Y., Inada T., Maeda Y., Sasaki H., Iyo M.
Effects of a single injection of methamphetamine on central dopaminergic systems in rats with hippocampal lesions. Neurosci Res Comm 19(1) 1-7, 1996.
Iyo M., Bi Y., Hashimoto K., Inada T., Fukui S.
Prevention of methamphetamine-induced behavioral sensitization in rats by a cyclic AMP phosphodiesterase inhibitor, rolipram. Eur J Pharmacol 312:163-171, 1996.
Iyo M, Bi Y, Hashimoto K, Tomitaka S, Inada T, Fukui S.
Does an increase of cyclic AMP prevent methamphetamine-induced behavioral sensitization in rats ? Ann N Y Acad Sci 801:377-83. 1996.
Noda S, Yamanouchi N, Okada S, Kodama K, Murakami A, Sekine H, Sakamoto T, Komatsu N, Sato T, Ikehira H, Morita F.
Proton MR spectroscopy in solvent abusers. Ann N Y Acad Sci 1996;801:441-4.

1995年開く閉じる

Iyo M., Maeda Y., Inada T., Kitao Y., Sasaki H., Fukui S.
The effects of a selective cAMP phophodiesterase inhibitor, rolipram on methamphetamine-induced behavior. Neuropsychopharmacology 13(1): 33-39, 1995.
Sasaki H., Hashimoto K., Maeda Y., Inada T., Kitao Y., Fukui S., Iyo M.
Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Life Sci 56(25): 443-447, 1995.
Sasaki H., Hashimoto K., Inada T., Fukui S., Iyo M.
Suppression of orofacial movements by rolipram, a cAMP pohosphodiesterase inhibitor, in rats chronically treated with haloperidol. Eur J Pharmacol 282(1-3): 71-76, 1995.
Nakagawa K., Namba H., Iyo M., Fukushi K., Irie T., Yamanouchi M., Shikama N., Himi T., Yoshida K., Masuda Y.
Simplified PET Quantitation of Myocardial Glucose Utilization. J Nucl Med 36(11): 2094-2102, 1995.
Arase H, Ono S, Arase N, Park SY, Wakizaka K,Watanabe H, Ohno H, and Saito T.
Developmental Arrest of NK1.1+ T Cell Antigen Receptor (TCR)-?/?+ T Cells and Expansion of NK1.1+ TCR-?/?+ T Cell Development in CD3?- deficient Mice. J Exp Med 182: 891-895. (1995).
Shimizu E, Shirasawa H, Kodama K, Koseki K, Sato T, Simizu B.
Cloning and sequencing of the murine Mxi1 cDNA. Gene 1995; 152(2):283-4.
Hashimoto, K. and London, E.D. (1995)
Interaction of erythro-ifenprodil, threo-ifenprodil,erythro-iodoifenprodil and eliprodil (SL 82.0715) with subtypes of sigma receptors. Eur J Pharmacol 273: 307-310.
Hashimoto, K., Scheffel, U. and London, E.D. (1995)
In vivo labeling of s receptors in mouse brain with [3H]4-phenyl-1-(4-phenylbutyl)piperidine. Synapse 20: 85-90.
Takahashi, H., Kirsch, J.R., Hashimoto, K., London, E.D., Koehler, R.C. and Traystman, R.J. (1995)
PPBP [4-phenyl-1-(4-phenylbutyl)piperidine], a potent sigma receptor ligand, decreases brain injury following transient focal ischemia in cats. Stroke 26: 1676-1682.
Narita, N., Hashimoto, K., Iyo, M., Minabe, Y. and Yamazaki, K. (1995)
Lack of neuroprotective effects of sigma receptor ligands on the neurotoxicity of p-chloroamphetamine in rat brain. Eur J Pharmacol 293: 277-280.
Tomitaka, S., Hashimoto, K., Narita, N., Minabe, Y. and Tamura, A. (1995)
Amantadine induces c-fos protein in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists. Eur J Pharmacol 285: 207-211.
Yamanouchi N, Okada S, Kodama K, Hirai S, Sekine H, Murakami A, Komatsu N, Sakamoto T, Sato T.
White matter changes caused by chronic solvent abuse. AJNR Am J Neuroradiol 1995;16(8):1643-9.
Kodama K, Murakami A, Yamanouchi N, Koseki K, Iwasa H, Okada S, Sakamoto T, Noda S, Komatsu N, Sato T.
MR in temporal lobe epilepsy: early childhood onset versus later onset. AJNR Am J Neuroradiol 1995;16(3):523-9.